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Abstract 
C-reactive protein (CRP) is a homopentameric acute-phase inflammatory 
protein that exhibits elevated expression during inflammation. CRP can be found in 
its pentameric form (nCRP) or monomeric form (mCRP). To date there has been 
little research investigating the effects of these CRP isoforms in wound healing 
processes and age-related impaired healing, which is known to have an altered 
inflammatory response.  
 
The study investigated CRP isoform localisation in murine wounds (detected 
by immunohistochemistry) and circulating blood (measured by immunoblotting) 
using models of acute healing in young adults and age-related impaired healing 
(n=3). Using in vitro inflammatory cell assays developed with the monocytic U937 
cell line this study investigated the effects of CRP isoforms in nitric oxide release 
(detected by an immunoassay), phagocytosis (measured by a bacterial recovery 
assay), apoptosis (detected via DNA fragmentation) and cytokine secretion 
(measured by a multiplex immunoassay) in both monocyte and macrophage-like 
cells (n=6).  Pharmacological inhibitors were used to determine the potential CRP-
induced pathways or mechanisms. 
 
Both isoforms were localised to sites of inflammation, implying that they 
may play an active inflammatory role during wound repair. Moreover, the ratio of 
CRP isoforms (mCRP:nCRP) reflected the degree of inflammation, with higher values 
indicating elevated mCRP localisation and pronounced inflammation in the model 
of age-related impaired healing. In in vitro inflammatory cell assays, nCRP exhibited 
a more anti-inflammatory effect leading to significantly (P=0.01) increased 
phagocytosis, increased apoptosis, decreased nitric oxide (NO) production, and 
reduced overall pro-inflammatory cytokine production  in monocytes and 
macrophages. The mCRP isoform significantly (P<0.001) increased NO production 
and overall levels of pro-inflammatory cytokines, thus confirming its pro-
inflammatory nature indicated in the literature. 
xix 
 
This research highlighted that estrogen mediated CRP-induced responses in 
a cell type- and status-specific manner, being pro-inflammatory in circulating cells 
(monocytes) but anti-inflammatory in wound tissue cells (mature activated 
macrophages). The profile of CRP isoforms shifted in age-related (estrogen-
deprived) impaired healing to relatively higher levels of mCRP compared to nCRP, 
suggesting impaired healing in the elderly may result from the dissociation of nCRP 
to mCRP following the decline in estrogen with increasing age.  
 
In conclusion, this study has provided novel data showing that both isoforms 
of CRP may differentially mediate inflammatory responses during wound healing 
and may play key roles in age-related impaired healing and may ultimately provide 
potential therapeutic strategies for the treatment of chronic wounds in the elderly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
 
Declaration 
 
I declare that no portion of the work referred to in this thesis has been submitted in 
support of an application for another degree or qualification of this or any other 
university or institute of learning.  
Many thanks to Dr J Ashworth and J Hynes for the collection of the data used in 
Chapter 4 of this thesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
Acknowledgements 
Firstly, to Dr Jason Ashworth, my Director of Studies; it has been a bit of a 
rollercoaster however I could not have completed this without your support and friendship. 
Thank you for putting up with me through all the laughter, stressing out and tears. The past 
few years have generated many memories and I find myself grateful for the help you have 
given in making me the scientist that I have become. Also thank you to Professor Mark 
Slevin for your help and guidance over the years.  
 
There are many others that I must thank here and I apologise now, as I cannot 
mention every one by name. In my many years of studying I have met with so many people 
and I am grateful to each and every one of you. Thank you to everyone on the third floor 
who made me smile; from birthday parties in the office, to break-out rooms and the 
collecting of freebies. My years here are full of fond memories that will always be 
treasured. I also want to thank Stuart; the one who was there on day one; thank you for 
keeping me laughing. Then Glenn; sorry for all the bugging but I could not have survived 
without your technical knowledge. To Paul; for teaching me microbiology. And Gary; I kept 
swimming just as you said to.  
 
Then to the Ashworth Group; Nazeedah, Mohamed, Catrin, Fadel, Lily and Sasha 
(and the numerous project students). Our research group has expanded over the years and 
it has been an honour to work with each one of you. I am still sure that Jason is still trying 
to take over the world using our research but I know we will always stay in contact. 
 
Then to my best friends; Alison, James, Dan and Liam. You guys have seen the best 
and worst of me as I have found my way through this work but you have all been amazing. 
From trying to understand what I actually do (and getting it right on occasion) to just being 
there for gaming nights and cinema trips. You have all kept me sane (I think) and I hope I 
will be a bit calmer now. 
 
To my sister, Gemma and my brother-in-law David, thank you for both 
understanding that what I do is not simple. And Gemma, I know you never understood why 
I got excited about graphs but at least your comments about how weird I was made me 
laugh along the way. 
 
To my Nanna and Grandad; again you have been there through thick and thin for 
me. I know it has been a long time coming but here it is and I hope you like it.  And I will 
never forget the advice you gave me.  
 
To my Mum and Dad. Words cannot describe all that you have done for me over 
the years. To say that I could not have done it without you is an understatement. You have 
both pushed me, supported me and loved me throughout. I know it has been a tough road 
but I hope I have done you proud. 
 
Finally, to Mike. You were there the day I got the phone call starting this whole 
process and here you are at the end. It has been an interesting few years but I am glad I 
had you beside me. You have made me the happiest person ever, and I know we have an 
amazing future to look toward. Thank you for being you and thank you for being my knight 
in shining armour; coming to rescue me from failing experiments.  
 
1 
 
Chapter 1: Introduction 
1.1 Wound Healing and Inflammation 
1.1.1 Wound Healing 
 The healing of acute wounds is a dynamic process consisting of four main 
overlapping phases; haemostasis, inflammation, proliferation and remodelling, 
which start as soon as the injury occurs (Diegelmann & Evans, 2004). These phases 
utilise soluble mediators, blood-derived cells, the extracellular matrix and 
parenchymal cells (Singer & Clark, 1999). 
 Following wounding, components in the blood such as platelets enter the 
injury site and become exposed to collagen and the extracellular matrix. This first 
phase is made up of two stages: development of the fibrin clot and coagulation (Li 
et al, 2007). Platelets release clotting factors, growth factors and cytokines 
including  platelet derived growth factor (PDGF), that initiates the chemotaxis of 
neutrophils, macrophages, smooth muscle cells and fibroblasts, and transforming 
growth factor β (TGFβ) and monocyte chemoattractant protein-1 (MCP-1) that 
mediate the infiltration of  monocytes and macrophages (Dipietro, 1995). TGFβ also 
stimulates macrophages to release fibroblast growth factor (FGF), PDGF, tumour 
necrosis factor-α (TNF-α) and interleukin-1 (IL-1) (Bennett & Schultz, 1993). 
Platelets initiate the formation of a fibrin clot at the wound site to create a 
provisional matrix and re-establish haemostasis (Singer & Clark, 1999). 
 After the haemostasis stage, neutrophils are attracted to the wound site by 
the release of the cytokines in the inflammatory phase of healing such as 
interleukin-1β (IL-1β), interleukin-6 (IL-6) and interferon-γ (IFN-γ) (Bennett & 
Schultz, 1993), and begin to phagocytose debris, pathogens, damaged non-
functional cells and damaged matrix components (Diegelmann & Evans, 2004). This 
occurs within 24 hours following the injury. The activation of mast cells also occurs 
during this phase, resulting in the release of granules containing enzymes, 
histamine and active amines that disrupt surrounding blood vessels and cause the 
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extravasion of blood constituents (Singer & Clark, 1999). By allowing the leakage of 
components from blood vessels, mast cells promote the passage of other cells into 
the wound site. This leads to the activation of fixed tissue monocytes into 
specialised wound macrophages when the monocytes are exposed to matrix 
proteins (Singer & Clark, 1999), the induction of phagocytosis by lymphocytes and 
the release of growth factors and cytokines such as PGDF and TGFβ (Broughton et 
al, 2006). During this inflammation stage, the wound site is phagocytosed of foreign 
material, dead cells and debris before fibroblasts arrive at the wound site to begin 
the overlapping proliferation stage.  
  A new matrix is generated via deposition of collagen by the fibroblasts and 
crosslinked so that the overlapping remodelling stage can begin. Collagen provides 
strength, integrity and structure to the healing wound (Reinke & Sorg, 2012). TGFβ 
increases the gene transcription of collagen, proteoglycans and fibronectin as well 
as the decrease in secretion of proteases responsible for matrix breakdown by 
stimulating the release of protease inhibitors (Diegelmann & Evans, 2004; 
Broughton et al, 2006). Epithelisation is stimulated by endothelial growth factors 
and forms an epithelial bridge which then dissolves (Singer & Clark, 1999). The pH 
at the wound site is lowered leading to reduced oxygen tension and increased 
lactate that induce a new blood supply through angiogenesis and 
neovascularisation (Witte & Barbul, 1997). This process is stimulated by vascular 
endothelial growth factor (VEGF), FGF and TGFβ (Singer & Clark, 1999).  
 The wound closes when the epithelial cells and the new matrix interact. This 
causes wound contraction; the movement of the tissue towards the direction of the 
centre of the wound which is supported by the release of nerve growth factor and 
interleukin-8 (IL-8) (Reinke & Sorg, 2012).  
 There are four main responses after an injury. Normal repair occurs when 
equilibrium is re-established without issue. The second is excessive healing; where 
the host creates too much connective tissue leading to fibrosis and altered 
structure. The third is deficient healing where not enough connective tissue is 
generated leading to weak and unstable wound repair (Reinke & Sorg, 2012). The 
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final type is regeneration, where there is a loss of structure and function due to the 
injury but the host has the ability to regenerate the affected tissues and their 
functionality. Humans have lost this regeneration ability in general but some tissues 
such as the liver, nerves and foetal tissue can still exhibit this trait (Reinke & Sorg, 
2012).  
 
1.1.2 Age-Related Impaired Healing 
The definition of impaired healing is a wound, which has failed to proceed 
through the phases of healing in an orderly and timely process (Lazarus et al 1994), 
and they are characterised by a pronounced inflammatory profile. By general 
definition, age-impaired healing only relates to the delay in healing rather than an 
impairment on the quality of healing (Guo & Dipietro, 2010). 
In age-impaired wound healing there is a delay in most of the major 
processes of wound healing and inflammation. Swift et al (1999) discovered that 
aged mice showed a delay in angiogenesis with a decline in capillary growth as well 
as a delay in re-epithelialization and collagen synthesis. This study also identified 
that wounds on the aged mice contained less of the angiogenic mediators fibroblast 
growth factor-2 and VEGF than wounds in young mice (Gosain & DiPietro, 2004).  In 
aged wounds, there is a different inflammatory profile when compared to young 
wounds such as delayed T-cell infiltration, alterations in cytokine production and 
reduced macrophage phagocytic capacity (Swift et al, 1999).   
 
1.1.3 Chronic Wounds 
  Chronic wounds form when healing is deficient and when inflammation is 
not resolved in the wound healing process. Most chronic wounds are associated 
with ischaemic vascular disease, diabetes mellitus, venous stasis disease or 
sustained pressure over bony joints leading to ischaemic events in local tissues (Guo 
& DiPietro, 2010). In the UK, 200,000 patients have a chronic wound with the 
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National Health Service (NHS) budgeting an estimated £2.3 billion - £3.1 billion 
annually to treat these wounds. However, one in three chronic wounds are 
reported to be unhealed after six months, and one in five for over a year (Posnett & 
Franks, 2008). In the USA, chronic wounds affect 3-6 million people with 85% of 
these being over the age of 65 (Guo & DiPietro, 2010) indicating that the issue 
increases with age. 
 By definition, a chronic wound is a wound that fails to proceed through the 
phases of wound healing in the appropriate order and within an acute wound 
healing time frame. Although various types of chronic wound have different 
aetiologies, all chronic wounds share similar features. These include excessive and 
prolonged inflammation and tissue breakdown (Frykberg & Banks, 2015), 
production of pro-inflammatory cytokines, proteases and reactive oxygen species, 
often with the addition of persistent infection (Frykberg & Banks, 2015).  
   
1.1.4 Inflammation 
 Inflammation is the innate protective response of the body in response to 
stimuli such as injury, pathogens or damaged cells. The inflammatory stages of 
wound repair are subdivided into cellular and vascular responses with the main 
function of this process being to cease the stimuli that are causing the inflammation 
and to clean up the damage afterwards (Li et al, 2007). This process consists of 
many other smaller processes such as phagocytosis and apoptosis, in order for the 
tissue to repair itself (Li et al, 2007). 
 There are five main features of inflammation. Calor and Ruber, meaning 
heat and swelling, occur due to vasodilation and increased blood flow. Tumor 
(swelling) occurs due to increased vascular permeability allowing plasma fluid to 
leak out into the tissues. Dolor (pain) occurs because of the increased fluid pressure 
around nerve endings in the tissue. The last feature is functio laesa, a loss of 
function of the tissue while there is an attempt at repair, caused by a combination 
of the other four features (Freire & Van Dyke, 2013).  
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Inflammation is the process of the recruitment of circulating leukocytes 
from the blood, their accumulation in tissues and their activation to destroy 
microbes. Many of these reactions need cytokines; produced by dendritic cells, 
macrophages, neutrophils, monocytes as well as other cell types from the innate 
immune system (Koh & DiPietro, 2011). 
 There needs to be a balance with inflammation. The main function of this 
process is to remove damaged cells and debris to ensure successful resolution of 
the injury and to prevent progressive bacterial infection (Medzhitov, 2010). 
However, excessive inflammation can lead to numerous degenerative diseases such 
as chronic wounds, rheumatoid arthritis and atherosclerosis. This is termed chronic 
inflammation and is associated with tissue destruction observed in chronic wounds 
(Koh & DiPietro, 2011). 
 Acute inflammation tends to have an immediate onset caused by injury or 
bacterial infection and is driven by neutrophils, eosinophils and mononuclear cells. 
Acute inflammation within the wound healing process typically resolves within a 
few days (Eming et al, 2007). Chronic inflammation, in contrast, tend to have a 
delayed onset and can last months or years. Chronic wounds are characterised by 
excessive and prolonged inflammation (Gethin, 2012). Chronic inflammation is 
characterised as abundant neutrophil infiltration with associated reactive oxygen 
species and destructive proteolytic enzymes such as collagenase and elastase that 
cause the degradation of the dermal matrix (Gethin, 2012). The usual outcome of 
chronic inflammation in various disease states is tissue degeneration, fibrosis or 
necrosis (Gethin, 2012). In chronic wounds for example, there is pronounced tissue 
breakdown due to inflammatory mediators (Medzhitov, 2010). 
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1.1.5 Role of Monocytes and Macrophages in Inflammation 
One of the major cell types in inflammation are the monocytes. Monocytes 
are a subset of white blood cells that circulate through the human body within the 
cardiovascular system. These cells have the potential to migrate into tissues and 
differentiate into macrophages or dendritic cells when there is infection or tissue 
damage (Auffray et al, 2009). Evidence shows that the monocyte contribute to the 
inflammation process by sensing changes in environment caused by exposure to 
pathogens or tissue damage (Xiong & Pamer, 2015). 
When recruited to the site of infection or tissue damage, monocytes 
become activated and in response produce numerous factors including TNF-α and 
inducible nitric oxide synthase (iNOS) which is dependent upon TLR-MYD88 
signalling and IFN-γ. Activation allows monocytes to participate in the clearance of 
pathogens (MacMicking et al, 1995). The production of iNOS leads to the 
production of nitric oxide (NO) from phagocytic cells, including monocytes and 
macrophages, which is involved in the killing of bacteria through the induction of 
DNA damage and the disruption of bacterial metabolism (Nathan & Shiloh, 2000). 
Inflammatory monocytes play a role in the activation of other immune cells 
in the process. Monocytes can present bacterial antigens to other cells in the 
immune process, such as T-cells, and activate them to participate in the immune 
response (Xiong & Pamer, 2015). Monocytes are released from the bone marrow 
into circulation and over the duration of a few days they seed into the tissues 
around the body, including the spleen where they are stored (Murray & Wynn, 
2011). When the monocytes extravasate though the endothelium they are 
differentiated into macrophages thereby increasing the pool of tissue-resident 
macrophages in preparation for an immune response (Murray & Wynn, 2011).  
Macrophages are a subset of white blood cells that have differentiated from 
monocytes. These cells can be located throughout the tissues in the human body. 
The main role of macrophages is to ingest and process both foreign materials and 
dead cells through phagocytosis, as well as activating other macrophages though 
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the release of inflammatory signals such as cytokines (Hart, 2002b). These can 
include ‘professional’ macrophages which have receptors for signals that are not 
normally found in healthy tissues. These include scavenger receptors on their 
surface which bind apoptotic and necrotic cells, opsonised pathogens and cell 
debris (Mantovani et al, 1972). 
Macrophages are divided into subpopulations based upon their localisation 
in the body and their function. For example, this can range from osteoclasts in the 
bone, alveolar macrophages in the lung and Kupffer cells in the liver. These 
subpopulations can then be further classified into subsets based upon the 
macrophage phenotype (Mosser & Edwards, 2008). Classically activated 
macrophages (M1 macrophages) function in the defence of the host against viruses, 
bacteria and fungi as well as having anti-tumour effects. Alternatively activated 
macrophages (M2 macrophages) have an anti-inflammatory function mainly in the 
wound healing process (Sutterwala et al, 1997; Sutterwala et al, 1998). Regulatory 
macrophages secrete interleukin-10 (IL-10) in response to Fc-γ receptor ligation. 
Tumour associated macrophages suppress antitumor immunity. It has been shown 
however that these subsets of macrophages are flexible and will re-programme 
their function dependent upon the environment and the signals that are produced 
(Mosser & Edwards, 2008).  
In macrophage-depleted wounds, tissue debridement and new-tissue 
deposition is severely impeded (Trowbridge & Emling, 1997) suggesting that 
macrophages are involved in acute wound debridement but also have a crucial role 
in inducing tissue formation (Trowbridge & Emling, 1997). Macrophages conduct 
phagocytosis and release proteinases into their surroundings to clear wound debris, 
pathogens and apoptotic neutrophils (Trowbridge & Emling, 1997).  
When macrophages are exposed to the environment at the site of an acute 
wound they start to synthesise a variety of intercellular signalling molecules 
(growth, regulatory and chemotactic factors) which recruit other inflammatory 
cells, together with cells required for new tissue synthesis (Hart, 2002a).   
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1.2 C-Reactive Protein 
1.2.1 Structure and Function 
There is increasing evidence that C-reactive protein (CRP), an inflammatory 
protein, may play a role in the inflammation and wound healing processes. During 
the cutaneous wound healing process a number of cytokines and inflammatory 
mediators are secreted by inflammatory cells, including TNFα, IL-6 and migration 
inhibitory factor (MIF), alongside an increased expression of C-reactive protein 
(Black et al, 2004).   
CRP is a homopentameric acute-phase inflammatory protein that exhibits 
elevated expression during inflammatory conditions such as rheumatoid arthritis, 
some cardiovascular diseases and infection (Du Clos & Mold, 2004). As an acute 
phase protein this means that the plasma concentration of the protein increases or 
decreases by at least 25% during inflammatory disorders (Gabay & Kushner, 1999). 
The highest concentrations of CRP are found in the serum and it has been shown 
that during some infections levels can increase up to 1000-fold (Thompson et al, 
1999). However when the stimuli ends, values decrease exponentially over 18-20 
hours, close to the half-life of CRP (Ridker, 2003). CRP plasma levels have been 
reported to increase from around 1µg/ml to over 500µg/ml within 24-72 hours of 
severe tissue damaging effects such as trauma and progressive cancer (Ciubotaru et 
al, 2005). IL-6 is considered to be the main inducer of the CRP gene, with IL-1 
enhancing the effect (Szalai et al, 1998). However even though IL-6 is necessary for 
the induction of the CRP gene, it cannot achieve this alone (Weinhold et al, 1997). 
 CRP is a phylogenetically/highly conserved plasma protein that was initially 
discovered in 1930 by Tillet and Francis while investigating the sera of patients 
suffering the acute stage of Pneumococcus infection (Tillet & Francis, 1930). CRP 
was named for its specificity of calcium binding for phosphocholine (PCh), which is 
also a part of the activation of the complement pathway of innate immunity 
(Volankis, 2001). CRP has many homologs in vertebrates and some invertebrates 
(Black et al, 2006) and is a member of the pentraxin family which also includes 
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other structurally related molecules such as serum amyloid A (Gewurz et al, 1982). 
Transcriptional induction of the CRP gene mainly occurs in the hepatocytes in the 
liver in response to increased levels of inflammatory cytokines, especially IL-6 
(Boras et al, 2014). The role of CRP is that it can activate the classical complement 
pathway through the recognition of phosphorycholine and activating C1q in the 
pathway (Schwalbe et al, 1992). 
There are many factors that can alter baseline CRP levels including age, 
gender, smoking status, weight, lipid levels and blood pressure (Hage & Szalai, 
2007). The average levels of CRP in the serum in a healthy Caucasian is around 
0.8mg/L but this baseline can vary greatly in individuals due to other factors, 
including  polymorphisms in the CRP gene (Devaraj et al, 2006). The human CRP 
gene can be found at 1q23.2 on the long arm of chromosome 1 and to date there 
have been no allelic variations or genetic deficiencies discovered for this gene, 
though some polymorphisms have been identified (Hage & Szalai, 2007). The 
baseline levels of CRP are regulated by genetic variations in the number of 
dinucleotide repeats found in the intronic region of the gene, with the suggestion 
that up to 50% of baseline variance is due to these variations (Eisenhardt et al, 
2009).  
There is no significant seasonal variation in base-line CRP concentration; 
however, twin studies show a significant heritable component in base-line CRP 
values that is independent of age and body mass index (BMI) (Pepys & Hirschfield, 
2003). Pankow et al (2001) found evidence that inter-individual variation in blood 
CRP levels is 35-40% heritable. Raised CRP levels are typically associated with 
disease but liver failure is one condition observed to impair CRP production. Very 
few drugs reduce elevated CRP levels unless they treat the underlying pathology 
that is causing the acute-phase stimulus (Pepys & Hirschfield, 2003).  
 
 
 
10 
 
1.2.2. Isoforms of C-reactive Protein 
 The pentameric protein, termed native CRP (nCRP) is characterised by a 
discoid configuration of five identical non-covalently bound subunits, each 206 
amino acids long with a molecular mass of about 23kDa (Figure 1.1). These five 
subunits lie in the same orientation around a central pore and arranged in a 
characteristic ‘lectin fold’ with a two-layered beta sheet (Eisenhardt et al, 2009).  
Each subunit lies with the PCh binding site facing the ‘recognition’ face of the nCRP 
molecule (Boncler & Watala, 2009). The molecule has a ligand binding face which 
has a characteristic feature of having two calcium ions per protomer. These ions are 
greatly important for the stability and binding of ligands. The ‘opposite’ face 
interacts with the C1q aspect of the complement pathway as well as interacting 
with Fc receptors (Du Clos & Mold, 2004).   
 
 
 
 
 
 
 
 
The pentameric protein is synthesised primarily in liver hepatocytes but has 
also been reported to be synthesised in other cell types such as smooth muscle cells 
(Calabró et al,  2003), macrophages (Devaraj et al, 2009), endothelial cells (Pasceri 
et al, 2000), lymphocytes (Kuta & Baum, 1986) and adipocytes (Calabró et al,  
2005). CRP is first synthesised as monomers and then assembled into the pentamer 
Figure 1.1 – Structure of human pentameric C-reactive protein as viewed down the 
5-fold symmetry axis. The effector face is on top with the opposite face where 
calcium and PCh binding sites underneath (Taken from Shrive et al, 1996) 
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in the endoplasmic reticulum of the cell.  In hepatocytes, the pentameric protein is 
retained in the endoplasmic reticulum by binding to two carboxylesterases, gp60a 
and gp50b (Macintyre et al, 1994). While in a resting state, the CRP is released 
slowly however in response to an increase in cytokine levels, the binding to these 
carboxylesterases decreases and secretion time is reduced, thus allowing an influx 
of CRP to be seen in response to an inflammatory stimulus such as bacterial 
infection or injury (Du Clos & Mold, 2004). The stimulation of CRP synthesis mainly 
occurs in response to pro-inflammatory cytokines, most notably IL-6 and to a lesser 
degree IL-1 and TNF-α (Zhang et al, 1996). 
Pentameric CRP can be irreversibly dissociated, with the resultant free 
subunits (Figure 1.2) termed monomeric (or modified) CRP (mCRP). The dissociation 
of nCRP into free subunits has been observed at either high concentrations of urea 
(Potempa et al, 1987) or high temperatures in the absence of calcium (Potempa et 
al, 1983), although the precise process is not fully documented. Taylor and Van den 
Berg (2006) found that by increasing the temperature of the nCRP to 90°C allowed 
for total dissociation of the protein, but near 100% monomerisation can also be 
achieved at 70°C, with the process starting after 10 minutes and taking nearly an 
hour to complete. This process was sped up to 5 minutes at 63°C when there was 
an absence of calcium. Dissociation has also occurred under exposure of nCRP to 
lysophosphatidylcholine (LPC), a lipid messenger exposed on cell membranes, 
which is generally found in apoptotic cells or activated platelets (Kim et al., 2002).  
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The mCRP molecules are distinguished from nCRP by their different 
antigenic, biological and electrophoretic activities (Kresl et al, 1998) and by the fact 
they express different neoepitopes (Khreiss et al, 2004). The two isoforms of CRP 
have been shown to have distinct biological functions in the inflammatory process. 
For example, Khreiss et al (2004) provided evidence that nCRP suppresses 
adherence of platelets to neutrophils, whereas mCRP enhances these adhesive 
interactions. This difference in function can be explained by that the two isoforms 
having different types of Fcγ-receptor involved in the signalling process; mCRP 
utilises the low-affinity immune complex binding immunoglobulin G (IgG) FcγRIIIb 
(CD16b) on neutrophils, FcγRIIIa (CD16a) on monocytes while nCRP binds to the 
low-affinity IgG receptor FcγRIIa (CD32) (Bharadvaj et al, 1999; Stein et al, 2000; 
Tebo & Mortensen, 1990).  
Evidence shows that nCRP tends to exhibit a more anti-inflammatory 
function relative to the mCRP isoform. It is suggested that this occurs by the nCRP 
binding at sites of tissue injury to limit the generation of the membrane attack 
complex (MAC) and C5a, thus inhibiting complement activation (Thiele et al, 2014). 
On the other hand, mCRP had marked pro-inflammatory properties in vitro and in 
Figure 1.2- Structure of human monomeric C-reactive protein (mCRP). The β-
strands are labelled A-N with the positions of key amino acid residues indicated. 
Also two ligated calcium ions are shown as spheres. (Taken from Shrive et al, 
1996) 
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vivo by promoting monocyte chemotaxis as well as the recruitment of circulating 
leukocytes to areas of inflammation via Fcy-RI and Fcy-RIIa signalling (Thiele et al, 
2014). 
 
1.2.3. C-Reactive Protein and Complement 
 Complement is one of the major defences of the human immune system 
which is involved in the clearance of foreign particles and organisms once they have 
been recognised by antibody. The complement pathway is made up of 35 plasma or 
membrane proteins that is an important system in immunity and the defence of the 
host against microbial infection. The components of the complement pathway can 
be activated in three different pathways to trigger a cascade of proteins, which are 
used to help bind microbial surfaces for the immune system to recognise and 
activate phagocytosis (Li et al, 2007). The classical pathway is triggered by a target 
bound antibody whereas the lectin pathway is triggered by microbial repetitive 
polysaccharide structures and the alternative pathway is triggered by the 
recognition of other foreign surface structures. Even though the triggers are 
different, the three pathways merge at a pivotal activation of the C3 and C5 
convertases. The majority of the components are synthesised in the liver, C1 in the 
intestinal epithelium and factor D in the adipose tissue (Li et al, 2007). 
CRP has been extensively researched in its role to activate the complement 
pathway. In 1974, Kaplan and Volanakis first described the ability of CRP to activate 
the classical complement pathway using C-polysaccharide and phospholipid ligands 
(Kaplan and Volanakis, 1974). Siegel et al (1974) also showed the same result using 
CRP-protamine complexes. The activation of complement by CRP is considered a 
crucial step since when complement was depleted, the effects of CRP were 
abrogated (Thiele et al, 2014). 
The opposite face of the CRP molecule, complexed with polyvalent ligand or 
chemically cross-linked, binds to C1q and activates the classical complement 
pathway (Du Clos, 2004). This binding however is different from IgG binding as CRP 
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is localised to collagen-like regions rather than the globular head groups of C1q 
(Jiang et al, 1991). C1q is a large 460kDa molecule made up of six identical subunits, 
each made up of 3 structurally similar but distinct polypeptide chains (Agrawal et al, 
2001).  This process requires the use of calcium ions for the stable formation of the 
C1 complex (Paul, 2008). CRP is most effective during the early classical pathway 
activation of C1, C4 and C2 (Mold et al, 1999). This is because the ligand-bound 
interaction with C1q leads to the formation of C3 convertase, triggering the 
complement activation of C1-C4 but with little activation of the late complement 
proteins C5-C9 (Eisenhardt et al, 2009).  
Activation of complement by CRP varies from activation by antibody in that 
CRP has a selective activation of early components without the need to form the 
MAC. In addition to activating the classical complement pathway, it has been 
indicated that CRP can inhibit the alternative complement pathway by decreasing 
C3 and C5 convertase activities and inhibiting the complement amplification loop. 
This is achieved by the recruitment of factor H to the cell surface as well as 
preventing C5 converatase cleaving C5 to recruit neutrophils and prevent the 
formation of the MAC (Marnell et al, 2005).  As levels of CRP increase this causes 
decreased binding of C3b and C5b-9 to liposomes, possibly also explaining the lack 
of C5-C9 consumption by CRP during classical pathway activation (Mold et al, 1999). 
 
1.2.4. Confliction in C-reactive Protein Research 
 There have been numerous research papers looking at the roles and effects 
of CRP as a whole however there can be a source of conflict when addressing these 
papers.  
 There are two main issues that need to be considered when researching 
previous studies in CRP. The first is that a majority of papers refer to CRP as a single 
entity; disregarding the fact that there are two isoforms of the protein which have 
distinct structures and functions. This means it can be sometimes impossible to 
determine which of the isoforms had the causative effect in these studies.  
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 The second issue is taken into consideration with some older studies. These 
papers state that CRP was measured. It is known now that these papers were 
measuring nCRP due to a lack of antibodies and assays that could be used to detect 
mCRP. It can also be assumed that more recent papers have the same issue as their 
antibodies used to detect mCRP are not commercially available and can only be 
accessed by a few laboratories.  
 Taking these two points into consideration it is assumed that most previous 
studies that refer to CRP have analysed the native form of the protein unless 
otherwise stated.  
 
1.2.5. C-Reactive Protein and Estrogen 
There is emerging research that hormone replacement therapy (HRT) causes 
CRP levels to increase significantly in postmenopausal women. This has many 
effects including an increased risk of cardiovascular events (Kurtz, 2011). It was also 
observed that in older men and postmenopausal women, estrogen caused a 
variable response in CRP levels whereas testosterone had no effect providing 
evidence of a link between estrogen and CRP levels (Corcoran et al, 2010). Other 
studies have shown that a correlation between CRP and estrogen levels exist. 
Ridker et al (1999) found that apparently healthy postmenopausal women had 
nearly two-fold increased levels of CRP when they were taking HRT. As CRP is a 
marker of cardiovascular risk, this suggested that those on HRT were at a higher risk 
of cardiovascular implications. 
Most of the research conducted into the interactions of CRP and estrogen is 
based upon cardiovascular risk, with no investigations of wound healing performed 
to date.    
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1.2.6. C-reactive Protein in Disease Pathology 
The majority of research into CRP has focused upon the role of CRP and its 
isoforms their effects upon the risk of cardiovascular risk and stroke. However, 
correlations between CRP levels and other disease states have also been found. 
Studies conclude that CRP levels increase due to inflammation. CRP is used as a 
clinical marker of inflammation, as elevated serum levels are a strong independent 
predictor of cardiovascular disease in asymptomatic individuals (Ridker et al, 2002). 
CRP levels have been linked to prognosis in patients with atherosclerotic disease, 
congestive heart failure, atrial fibrillation, myocarditis, aortic valve disease and 
heart transplantation, confirming that it has an active role in the pathophysiology of 
cardiovascular diseases (Osman et al, 2006).  
High sensitivity assays, such as nephelometric assays, are used to detect 
baseline levels of CRP and are used to detect patients who are at risk of 
cardiovascular disease. An individual with a CRP level higher than 3mg/L has an 
increased risk of coronary heart disease (Kushner, 1990) and this risk increases in 
those with type 2 diabetes (Soinio et al, 2006). 
Increased levels of CRP have also been found in patients suffering from 
appendicitis, cholecystitis, pancreatitis and meningitis (Clyne & Olshaker, 1999). In 
patients suffering with the symptoms of appendicitis, those with CRP levels greater 
than 25mg/L after 12 hours were given a definitive diagnosis of acute appendicitis 
(Albu et al, 1994). When symptoms of cholecystitis were combined with a CRP level 
of over 30mg/L this led to an accurate diagnosis, with 78% sensitivity indicating  
CRP was a more sensitive marker than erythrocyte sedimentation rate and white 
cell count in the diagnosis (Juvonen et al, 1991). In terms of pancreatitis, CRP levels 
of more than 210mg/L were able to discriminate between mild and severe 
etiologies, with 83% sensitivity and 85% specificity (Wilson et al, 1989).   
Serum CRP levels have been able to accurately diagnose bacterial meningitis 
with levels also corresponding to the resolution of symptoms after treatment with 
antibiotics (Peltola, 1982). When cerebrospinal fluid was analysed for CRP the test 
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had a sensitivity of 100% with 94% specificity and was more accurate than 
neutrophil count and gram stain in the diagnosis of infection (Corrall et al, 1981). 
However it is stated that there is the chance for false positive and negatives with 
this test. False negatives arise if the test is conducted too early in the infection 
process or if there is poor diffusion of CRP into the cerebrospinal fluid while false 
positives are generated during viral meningitis, brain abscesses and other sources 
of inflammation. This test is also not able to distinguish between bacterial and viral 
infections so cannot aid diagnosis (Gershôm et al, 1986; Macfarlane & Narla, 1985).  
While studies have shown correlations between CRP levels and various 
aetiologies, the precise role of CRP isoforms in disease development and 
progression remains largely unknown. Thus, investigations are required to 
determine the effects of each CRP isoform on specific cellular processes.  
 
1.2.7 C-Reactive Protein and Inflammation 
CRP is mainly classed as an acute marker of inflammation and very little 
research has been conducted into the role that CRP plays in inflammation, 
particularly in relation to wound healing. CRP levels are known to increase 
dramatically in response to injury, infection and inflammation.  
CRP is the principal downstream mediator of the acute phase response 
following an inflammatory event and is primarily synthesised by IL-6-dependent 
hepatic biosynthesis (Pradhan et al, 2001). The main role of CRP in inflammation 
tends to focus around the activation of the C1q molecule in the complement 
pathway leading to the opsonisation of pathogens. Although CRP can initiate the 
fluid phase pathways of the host defence by activating the complement pathway, it 
can also initiate cell-mediated pathways by activating complement as well as to 
binding to Fc receptors of immunoglobulin G (Pradhan et al, 2001). CRP binds to Fc 
receptors with the resulting interaction leading to the release of pro-inflammatory 
cytokines (Du Clos, 2000). CRP also has the ability to recognise self and foreign 
molecules based on pattern recognition, something that other activators of 
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complement such as IgG cannot achieve since these molecules only recognise 
distinct antigenic epitopes (Du Clos, 2000).  
 
1.3 The Effect of CRP Isoforms on Inflammation Processes 
 Evidence suggests that CRP is not only just a marker of inflammation but 
also plays an active role in the process. Most previous research only refers to CRP as 
a singular molecule and does not identify between the two isoforms. This would 
offer an explanation as to why there is conflicting evidence in literature, with 
reports of both pro-inflammatory and anti-inflammatory effects attributed to the 
protein. Thus to provide greater clarity in the field, this study investigated the 
differential effects of each CRP isoform on specific inflammatory processes. Since 
antibodies for mCRP are not commercially available, very few laboratories in the 
world are able to conduct studies to investigate the mCRP isoform. However, since 
non-commercial antibodies specific for each isoform were available during this 
project, the study was in a unique position to be able to investigate both CRP 
isoforms and differentiate between their effects on inflammatory processes.   
 
 1.3.1. Inflammatory Signalling Pathways and Inhibition 
 Cells require the use of various intracellular pathways in order to regulate 
cellular processes such as proliferation, survival and gene expression.  It can be 
suggested that CRP utilises these signalling pathways to exert some of the effects 
observed in previous research.  
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1.3.1.1. The Phosphoinositide-3 Kinase (PI3K) Pathway and C-Reactive Protein 
 The phosphoinositide-3 kinase (PI3K) pathway is an intracellular signalling 
pathway important in regulating the cell cycle and is important in processes 
involved in cellular quiescence, proliferation, cancer and longevity (Cantley, 2002). 
The PI3 kinases are a group of enzymes that catalyse phosphorylation of one or 
more inositol phospholipids in the 3’ position of the inositol ring. The main focus of 
these enzymes is to catalyse the production of phosphatidylinositol-3,4,5-
triphosphate (PI(3,4,5)P3) from the plasma membrane lipid phosphatidylinositol-
4,5-biphosphaste (PI(4,5)P2) (Cantley, 2002). The enzyme is a heterodimer 
consisting of a 110kDa catalytic subunit and a 85kDa regulatory subunit allowing it 
to selectively phosphorylate inositol lipids at the 3’ position (Norman et al, 1996). A 
simplified version of the PI3K pathway can be seen in Figure 1.3. 
Figure 1.3 – A simplified PI3 kinase pathway. Growth factors bind to the 
receptor tyrosine kinase which activates PI3K. This leads to the conversion of 
PIP2 to PIP3, leading to the phosphorylation of Akt. When phosphorylated Akt 
acts upon multiple substrates. Wortmannin inhibits PI3K (see Section 1.3.1.2 for 
further details). Modified from Porta et al (2014). 
 
PI3K - phosphoinositide-3 kinase; PIP2 - phosphatidylinositol-4,5-biphosphaste; 
PIP3 - phosphatidylinositol-3,4,5-triphosphate ; PDK1 - Pyruvate Dehydrogenase 
Kinase, Isozyme 1; PDK2 - Pyruvate Dehydrogenase Kinase, Isozyme 2 
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There are three classes of PI3K (I, II and III) and each of them have different 
isoforms. Each class of kinase has a different selectivity to ensure there is the 
generation of several types of molecular messenger produced in order to activate 
tyrosine growth factors such as epidermal growth factor receptors (EGFR) and 
insulin-like growth factor receptors (IGF-R) as well as cell adhesion molecules such 
as integrins, G-protein coupled receptors (GPCR) and oncogenes (Domin & 
Waterfield, 1997).  
 
1.3.1.2. Inhibition of the PI3K Pathway by Wortmannin 
 The PI3K pathway can be irreversibly inhibited by wortmannin; a fungal 
metabolite isolated from Penicillium wortmanni (Brian et al, 1957). This natural 
product had early signs of being anti-inflammatory and anti-proliferative (Wiesinger 
et al, 1974); however the most potent target of wortmannin were the class I PI3 
kinases. These kinases are inhibited with an IC50 in the range of 1-10nM (Knight, 
2010). There is some evidence that class II PI3 kinases are inhibited by wortmannin 
but not as strongly as the class I group (Walker et al, 2000).  
 Wortmannin inhibits PI3 kinases by covalent inactivation of the enzyme 
(Walker et al, 2000) as seen in Figure 1.3. This is achieved by the electrophillic furan 
ring of the wortmannin molecule being targeted by a lysine residue in the kinase 
active site. This leads to the ring opening forming a stable enamine. The lysine 
residue is conserved in all PI3 kinases so this amino acid conservation leads to 
inhibition of multiple kinases. The wortmannin molecule also binds to the kinase 
with high affinity through the use of multiple hydrogen bonds and hydrophobic 
interactions (Walker et al, 2000). 
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1.3.1.3. The Ras/Raf/Mitogen-Activated Kinase/ERK Kinase Pathway (MEK 
pathway) and C-Reactive Protein 
The Ras/Raf/Mitogen-activated kinase/ERK kinase pathway (MEK pathway) 
is an extracellular regulated kinase cascade which couples signals from cell surface 
receptors to transcription factors to help in the regulation of gene expression 
(Chang et al, 2003). This pathway plays a role in the proliferation of cell and the 
prevention of apoptosis. There are many molecules involved in this pathway (Figure 
1.4) including small GTP-binding proteins such as Ras, Raf which is a 
serine/threonone kinase and their downstream transcription factor targets such as 
nuclear factor-κβ (NF-κβ), AP-1 and c-Myc (Chang et al, 2003).  
Figure 1.4 The Ras/Raf/Mitogen-activated kinase/ERK kinase pathway (MEK 
pathway). This pathway shows both the classical activation pathway though the 
activation of RAS and the non-classical pathway through the activation of RHO. 
PD98059 is a MEK pathway inhibitor while SB203580 is a p38 MAP kinase 
inhibitor. Modified from Irrera et al (2014). 
GPCR –G-protein coupled receptor; NF-κβ – Nuclear Factor-κβ; MMK – multiple-
mitotic kinase; MKK – MAP Kinase Kinase; JNK – c-Jun N-terminal kinase; TNF-α 
– Tumour Necrosis Factor-α; IL-1 –Interleukin 1; IL-6 – Interleukin-6; MAP – 
mitogen-activated protein 
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The MEK pathway is heavily upregulated in conditions such as cancer, where 
mutations lead to the overexpression of receptors. This pathway also has a role in 
the regulation of apoptosis through the post-translational phosphorylation of 
apoptotic regulatory molecules (McCubrey et al, 2007). 
 
1.3.1.4 Mitogen Activated Protein Kinases (MAPK) and C-Reactive Protein 
 Mitogen activated protein kinases (MAPKs) are a group of kinases involved 
in cell differentiation, apoptosis and autophagy and are related to the MEK 
pathway. There are four mitogen activated protein (MAP) kinases which have been 
identified and can be activated by a variety of methods (Zhao & Adjei, 2014). These 
kinases are regulated by a phosphoprotein relay system in which a series of three 
proteins are consecutively phosphorylated and activated. The MEK pathway is the 
most characterised MAPK pathway which is classed as the classical pathway 
involving the Ras, Raf, MEK 1 and 2 proteins and ERK proteins (Zhao & Adjei, 2014). 
The non-classical pathway involves other proteins including the p38-MAPK proteins. 
 MAP kinases are implicated as key regulators of inflammatory diseases as 
well as increasing evidence that they can contribute to progression of some 
disorders such as acute pancreatitis (Irrera et al, 2014).  
The p38 mitogen-activated protein kinases react to stress stimuli such as 
heat shock and osmotic shock but can also be activated in response to pro-
inflammatory stimuli such as cytokine levels. There are four of these kinases; p38α, 
β, γ and δ. Activation of these kinases is necessary for cell processes such as gene 
expression, cell survival and cell division (Irrera et al, 2014).  
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1.3.1.5. Inhibition of the MAPK Pathway by MEK 
 MEK 1 and 2 are homologous proteins that are ideal targets for inhibition. 
Both of these proteins have a kinase domain, a MAPK-docking region, a negative 
regulatory region, a proline rich insert and a nuclear export sequence (Liang et al, 
2011). In addition to this structure there is a pocket structure adjacent to the ATP-
binding pocket. When inhibited, conformational changes occur to revert the protein 
into a catalytically inactive state. This non-competitive mechanism does not exert 
its inhibition on the ATP-binding pocket and therefore does not have the same 
adverse effects as other competitive inhibitors (Zhao & Adjei, 2014). Inhibitors of 
this process, such as PD98059, tend to be selective, reversible and cell permeable 
and inhibit MAP kinase activation and subsequent phosphorylation of the MAP 
kinase substrates. They achieve this by preventing the activation of MEK1 and 
MEK2 by upstream kinases; however, they do not inhibit activated MEK or the non-
classical pathway through the p38 MAPK pathway (Alessi et al, 1995). 
 
1.3.1.6. Inhibition of the p38 MAP Kinase Pathway by LML 
 Inhibitors of the p38 MAP kinases, such as SB203580, tend to target the β 
isoforms while not inhibiting the ERK and JNK pathways (Cuena et al, 1995). 
Inhibition is achieved through direct binding of the inhibitor to the kinase. These 
selective inhibitors work by binding to the ATP binding pocket of the kinase. 
However, they do not inhibit the phosphorylation of p38 by upstream kinases 
(Kumar et al, 1999).  
  
`1.3.1.7 C-Reactive Protein and Inhibition by Nystatin 
Nystatin is an inhibitor which is isolated from Streptomyces and is 
considered a polyene antibiotic.  Nystatin is used to treat fungal infections  (Kristanc 
et al, 2012) since it targets the plasma membrane, especially ergosterol in cell 
membrane of fungi, which is the equivalent of cholesterol in human cell 
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membranes. As bacteria are devoid of sterols, nystatin is not effective against these 
types of infections (Kristanc et al, 2012). 
 Nystatin disrupts the plasma membrane of fungal cells, leading to 
membrane leakage by forming barrel-like pores in the lipid bilayer, thus allowing 
potassium and other cell constituents to pass across the membrane and cause cell 
death (Razonable et al, 2005; Coutinho & Prieto, 2003). The formation of pores in 
the bilayer leads to the disturbance of electrochemical gradients and an increase in 
plasma membrane permeability. This permeability allows ions and small molecules 
no bigger than glucose to enter into the cell (Holz & Finkelstein, 1970; Marty & 
Finkelstein, 1975). 
Nystatin also induces the secretion of IL-1β, interleukin-8 (IL-8) and TNF-α in 
toll-like receptor 2 (TLR2)-expressing (but not TLR2-deficient) cells in a dose 
dependent manner, resulting in a pro-inflammatory effect (Razonable et al, 2005). 
The exact mechanism by which nystatin achieves this is still unknown (Kristanc et al, 
2012). 
 
 
1.4 Aims  
 The aim of this project was to determine the effects of the two isoforms of 
CRP on specific inflammatory processes, particularly in relation to wound healing. 
The study utilised various in vitro models of inflammation, together with murine 
models of wound healing to investigate endogenous production or exogenous 
supplementation of CRP isoforms.  
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1.5 Objectives 
The specific objectives of the project were: 
 To determine the localisation of the CRP isoforms in murine histological 
samples of the inflammatory phase of wound healing. 
 To determine endogenous levels of CRP isoforms in unactivated and 
activated  monocyte- and macrophage-like cells grown in culture using in 
vitro models of inflammation, infection and ageing.  
 To analyse the effects of exogenous supplementation  of CRP isoforms on 
monocyte/macrophage: 
o growth and viability 
o apoptosis 
o nitric oxide production 
o cytokine production 
o phagocytosis 
 To analyse the effects of pH and calcium concentration on the conversion of 
nCRP to mCRP. 
 To investigate the effects of estrogen on circulating and wound levels of the 
CRP isoforms using a murine model of age-related impaired healing. 
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Chapter 2: General Materials and Methods 
 
2.1 Ethics 
Ethical approval for the study was granted by Manchester Metropolitan 
University (MMU), including the use of murine blood and wound protein samples 
kindly provided by Dr M Hardman, University of Manchester (UoM) in strict 
accordance with UK Home Office regulations and UoM ethical approval. 
 
 
2.2 Procedure 
2.2.1 Cell Culture 
The commercial U937 cell line was used to generate 
monocyte/macrophage-like cells in an in vitro model of inflammation. U937 cells 
were activated with lipopolysaccharide (LPS) from the cell wall of Escherichia .coli to 
model responses following bacterial infections and differentiated into a 
macrophage-like phenotype using phorbol 12-myristate 13- acetate (PMA). Cell 
viability was assessed using trypan blue exclusion in which cellular uptake of the 
dye indicates cell death.  
  
2.2.2 C-reactive Protein Purification 
 Commercial C-reactive protein (CRP) was purchased in its native form. 
However it was imperative to confirm the purity of the native isoform since the 
protein can dissociate into the monomeric form. The commercial CRP also 
contained sodium azide to prevent microbial contamination of the protein during 
transit and storage but it removal was required prior to use in cell culture. Thus, the 
commercial native CRP sample was purified to ensure exclusion of the monomeric 
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isoform and remove the sodium azide. The purification was conducted in a two-
step process. The first step utilised the float-a-lyzer dialysis system that 
incorporates a low protein-binding synthetic membrane with a molecular weight 
cut-off of 50 KDa. This dialysis allowed the larger pentamer to be retained in the 
unit while smaller contaminants (including mCRP and sodium azide) diffused across 
the membrane. The dialysis buffer contained calcium in order to prevent the 
dissociation of the pentamer to the monomer, thus maintaining the purity of nCRP. 
The second step utilised a phenyl hitrap that consists of a column containing phenyl 
sepharose beads for high-resolution hydrophobic interaction chromatography. This 
column contained hydrophobic groups that bind proteins in aqueous solutions in a 
manner that is dependent on protein structure. 
 To create the mCRP isoform the pentameric protein was dissociated. This 
was achieved through the chelation of the protein using 
ethylenediaminetetraacetic acid (EDTA) and urea to break the covalent bonds of 
the pentamer. Dialysis was performed to remove contaminants from the chelated 
protein using a dialysis buffer lacking calcium to aid the process of dissociation. 
Samples were then dot blotted (Section 2.2.3) to ensure purity before being used in 
future investigations.  
After purification both isoforms were run through an endotoxin removal kit. 
This step removed any trace amounts of LPS in order to ensure any biological 
effects induced by the CRP isoforms during subsequent investigations were not 
simply due to contamination with LPS.   The column of the kit contained resin which 
combine cellulose beads and other preservatives as an affinity ligand to bind and 
selectively remove endotoxins.  
The protein concentration of CRP samples were then quantified using a 
bicinchronic acid detection kit which utilises the chemical reaction of converting 
copper II sulphate solution into a CU2+ complex in alkaline conditions followed by 
further reduction to Cu1+.  This sensitive assay allows the quantification of proteins 
against a set of known samples. An example standard curve for this process can be 
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located in Appendix 1.  During the chemical reaction, a colour change from blue to 
purple was proportional to the amount of protein present in the sample. 
 
2.2.3 Dot Blot 
 Nitrocellulose membrane is designed as a matrix to be utilised in the 
detection of protein. The membrane immobilises the protein though hydrophobic 
interactions as well as high salt with low methanol concentrations. The protein 
binds the membrane with high affinity and enables a variety of detection methods 
to be used, including chemiluminescence. 
Samples were blotted onto the membrane and the membrane was then 
treated with a blocking buffer containing a non-target protein which binds to all 
non-specific bindings sites on the membrane, thus blocking subsequent signal 
generation at sites lacking the protein of interest. The membrane was then 
incubated with primary antibody specific for the C-reactive protein. After 
incubation, the membrane was washed to ensure that only bound antibody 
remained and the membrane was then incubated in secondary antibody that binds 
at the exact location as the primary antibody. Since the primary antibody was raised 
in mouse, the secondary antibody was raised against mouse in rabbit. The 
secondary antibody was made up in milk solution to reduce background signal and 
prevent non-specific antigen recognition by the secondary antibody. The secondary 
antibody also had horseradish peroxidase (HRP) attached to it which would allow 
the chemiluminescence kit to bind to the secondary antibody in order to generate a 
signal that can be detected visually. After incubation, further washes were 
conducted before treated with the chemiluminescence kit that works by binding to 
the HRP of the secondary antibody and undergoing a chemical reaction by which 
light is emitted. This chemiluminescent reaction was captured so that the protein 
can be detected and quantified. Example dot blots can be seen in Appendix 2. 
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2.3 Materials 
2.3.1 Cell Culture 
Human monocyte cell line U937 (Health Protection Agency Culture Collections, 
Salisbury) 
RPMI-1640 Media (Lonza, Slough) 
Foetal Bovine Serum (Sigma-Aldrich, Dorset) 
Penicillin-Streptomycin (Lonza, Slough) 
Lipopolysaccharide (Sigma-Aldrich, Dorset) 
Phorbol 12-myristate 13-acetate (Applichem, Darmstadt) 
0.4% Trypan Blue (Lonza, Slough) 
Trypsin (Thermo Fisher Scientific, Loughborough) 
 
2.3.2 C-reactive Protein Purification 
C-reactive Protein, human >95% native, 5mg/ml (MyBioSource, San Diego) 
EDTA/urea buffer: 
 8M Urea (Fisher Scientific, Cheshire) 
 10mM Ethylenediaminetetraacetic acid (Sigma-Aldrich, Dorset) 
 
Dialysis buffer for purifying native C-reactive protein, adjusted to pH 7.4 
 50mM Tris-hydrochloride (Fisher Scientific, Cheshire) 
 2mM Calcium Chloride (Sigma-Aldrich, Dorset) 
 
Dialysis buffer for purifying monomeric C-reactive protein, adjusted to pH 7.3 
 13mM Tris-hydrochloride (Fisher Scientific, Cheshire) 
 50mM Sodium Chloride (Sigma-Aldrich, Dorset) 
Dialysis Tubing 21.5mm (Laboratories Supplies, Nottingham) 
50,000 Da Float-a-Lyzer (Medicell, London) 
Phenyl Hi-trap (Scientific Laboratories Supplies, Nottingham) 
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E-Toxate Endotoxin Kit (Sigma-Aldrich, Dorset) 
1% Sodium Deoxycholate (Sigma-Aldrich, Dorset) 
Bicinchronic Acid Detection Kit (Sigma-Aldrich, Dorset) 
 
2.3.3 Inhibitors 
100nM Wortmannin (Sigma-Aldrich, Dorset) made up in RPMI-1640 media 
100μM SB203580 (LML inhibitor) (MedChem Express, Stockholm) made up in RPMI-
1640 media 
100μM PD98059 (MEK inhibitor) (MedChem Express, Stockholm) made up in RPMI-
1640 media 
25μg/ml Nystatin (Sigma-Aldrich, Dorset) made up in RPMI-1640 media 
 
2.3.4 Dot Blot 
Nitrocellulose membrane (Scientific Laboratories Supplies, Nottingham) 
C-reactive protein buffer, adjusted to pH 7.4 
 140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
 20mM Tris-hydrochloride (Fisher Scientific, Cheshire) 
 2mM Calcium Chloride (Sigma-Aldrich, Dorset) 
 
Primary antibody: Mouse anti-human monomeric-CRP made up 1:10 ratio with 
blocking buffer 
 Mouse anti-human monomeric-CRP 8C10 culture supernatant (this was a 
kind gift from Dr LA Potempa) 
 
Primary antibody: Mouse anti-human native-CRP made up 1:10 ratio with blocking 
buffer 
 Mouse anti-human native-CRP 1D6 culture supernatant (this was a kind gift 
from Dr LA Potempa) 
 
TBS/Tween buffer, adjusted to pH 7.4 
 10mM Tris-base (Fisher Scientific, Cheshire) 
 140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
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 0.1% Tween-20 (Sigma-Aldrich, Dorset) 
 
Blocking buffer, adjusted to pH 7.4 
 1% Albumin from Bovine serum (Sigma-Aldrich, Dorset) in TBS-Tween 
 
Milk Solution, adjusted to pH 7.4 
 5% semi-skimmed milk powder in TBS-Tween 
 
Polyclonal rabbit, anti-mouse immunoglobulins/horseradish peroxidase (HRP) 
(Dako, Cambridge) 
 1:1000 dilution in milk solution 
 
EZ-ECL chemiluminescence detection kit (Geneflow, Lichfield) 
 
 
2.4 Methods 
2.4.1 Cell Culture 
The commercial human monocyte cell line U937 was cultured in RPMI-1640 
media supplemented with 10% foetal bovine serum (FBS) and 2% penicillin-
streptomycin under aseptic conditions at 37°C and 5% carbon dioxide (CO2).  Cell 
growth and viability was assessed using 0.4% trypan blue dye in a 1:1 ratio on a 
Biorad TC10 automated cell counter. Cell viability was maintained above 90% for all 
experimental assays.  
 
2.4.2 Cell Activation 
The U937 cells were activated with 0.05mg/ml lipopolysaccharide (LPS) and 
incubated for a period of 24 hours to model bacterial infection. Cell activation for 
the phagocytosis assay differs from this process; see Section 8.6 for more details on 
this.  
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2.4.3 Cell Differentiation 
The U937 cells were differentiated from monocyte-like cells to macrophage-
like cells using 50ng/ml phorbol-12-myristate 13-acetate (PMA) and incubated for 
72 hours. 
 
2.4.4 C-Reactive Protein Isoform Purification 
The C-reactive protein isoforms were purified from samples of commercial 
native C-reactive protein.  
 
2.4.4.1 Monomeric C-Reactive Protein 
The mCRP was purified using the Potempa method (Potempa et al, 1983). 
The commercial sample was chelated with 10mM EDTA and 8M urea and incubated 
at 37°C for 2 hours. The sample was then transferred to dialysis tubing and placed 
in TBS buffer (0.01 Tris-HCl and 0.05M NaCl) for 24 hours. The sample was checked 
for purity by dot blot, run through an endotoxin kit and quantified using 
bicinchoninic acid (BCA) analysis. 
 
2.4.4.2 Native C-Reactive Protein 
The nCRP was purified using a 50,000Da float-a-lyzer (Medicell, London) and 
left overnight in 2mM CaCl2 buffer. The sample was collected and run through a 
Hitrap hydrophobic interaction chromatography column (GE Healthcare, 
Buckinghamshire). The sample was tested for purity by dot blot, run through an 
endotoxin kit and quantified using BCA analysis. 
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 2.4.5 Endotoxin Removal 
Endotoxins were removed from the purified samples using the E-Toxate Kit. 
The column was conditioned using 1% sodium deoxycholate and basal media. The 
sample was allowed to run into the column and then left for two hours before 
collection. 
 
 2.4.6 Protein Quantification 
The purified protein samples were quantified using BCA analysis according 
to the manufacturer’s instructions. A standard curve was generated using a protein 
standard consisting of albumin from bovine serum (BSA). Samples were incubated 
with the working buffer for 30 minutes at 37°C prior to being read on a plate reader 
at 595nm.  The total protein concentration of unknown samples were quantified 
from the standard curve by interpolation and then normalised prior to storage at -
80oC for subsequent analysis.  
 
 2.4.7 Dot Blot 
Firstly, 5µl of each of the samples were blotted onto two separate 
nitrocellulose membranes. BSA at a concentration of 1mg/ml was used as a 
negative control while known concentrations of mCRP and nCRP were used as 
positive controls to generate a standard curve. The samples were allowed to dry 
and are treated with blocking buffer (1% BSA in TBS-Tween, pH 7.4) for one hour at 
room temperature with 60 rpm rotation. One membrane was then treated with 
anti-nCRP antibodies (1:10 monoclonal anti-native-CRP 1D6 culture supernatant: 
blocking buffer) and the other with anti-mCRP antibodies (1:10 monoclonal anti-
monomeric-CRP 8C10 culture supernatant: blocking buffer). The membranes were 
left overnight at 5°C with 50rpm rotation.  The primary antibody was then removed 
and the membranes were washed five times at five minutes each with TBS-Tween 
buffer. The membranes were then treated with the secondary antibody polyclonal 
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rabbit anti-mouse immungloblins/HRP in 5% milk/TBS-Tween solution for one hour 
with 60rpm rotation. The membranes were washed again five times at five minutes 
each and then treated with the EZ-ECL chemiluminescence detection kit. The image 
is captured using the Genesnap program (Version 7.07, Syngene) in a Syngene GBox 
with a 1 minute exposure time.  
 
2.4.8 CRP Treatment of Cells 
 Cells were treated for each assay with either 100μg/ml mCRP, 250μg/ml 
mCRP, 500μg/ml nCRP or 1000μg/ml nCRP for 24 hours prior to other treatments or 
collection of results as described in the particular method section. 
 
2.4.9 Inhibitors 
Cells were treated with CRP isoforms as previously described (Section 2.4.4) 
but were also simultaneously treated with the four inhibitors mentioned in Section 
2.3.3 at the CRP isoform treatment stage and incubated for 24 hours at 37oC and 
5% CO2. 
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Chapter 3: The Effect of calcium and pH on C-reactive protein 
stability 
 
3.1 Introduction 
 Research has shown that as pentameric CRP dissociates there is a change in 
structure and biological function. The dissociation of nCRP can be achieved in the 
presence of high concentrations of urea (Potempa et al, 1987) or at high 
temperatures (Potempa et al, 1983). Both of these processes need to be conducted 
in the absence of calcium. The process by which nCRP dissociates in the absence of 
calcium is not fully understood. Calcium-dependent binding of CRP to Pch provides 
an indication that calcium ions play a role in the function of CRP. However, nCRP 
can spontaneously dissociate in samples containing little or no calcium (Thiele et al, 
2014). Potempa et al (1983) tested the theory that calcium is required for CRP 
stability and provided evidence that the dissociation of the native protein into its 
monomeric form can be enhanced by the removal of calcium.  
 There has been little research conducted into the effects of changing 
concentrations of calcium on CRP dissociation. Wu et al (2002) showed that the 
spontaneous dissociation of CRP could be promoted by removing calcium but also 
by lowering the pH to acidic concentrations in vitro. Other in vivo methods of 
dissociation include the binding of nCRP to lysophosphatodylcholine monolayers or 
altered cell membranes (Wang & Sui, 2001; Ji et al 2007) and can occur on the 
surface of activated platelets or apoptotic monocytes (Eisenhardt et al, 2009; 
Molins et al, 2011). This dissociation requires the binding of nCRP to 
lysophosphatodylcholine, which is expressed on the cell surface. This is generated 
from phosphatidylcholine generated via the activation of calcium-independent 
phospholipase A2 (Wu et al, 2015). 
These studies would indicate that CRP stability is only assured at an optimal 
pH and calcium concentration and that fluctuations would cause the generation of 
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the more pro-inflammatory mCRP. This could have implications in terms of 
physiology including inflammatory responses during wound repair.   
 As humans age there is a reduction in the concentration of circulating 
calcium. In a normal healthy adult person during youth the concentration of 
calcium in blood is around 10.2mg/dl, which then decreases to around 9mg/dl in 
the elderly (Lansdown, 2002). There is a range of calcium concentrations 
throughout the skin; from 0.5mM in the basal layer to more than 1.4mM in the 
stratum granulosum (Lansdown, 2002). As calcium decreases with age this has an 
inhibitory effect on the generation of estrogen (Weitzmann & Pacifici, 2006), which 
in turn mediates the wound healing process. If the concentration of calcium is 
decreased, healing is generally impaired.  
 Calcium is a regulator in the wound healing process, acting as a signalling 
molecule between cells by regulating cellular organisation and directed migration 
of cells (Graham et al, 2013). Calcium is also used to aid the healing of wounds 
through the use of calcium alginate dressings; a gel substance generated from 
seaweed, which helps to keep wound sites moist and prevent bacterial infection 
while promoting the healing process (Doyle et al, 1998), with healing occurring up 
to four times faster than those without dressings (Sayag et al, 1996). Although 
these dressings cannot be used in all wound types, it can be used to treat diabetic 
foot ulcers, burns and surgical incisions. These types of dressing can also be made 
into ‘ropes’ and used to pack more open and chronic wounds (Doyle et al, 1998).  
 Wu et al (2002) indicated that pH also plays a vital role in the dissociation of 
nCRP. The blood pH of a healthy human is usually between 7.35 and 7.45 and is 
tightly regulated to remain between these two levels. Cell function and viability are 
dramatically affected by pH fluctuations beyond these levels. If the pH of the blood 
decreases below pH 7 or increases above pH 7.8 then death quickly occurs.  
If the pH of blood decreases below 7.35 it causes metabolic acidosis. This 
condition is due to an overabundance of acid or a loss of bicarbonate from the 
blood and generally arises when the kidneys and lungs are unable to keep the pH in 
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balance (Kraut & Madias, 2010).  There are several causes of metabolic acidosis and 
it can be acute or chronic in nature (Kraut & Madias, 2010). Diabetes is a major 
contributor to acidemia since the lack of insulin allows for the build-up of ketones. 
As the kidneys are typically damaged, the ketones cannot be processed correctly, 
leading to the acidification of blood. Another contributor is prolonged vomiting and 
diarrhoea causing hyperchloremic acidosis. This occurs when there a loss of sodium 
bicarbonate from the blood. Another major contributor, lactic acid acidosis, is 
caused by a build-up of lactic acid in the blood. This can be caused by chronic 
alcohol use, heart failure, seizures, cancer low blood sugar but also a lack of oxygen 
or prolonged exercise (Kraut & Madias, 2010). 
 If pH increases above 7.45 this is termed metabolic alkalosis. The main cause 
of metabolic alkalosis is a loss of electrolytes in the blood. This can be caused 
through excess vomiting, an overuse of diuretics, adrenal disease or a sudden 
decrease in potassium or sodium concentrations. Other contributors to akalemia 
are the use of laxatives, alcohol abuse and the accidental ingestion of bicarbonate 
(Galla, 2000).  
 There has been little research on the effect of altering pH within these 
ranges on the dissociation of nCRP to mCRP. Wu et al (2002) used pH 2 to cause 
spontaneous dissociation, but this was conducted using rabbit CRP and the pH was 
too acidic to model physiological levels observed in blood.  
 
 
3.2 Aims 
 The aim of this preliminary assay was to determine the effects of pH and 
calcium concentration on nCRP dissociation into mCRP. The findings were then used 
to establish the stability of nCRP in changing physiological conditions, which could 
be found in disease states or impaired healing in the elderly. 
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 3.3 Objectives 
The fundamental objectives of this section were: 
 To assess the effects of calcium concentration on the dissociation of nCRP 
into mCRP. 
 To assess the effects of pH on the dissociation of nCRP into mCRP. 
 
 
3.4 Summary of Procedure 
 A stability assay was used to model physiological conditions in healthy and 
disease states. By conducting the assay across a range of pH and calcium levels, it 
can be used to model the effect of pH and calcium changes on CRP profile during 
the wound healing process. The assay used a fixed concentration of purified nCRP 
and measured the amount of mCRP generated through dissociation under various 
pH and calcium conditions.  
 The pH levels used in this assay were representative of physiological levels 
of pH found in normal human blood (pH 7.4) as well as those in acidosis (pH 7.0) 
and alkalosis (pH 7.8) as well as levels beyond normal human physiological 
conditions (pH 6.0 and 8.0). The calcium concentrations used were representative 
of physiological concentrations in human blood in a healthy state as well as the 
diseased states acidosis and alkalosis.  
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3.5 Materials 
C - reactive protein, human >95% native, 5mg/ml (MyBioSource, San Diego) Purified 
as previously stated in Section 2.4.4. 
Nitrocellulose membrane (Scientific Laboratories Supplies, Nottingham) 
C-reactive protein buffer, adjusted to pH 7.4 (pH is varied for stability assay) 
140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
20mM Tris-hydrochloride (Fisher Scientific, Cheshire) 
2mM Calcium Chloride (Sigma-Aldrich, Dorset) – Calcium concentration is varied for 
stability assay 
Primary anti-monomeric-CRP made up 1:10 ratio with blocking buffer 
Anti-monomeric-CRP 8C10 culture supernatant (this was a kind gift from Dr LA 
Potempa) 
TBS/Tween buffer, adjusted to pH 7.4 
10mM Tris-base (Fisher Scientific, Cheshire) 
140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
0.1% Tween-20 (Sigma-Aldrich, Dorset) 
Blocking buffer, adjusted to pH 7.4 
1% Albumin from Bovine serum (Sigma-Aldrich, Dorset) in TBS-Tween 
Milk Solution, adjusted to pH 7.4 
5% semi-skimmed milk powder in TBS-Tween 
Polyclonal rabbit, anti-mouse immunoglobulins/HRP (Dako, Cambridge) 1:1000 
dilution in milk solution 
EZ-ECL chemiluminescence detection kit (Geneflow, Lichfield) 
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3.6 Methods 
3.6.1 Native C-reactive Protein Isoform 
 The nCRP isoform was purified and quantified as previously described in 
Section 2.4.4.  
 
3.6.2 Stability Assay Sample Preparation 
 A sample of nCRP isoform was normalised to a final concentration of 
500μg/ml. The nCRP was then treated with a buffer similar to the CRP buffer used 
in previous experiments (Section 2.3.4) but the buffers varied in calcium 
concentration (0mM, 0.5mM, 1mM and 1.5mM final concentration) and pH (pH 6.8, 
pH 7.0, pH 7.4, pH 7.8 and pH 8.0). Samples (n=4) were treated for 24 hours at 37oC 
(human body temperature) and then evaluated by dot blot to determine CRP 
isoform concentrations. 
 
3.6.3 Dot Blots 
 Dot blots were conducted as previously described in section 2.4.7. An 
example dot blot is located in Appendix 3. A set of control standards (Negative 
control, 10μg/ml, 20μg/ml, 30μg/ml and 50μg/ml mCRP) were used to allow for a 
standard cruve to be produced. An example standard curve is located in Appendix 
4. 
 
3.6.4 Statistical Analysis 
Images from the Bio-Rad ChemiDocTM Touch Imaging System were analysed 
using the Bio-Rad Image Lab Software (Version 5.2.1). Graphs were drawn using 
Microsoft Excel 2013 and all statistics performed using IBM SPSS Statistics (Version 
22). Data were analysed with the Shapiro-Wilkes normality test before t-tests or 
Mann-Whitney tests were conducted upon all the data.  
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3.7 Results 
 Figure 3.1 indicates the effect of calcium concentration and pH on the 
stability of nCRP by analysing how much mCRP was produced. Figure 3.1 shows that 
at each pH, less mCRP is produced in a concentration dependent manner as calcium 
concentration increases. Most mCRP is produced in the absence of calcium.  
 The amount of mCRP produced at pH 7.4 was generally lower than 
produced at the other pH values when calcium levels were at or below 1mM. Most 
mCRP was produced at both pH 7 and pH 7.8 at or below 0.5mM calcium, with 
slightly lower mCRP produced at pH 6 and pH 8 (than at pH 7 and 7.8) when calcium 
levels were at or below 1mM.  
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Figure 3.1 – The effect of pH and calcium concentration on the production of 
mCRP from nCRP.  Error bars represent standard error of the mean.  
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3.8 Discussion 
3.8.1 Stability Assay 
 When one molecule of nCRP dissociates it leads to the generation of five 
monomeric units (Potempa et al, 1983). The results of the assay indicated that not 
all of the nCRP dissociated but the amount of mCRP increased as the pH deviated 
from pH 7.4 or as calcium levels reduced. This could have led to an overall pro-
inflammatory effect if enough of the nCRP molecules dissociate to change the 
balance into a higher ratio of mCRP to nCRP. 
 
3.8.1.1 The Effect of Calcium Concentration on the Stability of nCRP 
 Figure 3.1 provides evidence that calcium plays a key role in the stability of 
nCRP. At all five pH levels there was a higher amount of mCRP produced when 
calcium was absent than when there was 1.5mM calcium present. This 
corroborates all studies that have stated that mCRP is produced in the absence of 
calcium (Potempa et al, 1983; Wu et al, 2002).  
 The physiological concentration of calcium in a healthy, young adult is 
around 1mM.  These findings indicate that increasing the amount of calcium 
stabilises the pentamer further and inhibits its dissociation. Thus as calcium levels 
decline through increasing age, there is an increased risk of spontaneous 
dissociation of the pentamer into the more pro-inflammatory mCRP isoform (Thiele 
et al, 2014) resulting in impaired healing due to a  prolonged and excessive 
inflammatory response due to mCRP accumulation at the wound site.  The results 
suggest that calcium supplementation in elderly subjects may to some extent, 
reverse the loss of nCRP stability due to increasing age.  
Furthermore, the addition of calcium into dressings for chronic wounds such as 
diabetic foot ulcers (Doyle et al, 1998) may in part be due to the high calcium 
concentration preventing the generation of mCRP at the wound site, thus reducing 
inflammation. When a calcium alginate dressing comes into contact with a wound, 
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there is a release of calcium ions into the wound site. The calcium aids coagulation 
and the alginate helps to regulate blood flow (Timmons, 2009) but it has been 
suggested that the calcium could also be acting in an anti-inflammatory manner. 
This study has provided a novel mechanism by which this type of wound dressing 
may be anti-inflammatory. Further studies are now required to confirm whether 
such dressings inhibit the dissociation of nCRP into mCRP in a clinical setting.  
The use of calcium in dressings for chronic wounds may also aid the function 
of CRP. The binding of PCh by nCRP requires the binding of two calcium ions per 
subunit (Mullenix & Mortensen, 1994). This binding leads the triggering of the 
complement pathway as well as the opsonisation of bacteria and dead cells (Mold 
et al, 1999). The addition of calcium to chronic wounds also leads to the activation 
of these pathways and improved healing by enhancing the host immune system  
detect and remove bacteria and dead cells by phagocytosis.   
 
3.8.1.2 The Effect of pH on the Stability of nCRP 
 The pH had a moderate effect on the production of mCRP, with little change 
in the presence of calcium but a more pronounced effect in the absence of calcium. 
This finding suggests that presence of calcium (rather than pH) is the critical 
stability factor for nCRP within a pH range that reflects normal and disease states. 
As the pH deviated away from pH 7.4 in the absence of calcium the amount of 
mCRP increased. This confirms that the normal (healthy) pH of blood (pH 7.4) is the 
most suitable pH for maintaining nCRP stability. However, more mCRP was 
produced in acidic conditions (indicative of metabolic acidosis) than in alkaline 
conditions, which supports Wu et al’s (2002) study that used acidic conditions to 
dissociate rabbit CRP.  
 The findings of this study indicate that wound dressings that maintain a pH 
around pH 7.4 are most optimal at maintaining the stability of the more anti-
inflammatory nCRP isoform.   
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3.9 Future Work 
 The assay could also be repeated at a series of different temperature to 
determine if slight temperature fluctuations can alter the stability of nCRP. It is 
known that high temperatures above 75oC can cause some dissociation of nCRP but 
could smaller temperature changes similar to physiological values observed in fever 
following acute infections affect the stability of nCRP. 
 Another aspect to be analysed would be to collect blood samples from 
patients with metabolic acidosis and alkalosis and determine if their mCRP levels 
are significantly affected.  Samples from elderly subjects taking calcium 
supplements would be valuable to determine whether they have lower levels of 
mCRP and improved healing.  
 
3.10 Summary 
 In summary, calcium concentration was the major factor mediating the 
stability of the pentameric nCRP isoform; with higher calcium concentrations 
maintain nCRP stability. However as pH deviated away from normal (healthy) values 
there was greater propensity for nCRP instability, particularly as calcium levels 
declined. Acidic conditions caused more mCRP production than alkaline conditions. 
This study indicated that the elderly are at greater risk of impaired healing and 
pronounced inflammation due a drop in calcium levels with increasing age. 
  This preliminary study indicates that further research needs to be conducted 
in order to fully understand how the tissue environment (including pH and calcium 
levels) might mediate mCRP concentration in vivo.  
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Chapter 4: The Localisation of C-Reactive Protein Isoforms in 
Monocytes and Macrophages during the Inflammatory Phase 
in Murine Wounds 
With special thanks to J Hynes and Dr J Ashworth for their contribution to the 
collection of data in this chapter. 
 
4.1 Introduction 
 There is increasing evidence that C-reactive protein (CRP) may have a 
functional role in the inflammatory process. It is well established that CRP is an 
acute marker of inflammation and that its concentration increases in the circulation 
during inflammatory events.  
 There has been some attempt to localise CRP to sites of inflammation and 
tissue damage. It has been demonstrated that CRP has been deposited in various 
conditions, both naturally occurring and in experimental conditions (Kushner & 
Kaplan, 1961; Kushner et al, 1963; Parish, 1977; Gitlin et al, 1978). However, there 
are some issues with the published research on the localisation of CRP. These 
studies investigated CRP without considering the 2 different isoforms separately. It 
is now established that there are two isoforms of CRP and that they have differing 
structure and biological function so there could also be differential localisation of 
the protein as well. When these studies were conducted it was not well established 
that there were two isoforms of the protein and available antibodies would have 
been raised to detect the pentameric nCRP alone. The second issue is that these 
studies localised the protein in cases of inflammation with specific tissue damage. 
Gitlin et al (1978) concluded that CRP was localised to the nuclei of cells within the 
synovium of rheumatoid arthritis patients but the cell type could not be identified 
at the time. 
It has been suggested that following tissue injury, CRP binds to damaged cell 
membranes and by activating complement contributes to the inflammatory 
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response (Kaplan & Volanakis, 1974) with CRP molecules becoming associated with 
terminal complement complexes, especially in atherosclerotic lesions (Torzewski et 
al, 1998). Lagrand et al (1997) provided evidence that CRP localises to infarcted 
heart tissue and promotes local complement activation, triggering further damage 
to the heart tissue.  However, other studies indicate no significant localisation of 
CRP in a number of pathologies, suggesting that CRP is found predominantly in the 
fluid phase rather than deposited in tissues at sites of inflammation or tissue injury 
(Vigushin et al, 1993).  
There has been little research conducted on the localisation of CRP in 
inflammatory cells and wounds to date. There is a correlation between the 
localisation of CRP in neutrophil infiltrates, especially in lesions of vasculitis and 
allergic encephalomyelitis (Du Clos et al, 1981; Parish, 1971). However, the 
localisation of distinct CRP isoforms in acute wounds of skin has not been 
conducted previously. 
 
 
4.2 Aims 
 The aim of this study was to determine the localisation of CRP isoforms in 
inflammatory cells of murine cutaneous wounds.   
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4.3 Objectives 
 The fundamental objectives of this assay were: 
 To analyse the effect of ‘hot’ and ‘cold’ antigen retrieval of CRP 
isoforms 
 To provide evidence that CRP is localised to sites of inflammation in 
cutaneous murine wounds 
 To assess the localisation patterns of CRP isoforms in inflammatory 
cells of murine wounds 
 To assess the effect of impaired healing on the localisation of CRP 
isoforms using a murine model of age-related impaired healing. 
 
 
4.4 Summary of Procedure 
Immunohistochemistry uses an antigen-antibody interaction to detect tissue 
and cellular constituents either by direct labelling of the antibodies or by a second 
labelling method (Bancroft & Gamble, 2008). The Vectastain Elite ABC kit uses an 
unlabelled primary antibody to bind to the target protein, followed by the binding of 
a biotinylated secondary antibody. This is then followed by the binding of a 
preformed avidin and biotinylated horseradish peroxidase (HRP) macromolecular 
complex, allowing the target protein to be visualised by a coloured dye due to the 
development of a peroxidase substrate when bound to the HRP complex. For 
example, Novared produces a dark red colour in the presence of the HRP complex.  
Prior to visualisation of an antibody- labelled, a process called antigen 
retrieval is vital to ensure the antigen is exposed to the antibody. Antigen retrieval 
breaks crosslinks between proteins and any fixative in the sample that could mask 
the antigen (Shi et al, 2001). A simple antigen retrieval method is the use of high 
temperature and an acidic buffer. However, for comparison this study also used a 
‘cold’ antigen retrieval method to ensure that the hot antigen retrieval was not 
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inadvertently affecting results by dissociating the pentameric nCRP resulting in false-
positive mCRP staining. 
 
 
4.5 Materials 
Wax embedded murine wound samples – Kindly provided by the University of 
Manchester 
Anti-monomeric-CRP 8C10 culture supernatant primary antibody ( kind gift from Dr 
LA Potempa) 
 
Anti-native-CRP 1D6 culture supernatant primary antibody (kind gift from Dr LA 
Potempa) 
 
Vectastain Elite ABC kit (mouse IgG) (Vector Labs, Burlingame) 
 Normal horse blocking serum 
 Horse anti-mouse biotinylated IgG 
 Avidin-biotinylated horseradish peroxidase (HRP) complex (ABC kit reagent) 
 
Vectastain Elite ABC kit (rat IgG) (Vector Labs, Burlingame, CA) 
 Norrmal horse blocking serum 
 Horse anti-rat biotinylated IgG 
 Avidin-biotinylated horseradish peroxidase (HRP) complex (ABC kit reagent) 
 
Tris-buffered Saline (TBS), adjusted to pH 7.5 
 10mM Tris-base (Fisher Scientific, Cheshire) 
 140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
 0.1% Tween-20 (Sigma-Aldrich, Dorset) 
 
Anti-CD105 antibody (Abcam, Cambridge) 
Anti-CD34 antibody (Abcam, Cambridge) 
Haematoxylin (VWR International, Leicestershire) 
Novared (Vector Labs, Burlingame) 
Ethylenediaminetetraacetic acid (EDTA)-Tween buffer, adjusted to pH 8.0 
 0.01M  EDTA (Sigma-Aldrich, Dorset) 
 0.01%Tween (Sigma-Aldrich, Dorset) 
Glycine, EDTA, Tween Buffer adjusted to pH 3.5 
 0.01M EDTA (Sigma-Aldrich, Dorset) 
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 0.05M Glycine (Sigma-Aldrich, Dorset) 
 0.01% Tween (Sigma-Aldrich, Dorset) 
 
Xylene (VWR International, Leicestershire) 
3% Hydrogen Peroxide (Sigma-Aldrich, Dorset) 
Methanol (Sigma-Aldrich, Dorset) 
Ethanol (Sigma-Aldrich, Dorset) 
Pertex Mounting Media (Cellpath PLC, Powys) 
Vectabond Coated Slides (Vector Laboratories, Burlingame) 
 
 
4.6 Methods 
4.6.1 Animals and Wounding  
Collaborators from the University of Manchester provided the wax 
embedded murine wounds for this study. The murine wound samples were 
collected from 10 week old female Balb/C wild-type mice that were either INTACT 
(possessing ovaries) or had undergone ovariectomy (OVX) 1 month previously. 
Wounds from OVX mice are an established murine model of age-related impaired 
healing whilst wounds from INTACT mice represent a model of acute wound healing 
during youth (Ashcroft et al 1997).  Isofluorane was used as an inhaled anaesthetic 
and the dorsum was shaved and cleaned with alcohol.  Mice were wounded on 
their dorsum making two equidistant 1 cm full thickness skin incisional wounds, 
placed 1cm from the base of the skull and 1cm from either side of the midline. 
These incisions were made through the skin and panniculus carnosus muscle.  
Healing of the wounds was by secondary intention and subsequent removal was by 
excision (6 mm excisional wounds) at 12 hours, 24 hours, 3 days and 7 days post-
wounding. The excised wounds were bisected and processed such that the 
midpoint of each wound was used for embedding in paraffin wax and histological 
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analysis following an established protocol (Bancroft & Gamble, 2008). For each time 
point the data represented 3 mice (n =3) and 5 separate images were collected for 
analysis from each wound. 
 
4.6.2 Immunohistochemical Chemical Staining Protocol 
Murine wound samples at specified time points during the wound healing 
process (12h, 24h, D3, D7 post-wounding) from both INTACT and OVX were stained 
for the nCRP and mCRP isoforms using the Vectastain Elite ABC mouse IgG kit, an 
avidin-biotin peroxidase system, and monoclonal mouse anti-human nCRP (2C10) 
and anti-mCRP (8C10) primary antibodies.  Paraffin wax embedded 5µm thick 
sections were cut from murine wounds using a microtome and mounted on 
Vectabond coated slides. Slides were deparaffinised using xylene, rehydrated 
through a graded ethanol series and then incubated in 3% hydrogen peroxide 
(H2O2) in methanol to block endogenous peroxidases. Antigen retrieval involved 
either incubation in a 0.01M EDTA and 0.1% Tween buffer for 6 hours at 600C 
(referred to as cold antigen retrieval) or incubated in an 0.01M EDTA, 0.05M 
Glycine and 0.1% Tween buffer for 20 minutes following 5 minutes heating in a 
microwave (referred to as hot antigen retrieval). After antigen retrieval, slides were 
washed for 15 minutes in TBS-Tween.  Slides were then incubated in normal horse 
serum for 1 hour to block non-specific binding sites followed by an  overnight 
incubation at 40C in primary antibody (2C10 or 8C10) diluted 1:10 with TBS 
containing normal horse serum.  To minimise cross reactivity, a secondary staining 
kit was used which was specifically designed to stain for mouse antibodies on 
mouse tissue. Negative controls were used to determine any non-specific binding of 
the antibodies. The negative control was treated with TBS containing normal horse 
serum instead of primary antibody with no other changes to the staining protocol. 
After the overnight incubation, the slides were washed in TBS-Tween for 15 
minutes followed by incubation in secondary biotin-conjugated horse anti-mouse 
antibody for 1 hour then washed again in TBS-Tween for 15 minutes. Slides were 
then incubated in an avidin-biotin peroxidase reagent for 30 minutes at room 
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temperature followed by a final wash in TBS-Tween for 30 minutes. Slides were 
stained with Novared for 2 minutes followed by counterstaining with haematoxylin. 
Slides were dehydrated through a graded ethanol series before mounting in Pertex. 
For each time point the data represented 3 mice (n =3) and 5 separate images were 
collected for analysis from each mouse. 
 
4.6.3 Dual Staining Protocol 
Murine wound samples (n=3) from D3 and D7 wild type mice were stained 
for nCRP and mCRP using the Vectastain Elite ABC mouse IgG kit and monoclonal 
mouse anti-human nCRP (2C10) and mCRP antibodies (8C10). Sequential sections 
were stained for neutrophils and macrophages using monoclonal anti-neutrophil 
and MAC3 antibodies respectively. This was conducted using a Vectastain Elite ABC 
rat IgG kit, an avidin-biotin peroxidase system using the previously described 
immunohistochemical staining protocol (3.6.2). Sequential sections were stained 
with appropriate primary antibodies and resulting images overlaid to determine co-
localisation of inflammatory cell markers and CRP isoforms. A negative control was 
used to determine any non-specific binding of antibodies during the dual staining 
process.  For the negative control, the primary antibody was replaced with TBS 
containing normal horse serum with no other changes to the staining protocol. For 
each time point the data represented 3 mice (n =3) and 5 separate images were 
collected for analysis from each mouse. 
 
4.6.4 Inflammatory Phase Analysis 
For histological sections at 12h, 24h, D3 and D7 post-wounding staining for 
both CRP isoforms was analysed from 5 pre-defined areas within the wound. 
Images were captured using the Axio Imager M1 microscope (Zeiss, Germany) with 
630x magnification. Area 1 was representative of mid-wound and areas 2, 3, 4 and 
5 represented right and left areas just under the epidermis and just above the fat 
layer in the dermis ensuring a representative proportion of the whole wound was 
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analysed. The amount of inflammatory cell staining was analysed using Image J 
software (Version 1.49 Rasband W., National institutes of Health, USA). Positive 
staining of inflammatory cells was expressed as a ratio of total inflammatory cells, 
thus providing a basis for comparison of the native and modified CRP. For sections 
at D3 and D7 post-wounding, inflammatory cells were manually stratified based on 
their morphology into neutrophils and macrophages respectively.   
 
4.6.5 Statistical Analysis 
Statistical analysis was performed using SPSS (Version 22). A Shapiro-Wilks 
normality test was performed followed by appropriate paired or unpaired t-tests 
for normally distributed data or Wilcoxon-Mann-Whitney U tests for non-
parametric situations. Tests were chosen depending on the distribution of each 
dataset generated and P<0.05 was considered statistically significant. Graphs were 
generated using Microsoft Excel 2013, with error bars representing the standard 
error of the mean (SEM).  
 
 
4.7 Results 
4.7.1 Comparison of Hot and Cold Antigen Retrieval Technique 
Antigen retrieval allows for the antigens in the wax-embedded samples to 
become exposed and available for primary antibody binding (Shi et al, 2001). This 
study looked at the difference between two techniques, the ‘hot’ and ‘cold’ antigen 
retrieval. This was conducted in order to determine the ability of the 2 retrieval 
processes to reveal the desired antigens and to assess the potential dissociation of 
the nCRP that may be caused by typical hot antigen retrieval methods. The data from 
this study indicated that there was no significant difference (nCRP p=0.9056, mCRP 
p=0.4074) between the staining of the CRP isoforms using the two techniques 
(Figures 4.1A and 4.1B). This showed that both methods consistently retrieved the 
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CRP antigens and that the hot retrieval method did not disrupt the integrity of the 
nCRP isoform.  
 
 
4.7.2 Presence of CRP Isoforms During the Inflammatory Phase of Wound Healing 
During the early and late inflammation phases, both mCRP and nCRP were 
detected within inflammatory cells. This would indicate that the source of these 
isoforms would most likely be the most predominant cell types at these time points; 
principally neutrophils and monocytes (Kaplanski et al, 2003).  
 
 
 
 
Figure 4.1: Comparison of hot and cold antigen retrieval techniques of CRP 
isoforms at D7 post-wounding. (A) Comparison of the two antigen retrieval 
techniques in detecting mCRP-positive inflammatory cells.  (B) Comparison of 
the two antigen retrieval techniques in detecting nCRP-positive inflammatory 
cells. Error bars represent the SEM.  
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4.7.2.1 Detection of CRP Isoforms in Murine Wound in the Early Inflammatory 
Phase 
The early inflammatory phase CRP detection was measured in the cutaneous 
murine wounds samples obtained at 12 hours and 24 hours post-wounding. The 
samples at both time points were sectioned and stained for mCRP (Figures 4.2B and 
4.3B) or nCRP (Figures 4.2C and 4.3C).  
At 12 hours post-wounding, mCRP-positive staining was 588 cells/mm2 whilst 
nCRP-positive staining was 437 cells/mm2, equating to be around 19% and 15% of 
the total inflammatory cell count respectively (Figure 4.2A). Thus, the proportion of 
total inflammatory cells demonstrating positive staining of nCRP or mCRP was 
significantly (P<0.01) lower than the proportion of inflammatory cells lacking CRP 
isoform localisation. However, no significant (P=0.1165) difference between mCRP 
and nCRP was identified in relation to the proportion of positively stained cells.   
Lastly, the ratio of mCRP:nCRP was 1.3 at 12 hours post-wounding. At 24 hours post-
wounding, mCRP-positive staining was 1765 cells/mm2 and 1619 cells/mm2 were 
positive for nCRP. This was calculated to be around 45% and 40% of the total cells 
present respectively (Figure 4.3A). Again, the proportion of total inflammatory cells 
demonstrating positive staining of nCRP or mCRP was significantly (P<0.01) lower 
than the proportion of inflammatory cells lacking CRP isoform localisation. However, 
no significant (P=0.1310) difference between mCRP and nCRP was identified in 
relation to the percentage of positively stained cells.  The ratio of mCRP:nCRP 
reduced to 1.1 at 24 hours post-wounding. 
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4.7.2.2 Comparison of 12 and 24 Hours Post-Wounding 
Detection of both CRP isoforms was analysed at the early phase of the 
inflammatory process to compare the amount of positive staining between the early 
inflammatory time points (12 hours and 24 hours). The amount of mCRP detected 
increased significantly (p<0.001) from 19% to 45% between these two early time 
points (Figure 4.4A) and nCRP increased significantly (p<0.001) from 15% to 40% 
(Figure 4.4B), suggesting a rapid increase in the proportion of both isoforms. Both 
CRP isoforms effectively doubled over the 12 hour period in terms of cell 
concentration and proportion of total inflammatory cells. No difference between 
mCRP and nCRP was detected at each of the time points in the early phase of 
inflammation but the ratio of mCRP:ncRP reduced from 1.3 at 12 hours post-
wounding to 1.1 at 24 hours post-wounding.  
 
 
 
Figure 4.4: Comparison of CRP positive inflammatory cells at 12 and 24 hours 
post-wounding.  (A) Comparison of mCRP positive inflammatory cells at 12 and 
24 hours post-wounding expressed as a ratio of total cells. ** represents 
P<0.001.  (B)  Comparison of nCRP positive inflammatory cells at 12 and 24 hours 
post-wounding expressed as a ratio of total cells. ** represents P<0.001. Error 
bars represent the standard error of the mean (SEM). ** indicates p<0.01. 
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4.7.2.3 Day 3 Post-Wounding. 
Neutrophils typically peak in numbers by day 3 (D3) post-wounding (Kaplanski 
et al., 2003), suggesting neutrophils should form a substantial proportion of  the total 
inflammatory cell count taken at this time point.  
Murine cutaneous wound samples at D3 post-wounding were sectioned and 
stained for CRP isoforms (Figures 4.5B and 4.5C). The mean cell density in these D3 
wounds was 4267 cells/mm2, indicating a significant (P<0.01) increase in total 
inflammatory cell density compared to wounds at 24 hours post-wounding. The 
concentration of mCRP and nCRP positive cells was 3286 cells/mm2 and 2347 
cells/mm2 respectively. To allow for a comparison of these results, these data were 
expressed as a proportion of the total inflammatory cell count (Figure 4.5A). The 
proportion of total inflammatory cells demonstrating positive staining of nCRP or 
mCRP was significantly (P<0.01) greater than the proportion of inflammatory cells 
lacking CRP isoform localisation. The results indicated significantly (p<0.001) more 
mCRP positive staining than nCRP positive staining at D3 post-wounding, with 77% of 
the total cells being stained mCRP positive compared to the 55% stained positively 
for nCRP. This represented another significant (P<0.01) increase in the proportion of 
CRP localisation from 24 hours post-wounding (45% mCRP-positive; 40% nCRP-
positive) to 3 days post-wounding (77% mCRP-positive; 55% nCRP-positive). The ratio 
of mCRP:nCRP also increased from 1.1 at 24 hours post-wounding to 1.4 at D3 post-
wounding. 
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4.7.3 Detection of CRP Isoforms in Murine Wound in the Late Inflammatory Phase 
4.7.3.1 D7 Post-Wounding 
To analyse CRP isoform levels at the later inflammatory phase, cutaneous 
murine wound samples from day 7 (D7) post-wounding were sectioned and stained 
for mCRP and nCRP (Figures 4.6B and 4.6C) 
The results indicated that at D7 post-wounding, 42% of total cells stained 
positively for mCRP and 45% stained positive for nCRP, with no significant (p=0.0977) 
difference in the proportion of positive staining between the two CRP isoforms 
(Figure 4.6A). The proportion of total inflammatory cells demonstrating positive 
staining of nCRP or mCRP was significantly (P<0.01) lower than the proportion of 
inflammatory cells lacking CRP isoform localisation. 
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4.7.3.2 Comparison of Staining in Inflammatory Cells D3 and D7 Post-Wounding  
To complete the analysis of CRP isoform staining in the inflammatory process 
a comparison of the positively stained cells at D3 and D7 post-wounding was 
performed (Figure 4.7A and 4.7B). 
When compared to D3 there was a significant increase in the number of total 
inflammatory cells.  The total cell density increased significantly (P<0.01) from 4270 
cells/mm2 at D3 to around 5000 cells/mm2 at D7. However, the proportion of total 
inflammatory cells with positive staining significantly decreased for both mCRP (77% 
to 42%) and nCRP (55% to 45%) between the two time points, with the ratio of 
mCRP:nCRP also decreasing from 1.4 at D3 post-wounding to 0.9 at D7 post-
wounding. 
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4.7.3.3 Localisation of CRP Isoforms in Neutrophils at D7 Post-Wounding 
Neutrophils are usually around 6-10μm in diameter and appear smaller and 
rounder than monocytes (Trowbridge & Emling, 1997). Based on these morphological 
differences this cell type could be easily distinguished from other cell types in D7 
wound sections (Figures 4.8B and 4.8C). The mean total neutrophil cell density D7 
post-wounding was approximately 3000 cells/mm2 based on morphology and 
positive staining was expressed as a ratio of total neutrophils (Figure 4.8A). The 
results showed there was no significant difference (p=0.1308) between the staining 
of the CRP isoforms in neutrophils at D7 post-wounding with mCRP being detected 
in 28% of neutrophils and nCRP in 31% of neutrophils. This shows that most 
neutrophils were not producing either CRP isoform at this time point during the 
healing process. This is in direct contrast to D3 post-wounding in which most cells 
became positively stained, with significantly (p<0.001) more mCRP staining observed 
Figure 4.7: Comparison of CRP positive staining of inflammatory cells at day 3 
(D3) and day 7 (D7) post-wounding. (A) Quantification and comparison of mCRP 
positive inflammatory cells at D3 and D7 post-wounding, expressed as a ratio of 
total cells. ** denotes P<0.001. (B) Quantification and comparison of nCRP 
positive inflammatory cells at D3 and D7 post-wounding, expressed as a ratio of 
total cells. ** denotes P<0.001. Error bars represent the standard error of the 
mean (SEM). 
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than nCRP (Figure 4.5). The ratio of mCRP:nCRP staining in neutrophils at D7 post-
wounding was 0.9. 
 
4.7.3.4 CRP Localisation in Macrophages at D7 Post-Wounding 
Numbers of tissue macrophages typically peak at around D7 post-wounding 
(Kaplanski et al, 2003). Tissue macrophages are much larger in size (typically around 
10-30μm) with a more lobular shape (Figures 4.9B and 4.9C) than neutrophils.  
The cell types were stratified according their morphology and the 
corresponding cell counts performed as described previously.  The CRP isoform 
staining is expressed as ratio of total macrophages and the comparisons were made 
between CRP isoforms (Figure 4.9A).  
No significant (p=0.6203) difference was identified between the two isoforms 
of CRP with 80% of macrophages staining positive for mCRP and 79% for nCRP (Figure 
4.9A). At D7 post-wounding the mean inflammatory cell density was calculated at 
around 5000 cells/mm2 with around 2000 cells/mm2 of those being morphologically 
identified as macrophages. Of these cells 1600 macrophages/mm2 (80%) stained 
positive for mCRP and 1580 (79%) macrophages/mm2 stained positively for nCRP. 
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This evidence suggests that most macrophages at D7 post-wounding were 
simultaneously producing both CRP isoforms due to the fact that both isoforms were 
detected in the majority of macrophages within the sample. The ratio of mCRP:nCRP 
in macrophages when identified by morphology was 1.0 at D7 post-wounding. 
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4.7.4 Dual Staining 
Dual staining was conducted for the detection of specific cell types at D7 post-
wounding at the same time as determining positive CRP isoform staining. Serial 
sections of wound samples were stained with antibodies specific to the two CRP 
isoforms as well as a second antibody to stain for cell-specific markers for neutrophils 
or macrophages. Images taken from each section were overlaid and areas of dual 
staining were highlighted using Adobe Photoshop image analysis software.  
 
4.7.4.1 Dual staining to Detect CRP in Neutrophils 
 The dual staining process identified some co-localisation of CRP isoforms in 
neutrophils at D7 post-wounding (Figures 4.10A and 4.10B). Cell counts were 
conducted to determine the number of cells positive for only the neutrophil antigen 
and another count for the number of cells in which both the neutrophil antigen and 
CRP isoform were detected. 
From the total number of inflammatory cells at D7 post-wounding, 22% 
showed dual detection for mCRP and the neutrophil antigen. This is in comparison to 
67% of cells staining positive for mCRP alone and 10% for the neutrophil antibody 
alone. Similarly, 25% of total inflammatory cells showed dual staining for both nCRP 
and the neutrophil antigen. This is in comparison to 65% staining positive for nCRP 
alone and 10% for neutrophil antigen alone. Using dual staining data the ratio of 
mCRP:nCRP in neutrophils at D7 post-wounding was 0.9. This is in agreement with 
the measurements obtained by morphological identification of neutrophils (Section 
4.7.3.3).  
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4.7.4.2 Dual staining to Detect CRP in Macrophages 
The literature suggests the number of macrophages peak at D7 post-
wounding. Dual staining with a macrophage antigen specific antibody (Mac3) and 
CRP specific antibodies identified substantial co-localisation of the macrophage 
marker and CRP isoforms at D7 post-wounding (Figures 4.11A and 4.11B). Cell counts 
were conducted to determine the number of cells positive for only the macrophage 
antigen and another count for the number of cells in which both the macrophage 
antigen and CRP isoform were detected.  
From the total number of inflammatory cells at D7 post-wounding, 53% 
showed dual detection for the Mac3 marker and mCRP. This is in comparison to 30% 
of cells staining positive for mCRP alone and 17% for the Mac3 marker alone. Also 
41% of the total cells showed dual staining for both nCRP and the Mac3 marker. This 
is in comparison to 33% staining positive for nCRP alone and 26% for the Mac3 
marker alone. Using dual staining the ratio of mCRP:nCRP in macrophages at D7 post-
wounding was 1.3.  
Figure 4.10: Dual staining of neutrophils and CRP isoforms at day 7 post-
wounding. (A) Staining with mCRP antibody (8C10) (red) overlaid onto an image 
of staining with an anti-neutrophil antibody (green). Areas of dual staining 
highlighted (yellow). (B) Staining with nCRP antibody (2C10) (red) overlaid onto 
an image of staining with an anti-neutrophil antibody (green). Areas of dual 
staining highlighted (yellow). 
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4.7.5. Presence of CRP Isoforms During Impaired Healing  
4.7.5.1 Comparison of CRP Isoforms During Inflammatory Phase of Acute Wounds 
in a Model of Age-Related Delayed Healing 
This study utilised a well-defined model of impaired wound-healing  using 
ovariectomised (OVX) mice in comparison to non-impaired acute healing found in 
INTACT mice. This OVX model is known to show increased inflammation, larger 
wounds and decreased matrix deposition (Ashcroft et al 1997). This section of this 
study analysed the presence of CRP isoforms in both INTACT and OVX wound healing 
states at day 3 (D3) and day 7 (D7) post-wounding.  
 
 
 
 
Figure 4.11: Dual staining of macrophages and CRP isoforms at day 7 (D7) post-
wounding. (A) Staining with mCRP antibody (8C10) (red) overlaid onto an image 
of staining with an anti-macrophage antibody (green). Areas of dual staining 
highlighted (yellow). (B) Staining with nCRP antibody (2C10) (red) overlaid onto 
an image of staining with an anti-macrophage antibody (green). Areas of dual 
staining highlighted (yellow). 
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4.7.5.1.1. Presence of CRP Isoforms in Non-Impaired (INTACT) Acute Wounds at D3 
Post-Wounding. 
Counts of inflammatory cells at D3 post-wounding from wound sections of 
INTACT mice were presented earlier (Figure 4.5). In summary, there was significantly 
(p<0.001) more mCRP staining than nCRP at D3 post-wounding, with mCRP present 
in 77% of the total inflammatory cells whereas nCRP was only detected in 55% of 
total inflammatory cells. The ratio of mCRP:nCRP in wounds of INTACT mice at D3 
post-wounding was 1.4. The absolute concentration of inflammatory cells staining 
positive for mCRP and nCRP were 3290 and 2350 cells/mm2 respectively. 
 
4.7.5.1.2 Presence of CRP Isoforms in a Model of Age-Related Impaired Healing at 
D3 Post-Wounding  
The presence of CRP isoforms were analysed in samples of impaired (OVX) 
healing at D3 post-wounding (Figures 4.12B and 4.12C) with detection levels 
expressed as a ratio of the total inflammatory cell count (7650 cells/mm2). The data 
show a significantly (p=0.013) higher number of inflammatory cells staining positive 
for mCRP than nCRP, with 49% staining positive for mCRP compared to 30% for nCRP 
(Figure 4.12). The ratio of mCRP:nCRP in the model of impaired murine healing at D3 
post-wounding was 1.6. The absolute concentration of inflammatory cells staining 
positive for mCRP and nCRP were 3750 and 2300 cells/mm2 respectively. 
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4.7.5.1.3 Presence of CRP Isoforms in a Model of Age-Related Impaired Healing at 
D7 Post-Wounding 
The presence of CRP isoforms were analysed in samples of impaired (OVX) 
healing at D7 post-wounding (Figures 4.13B and 4.13C) with detection levels 
expressed as a ratio of the total inflammatory cell count (8630 cells/mm2). The data 
show a significantly higher (P=0.03) number of inflammatory cells staining positive 
for mCRP than nCRP, with 37% staining positive for mCRP compared to 24% for nCRP 
(Figure 4.13A). The ratio of mCRP:nCRP in the model of impaired murine healing at 
D7 post-wounding was 1.5. The absolute concentration of inflammatory cells staining 
positive for mCRP and nCRP were 3190 and 2070 cells/mm2 respectively. 
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4.7.6 Comparison of CRP Isoforms in Non-Impaired and Estrogen-Deprived 
Healing States 
The ratio of mCRP:nCRP in the model of impaired murine healing at D3 post-
wounding was 1.6 compared to 1.4 found in acute wounds of INTACT mice at D3 
post-wounding. This finding suggests a more pro-inflammatory response in the 
model of impaired healing due to higher relative levels of mCRP. The concentration 
of positively-staining mCRP reflects this finding, with a significantly higher cell 
density of mCRP-positive cells (3750 cells/mm2) in OVX wounds than in INTACT 
wounds (3290 cells/mm2) at D7 post-wounding.    
Counts of inflammatory cells at D7 post-wounding from wound sections of 
INTACT mice were presented earlier (Figure 4.13). In summary, there was no 
significant difference between mCRP and nCRP staining at D7 post-wounding, with 
mCRP and nCRP present in 42% and 45% of total inflammatory cells respectively. The 
ratio of mCRP:nCRP in wounds of INTACT mice at D7 post-wounding was 0.9. The 
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absolute concentration of inflammatory cells staining positive for mCRP and nCRP 
were 2100 and 2250 cells/mm2 respectively. 
The ratio of mCRP:nCRP at D7-post wounding in model of impaired healing 
was 1.5 compared to 0.9 found in acute wounds of INTACT mice at D7 post-
wounding. These findings suggest a more pro-inflammatory response in the model 
of impaired healing due to higher relative levels of mCRP. The concentration of 
positively-staining mCRP reflects this finding, with a significantly higher cell density 
of mCRP-positive cells (3190 cells/mm2) in OVX wounds than in INTACT wounds (2250 
cells/mm2) at D7 post-wounding.    
 
 
4.8 Discussion 
4.8.1 C-Reactive Protein Isoforms and Inflammation  
 The role of c-reactive protein (CRP) and its isoforms has not been fully 
elucidated in the terms of wound healing and inflammation. Previous papers have 
agreed that CRP is a marker of inflammation and that there is some function being 
performed however there is much debate over that function with arguments for 
both anti-inflammatory and pro-inflammatory effects. The two isoforms have been 
shown to have both pro-inflammatory and anti-inflammatory effects upon 
numerous cells types including neutrophils and monocytes as well as other cells 
that have particular roles in the wound healing and inflammation processes (Khreiss 
et al, 2002; Khreiss et al, 2004; Khreiss et al, 2005; Eisenhardt et al, 2009).  
 The results of this study have indicated a temporal and spatial profile of 
both nCRP and mCRP during in both early and late inflammatory stages as well as in 
non-impaired and impaired wound profiles. These results have indicated that both 
mCRP and nCRP are present in the inflammatory cells of murine wounds with 
significantly differing levels observed in the various cell types and time points.  
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 It has been well established that levels of CRP can increase up to 1000 fold 
on the onset of inflammation hence why it is considered an acute marker of 
inflammation and is used for investigative purposes in cardiovascular disease 
(Eisenhardt et al, 2009). Thus, there are numerous studies on CRP levels and the 
risk of cardiovascular events and very little on other biological effects of the two 
isoforms including inflammation processes, such as nitric oxide release and 
phagocytosis (Eisenhardt et al, 2009).   
 
4.8.1.1 The Effect of CRP Isoforms in the Early Inflammatory Stages 
The inflammatory process in wound healing follows a set of predetermined 
stages. Neutrophils are always the first cell type that enters the wound site via 
diapedesis (Kapalanski et al, 2003) with numbers increasing dramatically over 12-24 
hours and  peaking at around day 3 (D3) post-wounding. This study provides 
evidence that at 12 hours post-wounding around 19% of the inflammatory cells 
within the wound stained positively for mCRP and 15% stained positively for nCRP, 
with no significant difference  (p=0.1165) in the levels of detection between the 
two CRP isoforms. By 24 hours this had increased to 45% of cells being positively 
stained for mCRP and 40% being stained positively for nCRP with no significant 
difference (p=0.2393) being detected between the two isoforms. The increase 
between the two time points however was significant for both isoforms (p<0.001).  
The results at day 3 (D3) post-wounding showed a different effect. Positive 
staining of mCRP was detected in 77% of inflammatory cells which was significantly 
(p<0.001) higher than the proportion of cells staining for nCRP (55%). Zouki et al 
(1997) stated that both CRP isoforms can downregulate L-selectin (CD62L) 
detection in neutrophils, of which L-selectin is expressed on leukocytes to mediate 
in leukocyte capture and rolling (Nagaoka et al, 2000). During activation L-selectin is 
shed leading to the up-regulation of Mac-1 (CD11b/CD18). This causes the 
enhancement of adhesion and trans-endothelial migration of neutrophils via their 
endothelial counter-ligands ICAM-1 and ICAM-2 (Zouki et al, 2001). The mCRP 
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isoform can increase the detection of Mac-1 and ICAM-1 (Khreiss et al 2004; Zouki 
et al 2001). This would suggest that high levels of mCRP in the day 3 (D3) post-
wounding cells would increase adhesion molecule expression on the cell surface of 
neutrophils, leading to the increased efficiency of the neutrophil transmigration. 
 
4.8.1.2 The Effect of CRP Isoforms in the Late Inflammatory Stages 
At day 7 (D7) post-wounding there was a significantly higher inflammatory 
cell count than that seen at day 3 (D3), which is not unexpected in the inflammatory 
process. However, the amount of positive staining for each of the CRP isoforms 
significantly reduced during this time. The amount of mCRP staining decreased by 
49% and the nCRP reduced by 24% during this period. This may be due in part to 
the change in cell type between the 2 time points, with the apoptosis of neutrophils 
(Li et al, 2007) following their peak at D3 and the subsequent recruitment of tissue 
macrophages (Kaplanski et al, 2003). This change is due to a change in the 
expression profiles of cytokines and chemokines during the inflammatory process; 
usually caused by an increase in macrophage inflammatory protein-1 and monocyte 
chemoattractant protein-1 (MCP-1) (Kaplanski et al, 2003; Dipietro, 1995).  
At day 7 (D7) post-wounding, the data indicated that around 80% of the 
inflammatory cells present had positive staining for both isoforms. These results 
show that some inflammatory at D7 are capable of simultaneously producing both 
CRP isoforms. Such co-localisation could possibly mediate the chemotaxis of 
monocytes (Torzewski et al, 2000) or the inhibition of neutrophil chemotaxis 
(Khreiss et al, 2002) noted at this time point.  
The differentiation of monocytes to tissue macrophages is a process that is 
mediated by the release of interleukin-4 (IL-4) during tissue injury (Mosser & 
Edwards, 2008) and activation of the macrophages can occur by various agents. 
Macrophage-activating agents can include neutrophils, red blood cells, bacterial 
antigens as well as platelet derived factors, chemokines and cytokines, especially 
MCP-1, IL-1 and IFN-γ (Dipietro, 1995). Tissue debris consisting of extracellular 
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matrix components such as fibronectin and collagen can also activate wound 
macrophages (Dipietro, 1995).  
Most published research to date does not take into account the two CRP 
isoforms and their differential biological functions, but some roles are beginning to 
emerge. It has been indicated that the mCRP isoform could be a potential stimulant 
for the activation of monocytes to phagocytic macrophages when combined with 
the activation of Mac-1 (Eisenheardt et al, 2009). It has also been suggested that 
mCRP is a potent inducer of reactive oxygen species (Eisenhardt et al, 2009). This 
elucidates a further role of mCRP in the phagocytic process. A further pro-
inflammatory response of mCRP is reported that mCRP has the ability to increase 
monocyte adhesion to a fibrinogen matrix in vitro (Eisenhardt, 2009). Eisenhardt et 
al (2009) also explained that the nCRP isoform could partially inhibit the effects of 
mCRP on monocytes and suggested that this was due to a regulatory attenuating 
function caused by the pro-inflammatory effects of mCRP. This is also indicated in 
this study since at day 7 (D7) in acute INTACT wounds, the levels of the CRP 
isoforms were similar (mCRP at 42% and nCRP at 45%). Inflammation peaks and 
then subsides after Day 7, suggesting that the pro-inflammatory effects of mCRP 
decline its level becomes similar to that of the nCRP (i.e. ratio of mCRP:nCRP 
becomes close to 1). Beyond this point (ratio less than 1) the anti-inflammatory 
effects of the nCRP would start to come into effect. This difference in biological 
function could also be suggested due to the fact that both isoforms bind to 
separate receptors (mCRP binds CD16 whereas nCRP binds CD32 and CD64) (Khreiss 
et al 2002).  These differing levels of CRP isoforms at different time points post-
wounding suggest that CRP isoforms may simultaneously work together in playing a 
role in the inflammation process. 
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4.8.2 C-Reactive Protein Isoforms and Model of Age-Related Impaired Healing 
 Previous studies have shown that age is a factor effecting CRP levels in the 
body indicating that the CRP isoforms have the potential to be involved in the 
impairment of the normal wound healing process (Gomez et al, 2005). Impaired 
healing is defined as healing that has failed to progress throughout the normal 
stages of healing within the usual timeframes and is usually accompanied by an 
altered and pronounced inflammatory profile which tends to be pro-inflammatory 
in nature (Lazarus et al, 1994). 
 This study analysed the detection of the CRP isoforms in an established 
model of age-related impaired murine healing using mice that have undergone 
ovariectomy (OVX) prior to wounding (Ashcroft et al, 1997). 
 The ratio of mCRP:nCRP should be considered when analysing the effects of 
the CRP isoforms on the wound healing process. The mCRP isoform is considered to 
be more pro-inflammatory (Khreiss et al, 2004) than the nCRP isoform. In the age-
related impaired (OVX) model of healing, both time points indicated a higher 
mCRP:nCRP ratio and therefore a higher number of mCRP-positive cells than nCRP-
positive cells. This high ratio at both D3 and D7 indicates that the inflammation in 
impaired healing is excessive and prolonged, while corresponding wounds from 
INTACT mice have a lower ratio of mCRP:nCRP indicating fewer cells with the pro-
inflammatory CRP isoform. It can be suggested that in the INTACT wounds 
this lower ratio of the two CRP isoforms leads to a resolution of inflammation, thus 
allowing the wound to heal more rapidly and successfully (Eming et al, 2007).   
The exact role of the CRP isoforms have not been fully investigated to date. 
However, this study has shown for the first time that both CRP isoforms are located 
to inflammatory cells of murine wounds and that levels change with time post-
wounding, cell type and the effects of aging. These data indicate that the CRP 
isoforms may have a role in the inflammation process that needs further 
investigation.  
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4.9 Summary & Future Work 
This study has shown that both CRP isoforms are present in inflammatory 
cells throughout the inflammatory phase of acute wound healing. Furthermore, 
differential staining in a model of age-related impaired healing suggests the ageing 
process may affect the profile of CRP isoforms present in wounds. Future work may 
include further characterisation of CRP isoforms in murine wounds to pinpoint the 
precise cell types and cellular structures involved. Techniques such as dual 
fluorescence microscopy or immunogold labelling could be adopted to enable 
staining of multiple proteins on a single wound section and confirm the co-
localisation of CRP isoforms with specific cell types present in wound sections.  
No evidence has been presented to show what role the CRP isoforms may 
play during the inflammatory phase of wound healing. However, this work has 
provided a basis to consider the effects of both CRP isoforms on models of wound 
healing and inflammation processes. It is speculated that the relative amounts of 
each CRP isoform may mediate inflammation and that a shift in this balance may 
contribute to impaired healing states and pronounced inflammation. The next steps 
would be to investigate the effect of CRP isoforms on a range of processes such as 
cell proliferation, cell death, nitric oxide and cytokine production and phagocytosis.  
Finally, this work should be repeated using human acute wounds taken from 
young and elderly subjects to determine whether the findings from this murine 
model can be extrapolated to healing in humans. Moreover, confirmation of an 
altered CRP isoform profile in chronic compared to acute human wounds together 
with data showing distinct biological roles for CRP isoforms could provide 
tantalising evidence to implicate CRP isoforms in chronic wound pathology. Such 
findings could ultimately elucidate novel and focused therapeutic strategies for the 
treatment of chronic wounds. 
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Chapter 5: The Effect of C-Reactive Protein Isoform on 
Growth and Viability in Monocytes and Macrophages 
5.1 Introduction 
5.1.1 Cell Proliferation and Recruitment 
 The cell cycle is a heavily regulated process which involves many different 
components. Cell proliferation is an increase in the number of cells through the 
regulation of cell division, death and differentiation (van den Heuvel, 2005).   
 Cell division is made up of four main phases which need to be completed in 
order for cells to divide. This process takes roughly 24 hours for many mammalian 
cells. The G1 phase (Gap phase) prepares for deoxyribonucleic acid (DNA) 
replication by synthesising the many enzymes that are needed for the process. The 
S phase (synthesis phase) allows for the replication of DNA and the packaging of 
DNA so that the chromosomes become segregated (Scholey et al, 2003). This is 
followed by the G2 phase where protein synthesis occurs, including the production 
of microtubules to help with mitosis. During this gap phase the cell proof-reads the 
DNA to ensure proper replication and prepares for division (Park & Koff, 1998; 
Alberts et al, 2008). 
The fourth phase, M phase (Mitosis phase), consists of karyokinesis and 
cytokinesis where nuclear and cytoplasmic division occur resulting in the formation 
of a new cell membrane. The cells then enter into G0 which is a rest phase until the 
cell receives growth-promoting signals or pro-differentiation signals (Scholey et al, 
2003). 
 This cell cycle is strictly controlled by cyclin-dependent kinases (Cdk) which 
turn specific proteins on and off through phosphorylation during the different 
phases of the cell cycle. Various cyclins are produced during the process and when 
it becomes phosphorylated it forms a cyclin-Cdk complex which then activates the 
production of the next cyclin (van den Heuvel & Harlow, 1993). The process can be 
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inhibited by proteins such as p16, p21 and p27 which bind directly to the Cdk-cyclin 
complexes and inhibit their protein kinase activity (Scholey et al, 2003). 
 The process of proliferation allows for cells to be replaced when they have 
been lost to injury or death. Cell death can occur in one of two main ways; necrosis 
or apoptosis.  
 
5.1.2 Apoptosis 
 Cell death is part of the proliferation of cells. Cells that are damaged or 
ageing need to be removed from the host to retain the balance of cells. All cells can 
commit a programmed cell death which is termed apoptosis. This is different to 
necrosis where cell death occurs following injury or inflammation, causing the cell 
membrane to become disrupted and the release of intracellular contents into the 
extracellular environment. 
 In apoptosis, cell death is highly regulated.  The cells shrink in size as the cell 
condenses down (pyknosis), the cytoskeleton of the cell collapses, the nuclear 
envelope disassembles and nuclear DNA fragments (karyorrhexis) (Elmore, 2007). 
This allows the cell contents to accumulate in apoptotic bodies in a process called 
budding. These bodies are then phagocytosed, taken up into phagosomes and 
degraded (Elmore, 2007). This process allows the cells to die without inducing an 
inflammatory response since all the intracellular components are recycled by 
phagosomes (Elmore, 2007).  
 Apoptosis relies upon a family of proteases called caspases. These proteases 
have cysteine in the active site that is able to cleave proteins at specific aspartic 
acids.  These caspases are synthesised as an inactive precursor termed procaspases 
which remain inactive until cleaved at the aspartic acids by another caspase. Once 
activated, these caspases will cleave other procaspases to amplify the proteolytic 
cascade (McIlwain et al, 2015). These caspases can also cleave cell proteins and 
nuclear lamina. These processes cleave the proteins that are responsible for 
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keeping DNAse inactive, meaning that it is released and able to fragment the DNA 
in the nucleus (McIlwain et al, 2015). 
 Apoptosis is a complete and irreversible process which is self-amplifying and 
destructive. In the early phases of apoptosis, procaspases are activated by adaptor 
proteins which brings initiator procaspases into close proximity to one another to 
form a complex to then be activated by signals from the death receptors on the cell 
surface. This triggers the recruitment of intracellular adaptor proteins which bind 
and aggregate procaspase-8 in order for it become cleaved and activated. This 
capsase-8 can then activate downstream procaspases to induce apoptosis 
(McIlwain et al, 2015).  
 The death receptor, Fas, is expressed in stressed or damaged cells in order 
to trigger the caspase cascade and induce apoptosis (Elmore, 2007). DNA damage 
can also trigger apoptosis through p53; a tumour suppressor gene that is able to 
activate apoptosis that encodes a transcription factor which can bind DNA in a 
sequence-specific manner (Ko & Prives, 1996). P53 has control of both the intrinsic 
and extrinsic pathways of apoptosis and functions by transcribing the gene that 
encodes the protein responsible for the release of cytochrome C from the 
mitochondria. These proteins belong to the Bcl-2 family, which includes Bax, Bad 
and Bak (Fridman & Lowe, 2003). 
 The members of the Bcl-2 family function in various ways. Some, like Bad, 
are promotors of procaspase activation in order to promote apoptosis while others 
are death inhibitors. Bad will bind to these death inhibiting members of the family 
while Bax and Bak stimulate cytochrome C being released by the mitochondria, a 
step which is crucial for the induction of apoptosis (Amaral et al, 2010).  
 There are many caspases that are involved with this process and each of 
them have a specific role based upon their biochemical features and role they play 
in the process. There are ten major caspases which can be split into three main 
groups. Caspases -2, -8, -9 and -10 are initiators of the apoptotic process; caspases -
3, -6 and -7 are effectors and executioners and caspases -1, -4 and -5 are 
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inflammatory. There are others that have a less defined role in the process. For 
example, caspase-11 regulates apoptosis and cytokine maturation in instances of 
sceptic shock; caspase-12 mediates endoplasmic specific apoptosis and caspase-14 
is expressed only in embryonic tissues (Elmore, 2007).   
 Apoptosis is one of the main regulators of the cell cycle. It helps to prevent 
against cancer by inhibiting the growth of tumour cells but also to remove damaged 
cells that are no longer useful in the inflammatory process. 
 
5.1.3 C-reactive Protein, Cell Proliferation and Apoptosis 
 There is little research that has been conducted into the effect of C-reactive 
protein (CRP) on the proliferation process. However there is evidence that CRP has 
a major role in the apoptosis process.  
 Firstly, Kim et al (2014) suggested that CRP produces pro-apoptotic 
cytokines and inflammatory mediators which cause the activation of Fc-γ receptors. 
These receptors allow monocytes, macrophages and vascular smooth muscle cells 
to produce interleukin-1β (IL-1β) and tumour necrosis factor-α (TNFα) which are 
pro-apoptotic and lead to the formation of atherosclerotic plaques. This also 
activates reactive oxygen species (ROS) which activates NADPH oxidase (Nox) and 
subsequently reactive oxygen species (Ryu et al, 2007).  
The upregulation of p53 in monocytes is also regulated by CRP which allows 
for the transcription of proteins that promote apoptosis. It was suggested that CRP 
affects the cell cycle kinetics of monocytes through CD32 (FcγRII) and therefore 
triggering the resulting cascade. This induces G2/M arrest in the cell cycle which 
results in apoptosis (Kim et al, 2014).  
These CD32 receptors have been shown to trigger apoptotic signals in 
granulocytes and eosinophils and is expressed in a subset of monocytes that have 
been shown to polarise to pro-inflammatory macrophages. The results of these 
studies would suggest that the functional activity of CRP may alleviate macrophage 
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driven pro-inflammatory responses (Kim et al, 2014). CRP bound apoptotic 
monocytes and macrophages could be potentially removed via FcγR mediated 
phagocytosis. However CRP can trigger lots of signalling pathways so it cannot be 
assumed that the consequences are exclusive to CRP signalling (Kim et al, 2014).  
CRP is elevated in cardiovascular disorders and has is a mediator of 
atherosclerosis. CRP localises directly in the atherosclerotic plaques where it 
induces the expression of genes that directly involved in the adhesion of monocytes 
and the recruitment of intracellular molecules such as E-selectin and monocyte 
chemoattractant protein-1. CRP has also been shown to play a role in the mediation 
of low density lipoprotein uptake in macrophages and activating the complement 
system which plays a role in atherogenesis (Torzewski et al, 2000). Apoptosis occurs 
in these atherosclerotic plaques and the number of apoptotic cells increase as the 
lesion becomes more advanced. As cells become apoptotic they start to cause 
plaque disruption. This disruption leads to the expression on growth arrest- and 
DNA damage-inducible gene 153 (GADD153) by cells. GADD153 can induce G1 arrest 
or can induce apoptosis in some cancer cell lines (Guyton et al, 1996). 
Blaschke et al (2004) found that CRP can induce the apoptosis of human 
coronary vascular smooth muscle cells through a caspase-mediated mechanism 
especially through increased capase-3 activity. CRP was co-localised to the 
GADD153 gene in atherosclerotic lesions suggesting that CRP is triggering the 
caspase cascade by inducing the expression of the GADD153 gene, and therefore 
inducing apoptosis.  
 There is little research on how the two isoforms of CRP interact with the 
apoptosis process. It is suggested that CRP can exert anti-apoptotic activity but only 
when the cyclic pentameric structure is lost. This would suggest that the majority of 
the apoptotic activity of CRP is caused through the native isoform. Apoptotic can be 
delayed by activating the CD16 receptors on the cell. Native CRP (nCRP) can bind to 
low affinity IgG FcγRIIa (CD32) and IgG FcγRI (CD64) which leads to depressed 
functional activities, degranulation and the generation of superoxide by inducible 
respiratory burst. On the other hand mCRP binds to low affinity IgG FcγRIIIb (CD16) 
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which is the receptor that can delay apoptosis by triggering cell survival pathway in 
neutrophils, even at low concentrations (Khreiss et al, 2002). 
Native CRP does not repress apoptosis in neutrophils (Khreiss et al, 2002). 
However it can bind to the surface of intact apoptotic cells. C-reactive protein has 
the ability to opsonise apoptotic cells and induce the phagocytosis of these 
damaged cells. CRP binds to apoptotic cells in calcium dependent manner and 
trigger the classical complement pathway (Gershov et al, 2000). This results in 
protection against the assembly of terminal complement membrane complex and 
promotes a non-inflammatory clearance of cells (Khreiss et al, 2002).  
 
 
5.2 Aims 
 The aim of this investigation was to analyse the effects of various 
concentrations of exogenous CRP isoforms on the growth and viability of 
monocyte/macrophage models of inflammation. The investigation also established 
dose response data to guide future work in terms of optimal CRP concentrations 
and treatment times. Finally, the investigation assessed whether any reduction in 
viability was due to apoptosis and whether this could be reversed using 
pharmacological inhibitors of CRP-mediated pathways. 
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5.3 Objectives 
 The fundamental objectives of this assay were: 
 To analyse the effect of treatment time and concentration of exogenous 
nCRP on the growth and viability of monocytes/macrophages 
 To analyse the effect of treatment time and concentration of exogenous 
mCRP on the growth and viability of monocytes/macrophages  
 To determine if a reduction in cell viability was due to apoptosis by 
detecting genomic DNA fragmentation. 
 To determine if apoptosis could be reversed with the use of pharmacological 
inhibitors of pathways mediated by CRP. 
 
 
5.4 Summary of Procedure 
5.4.1 Growth and Viability Assay 
 This assay utilised a dye exclusion method using trypan blue dye. Cells were 
treated with a range of concentrations and incubation times for each CRP isoform. 
Following treatments, cells were treated with trypan blue dye to assess viability. 
The semi-permeable cell membranes of viable (living) cells did not take up the 
trypan blue dye and appeared colourless by microscopy. However, the permeable 
cell membrane of non-viable (dead) cells took up the trypan blue dye and appeared 
blue by microscopy. An automated cell counter was used to obtain the total cell 
count and a viable cell count based upon the amount of trypan blue staining. This 
method measured cell death induced by CRP isoform treatments but could not 
provide information as to whether the cell death occurred as a result of apoptosis 
or necrosis. 
 
 
82 
 
5.4.2 Apoptosis Assay 
  An apoptosis assay was utilised to determine whether apoptosis was 
occurring in the non-viable (dead) cells determined by the trypan blue staining 
method. The apoptosis assay relied upon the detection of genomic DNA 
fragmentation via gel electrophoresis however this method differs slightly from 
others mentioned in literature in that DNA fragmentation was visualised as 
smeared bands across the gel rather than individual detectable bands. This 
indicated the presence of multiple sized DNA fragments and provided evidence for 
apoptosis. A single (unfragmented) band of genomic DNA indicated the absence of 
DNA fragmentation and apoptosis, suggesting that cell death (if present) was 
instead likely to be due instead to necrosis.  
  
 
5.5 Materials 
5.5.1 Growth and Viability Assay 
Human monocyte cell line U937 (Health Protection Agency Culture Collections, 
Salisbury) 
RPMI-1640 Media (Lonza, Slough) 
Foetal Bovine Serum (Sigma-Aldrich, Dorset) 
Lipopolysaccharide (Sigma-Aldrich, Dorset) 
Phorbol 12-myristate 13-acetate (Applichem, Darmstadt) 
Trypsin (Thermo Fisher Scientific, Loughborough) 
C-reactive Protein, human >95% native, 5mg/ml (MyBioSource, San Diego) – 
Purified as previously stated in Section 2.4.4.  
Inhibitors – made up as mentioned in section 2.4.9. 
 
83 
 
5.5.2 Apoptosis Assay 
Camptothecin (Sigma-Aldrich, Dorset) 
Quick Apoptotic DNA Ladder Detection Kit (Biovision, San Francisco) 
TE Lysis Buffer 
Enzyme A Solution 
Enzyme B, dissolved in distilled water 
Ammonium Acetate Solution 
DNA suspension buffer 
Phosphate Buffered Saline (PBS) (Sigma-Aldrich, Dorest) 
70% Ethanol (Sigma-Aldrich, Dorest) 
 
5.5.3 Gel Electrophoresis 
Midori Green (Geneflow, Lichfield) 
1.2% Agarose Gel (Melford, Suffolk) 
Electrophoresis Gel tank (Bio-Rad, Hertfordshire) 
TBE buffer 
900mM Tris-base (Fisher Scientific, Cheshire) 
890mM Boric acid (Fisher Scientific, Cheshire) 
16mM Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, Dorset) 
Bio-Rad ChemiDoc™ Touch Imaging System (Bio-Rad, Hertfordshire) 
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5.6 Methods 
5.6.1 Cell Culture 
Cells were cultured as previously stated in Section 2.4.1. 
 
5.6.2 CRP Purification 
CRP was purified as stated in Section 2.4.4. The samples were then diluted 
to experimental concentrations using RPMI-1640 media. 
 
5.6.3 Growth and Survival Assays  
The CRP isoforms were analysed to determine their effects on the growth 
and survival of U937 cells over a set of treatment times and CRP isoform 
concentrations.  Concentrations of mCRP were 1µg/ml, 5µg/ml, 10µg/ml, 25 µg/ml, 
50 µg/ml, 100µg/ml and 250 µg/ml and concentrations of nCRP were 100 µg/ml, 
250 µg/ml, 500µg/ml and 1000µg/ml. A negative control was set up of just media 
treatment to create a baseline. Three replicates of each CRP concentration were set 
up in cell culture wells with a final cell density  of 1x106 viable cells/ml and 
incubated for a range of time periods (0.5, 1, 3, 6, 15 or 24 hours) at 37oC and 5% 
CO2. Following incubation each individual well was analysed using 0.4% trypan blue 
in a 1:1 ratio of cells to trypan blue and cell counts measured on a Biorad TC10 
Automated Cell Counter. Cell counts were taken twice from each well to collect six 
separate counts for each CRP isoform concentration. 
 
5.6.4 Cell Activation 
Some U937 cells were activated with 0.05mg/ml lipopolysaccharide (LPS) for 
a period of 24 hours as a model of bacterial infection before conducting the growth 
and survival assay (Section 5.6.3). 
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5.6.5 Cell Differentiation 
Some U937 cells were differentiated into macrophage-like cells using 
50ng/ml phorbol-12-myristate 13-acetate (PMA) for 72 hours to model tissue 
macrophages before conducting the growth and survival assay (Section 5.6.3).  
 
5.6.6 Quick Apoptotic DNA Ladder Detection Kit 
The cells were collected after a 24 hour treatment (as described in Section 
5.6.3) with either media (negative control), camptothecin (apoptosis positive 
control), 250μg/ml mCRP (mCRP sample), 1000μg/ml nCRP (nCRP sample), or 
equivalent concentrations of BSA (non-specific protein controls). Cell counts were 
obtained from each sample as described in Section 5.6.5. The cells were then 
centrifuged and re-suspended in RPMI-1640 at a concentration of 1 million total 
cells. Samples were then centrifuged at 1000rpm for 7 minutes and the supernatant 
removed. The pellet was washed in PBS and then centrifuged again for 5 minutes at 
500xg. The supernatant was removed and 35μl of TE lysis buffer was added to the 
pellet with 5μl of Enzyme A. Following a 10 minute incubation at 37oC and 5% CO2 
5ul of Enzyme B was added and incubated for 30 minutes at 50oC. This stage was 
followed by the addition of 5μl of Ammonium Acetate and 50μl of isopropanol 
before being stored at -20oC for 10 minutes. The sample was centrifuged for 5 mins 
at 500xg to precipitate the DNA. The supernatant was removed and the resulting 
pellet was washed with 0.5ml 70% ethanol. The trace ethanol was removed and the 
pellet was allowed to air dry for 10 minutes. The pellet was finally dissolved in 
100μl of DNA suspension buffer prior to gel electrophoresis.  
 
5.6.7 Gel Electrophoresis 
A 1.2% agarose gel containing Midori green was prepared and 40μl of 
sample was loaded into separate lanes of the gel. The gel was run at 15v/cm. The 
gel was imaged using the Bio-Rad ChemiDocTM Touch Imaging System. 
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 5.6.8 Statistical Analysis 
Graphs were drawn using Microsoft Excel 2013 and all statistics performed 
using IBM SPSS Statistics (Version 22). The Shapiro-Wilkes normality test was 
conducted on the data and t-tests or Mann-Whitney tests were conducted upon all 
the data. Images from the Bio-Rad ChemiDocTM Touch Imaging System were 
analysed using the Bio-Rad Image Lab Software (Version 5.2.1). 
 
 
5.7 Results 
5.7.1 The Effect of CRP Isoforms on the Growth of Monocytes and Macrophages 
Over 24 Hours 
 The average growth of the unactivated monocytes after treatment with 
mCRP was plotted against time. There was a general trend of increased growth over 
time (Figure 5.1), with (on average) a 40% growth observed between 6 and 24 
hours for concentrations below 50μg/ml mCRP. Treatment with 250μg/ml mCRP 
resulted in a decline in cell number from the initial number of viable unactivated 
monocytes, as represented by a negative percentage and suggesting cell death had 
occurred.  
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Figure 5.1 – The effect of mCRP on unactivated monocytes over 24 hours.  Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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All concentrations exhibited positive cell growth until the 15 hour time 
point. The 250μg/ml mCRP treatment diverged from the trend, causing a decrease 
in viable LPS-activated monocytes below the initial number used to set up the 
assay, suggesting net cell death at 15 hours and particularly at 24 hours  
 
 
 
 
 
 
Figure 5.2 – The effect of mCRP on activated monocytes over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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 Figure 5.3 shows that 250μg/ml mCRP treatment reduced the growth of 
unactivated macrophages from the outset, with negative growth indicating net cell 
death from the initial cell density used to set up the assay. Between 1 hour and 6 
hours both the 50μg/ml and 100μg/ml treatments also caused negative cell growth 
of unactivated macrophages. However positive growth was observed from 15 hours 
onwards indicating recovery of cell growth at the later time points. All the other 
treatments with concentration below 50μg/ml retained positive growth across all 
time points. 
 
 
 
Figure 5.3 – The effect of mCRP on unactivated macrophages over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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 Figure 5.4 indicates that treatment with 250μg/ml mCRP resulted in a 
decrease in activated macrophages from the outset, with negative growth 
indicating net cell death until and including the 6 hour time point. However at the 
15 hour and 24 hour time points there was recovery in cell growth with positive 
growth observed with 250μg/ml mCRP. The other concentrations of mCRP below 
250μg/ml for the most part showed positive but typically declining growth of 
activated macrophages from the onset to the 24 hour time point.  
 
 
 
 
 
Figure 5.4 – The effect of mCRP upon activated macrophages over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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Figure 5.5 shows that when treated with high concentrations (500μg/ml and 
1000μg/ml) of nCRP there was a substantial decline in the growth of unactivated 
monocytes, with 1000μg/ml nCRP causing negative cell growth (net cell death) at all 
time points. Unactivated monocytes treated with 250μg/ml   nCRP showed 
recovery to positive cell growth after 3 hours and the 100μg/ml nCRP treatment 
showed positive growth at all time points.   
 
 
 
 
Figure 5.5 – The effect of nCRP on unactivated monocytes over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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Figure 5.6 shows that when monocytes were activated with LPS there was 
positive cell growth from 0.5 hours to 3 hours after which the results diverged.  
Activated monocytes treated with 500μg/ml and 1000μg/ml nCRP indicated 
negative growth (net cell death) after 6 hours. The two lower concentrations of 
nCRP (250μg/ml and 100μg/ml) exhibited over 20% more growth than in the 
negative control at 24 hours.    
 
 
 
 
Figure 5.6 – The effect of nCRP on activated monocytes over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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Figure 5.7 shows that nCRP at all concentrations caused positive cell growth 
in unactivated macrophages from 0.5 hours to 1 hour. However, cell growth 
following treatment with 1000μg/ml nCRP became negative after 1 hour with 
nearly 80% of the initial starting count lost by 24 hours.  The 500μg/ml treatment 
had a similar effect but only started to become negative at 15 hours and reaching 
50% of the initial cell count at 24 hours. The cells treated with 100μg/ml and 
250μg/ml exhibited positive cell growth across all time points but remained below 
that of the negative control from 6 hours onwards.  
 
Figure 5.7 – The effect of nCRP on unactivated macrophages over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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Figure 5.8 shows that nCRP maintained positive cell growth of activated 
macrophages at nCRP concentrations at (and below) 250μg/ml, although cell 
growth was below the negative control after the 0.5 hr time point. Treatment with 
1000μg/ml nCRP caused negative growth (net cell death) at all times points, 
particularly after 15 hours.  Treatment with 500μg/ml nCRP caused positive growth 
of activated macrophages at all time points before 24 hours, after which negative 
growth (net cell death) occurred.  
These figures (Figures 5.1 to 5.8) have identified the general timeline trends 
but only give some of the information captured by the growth and viability assay. 
Section 4.7.2 and 4.7.3 provides data on the significant changes in growth and 
viability at each specific time point.  
 
Figure 5.8 – The effect of nCRP on activated macrophages over 24 hours. Negative 
percentage represents a decrease in the number of cells compared to the initial viable 
count used in the assay. 
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5.7.2 The Effect of mCRP on Growth and Viability of Unactivated Monocytes  
Figure 5.9 indicates the effect on growth and viability of unactivated 
monocytes at each specific time point following treatment with mCRP at several 
concentrations.  
  
Figure 5.9 – The effect of various mCRP concentrations on growth and viability of 
unactivated monocytes at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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 From 6 hours onwards, there was a significant difference in cell growth of 
unactivated monocytes between the 250μg/ml mCRP treatment and the negative 
control. The assay was set up using 1x106 cells/ml and after 6 hours cell growth of 
unactivated macrophages became negative, with around a 20% reduction at 24 
hours, indicating net cell death compared to initial conditions. However, cell 
viability remained high, suggesting that either phagocytosis of dead cells was taking 
place by the remaining viable cells or that non-viable cells were undergoing lysis.  
 In general, treatment with mCRP (at all concentrations except 250μg/ml) 
resulted in a growth pattern similar to that of the negative control for the most part 
with few significant fluctuations observed.  
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5.7.3 The Effect of mCRP on Growth and Viability of Activated Monocytes  
 
 
Figure 5.10 – The effect of various mCRP concentrations on the growth and viability of 
activated monocytes at each time point (0.5hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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Figure 5.10 indicates the effects of the mCRP isoform upon activated 
monocytes at a range of concentrations. At 15 hours and 24 hours, treatment with 
250μg/ml mCRP showed a significant (p=0.001 and p=0.000 respectively) decline in 
cell growth compared to the negative control (as previously seen in Figure 5.9), 
suggesting net cell death.   
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5.7.4 The Effect of mCRP on Growth and Viability of Unactivated Macrophages.  
 
 
Figure 5.11 – The effect of various mCRP concentrations on the growth and viability of 
unactivated macrophages at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial cell density used to 
set up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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Absolute cell viability of unactivated macrophages remained relatively 
unchanged across all concentrations of mCRP and incubation times. 
At 6 and 24 hours, all mCRP concentrations showed a significant reduction 
in the growth of unactivated macrophages compared to the negative control, with 
the exception of 1μg/ml at 24 hours. At each time point there was a significant 
decrease in the growth of unactivated macrophages when treated with 50μg/ml, 
100μg/ml and 250μg/ml compared to the negative control. Treatment with 
250μg/ml mCRP caused cell growth of unactivated macrophages to remain negative 
(around 20% lower than the initial count used to set up the assay) at all six time 
points. For the treatments with 50μg/ml and 100μg/ml mCRP,  a significant (p<0.05) 
decline in unactivated macrophages was observed with negative cell growth 
indicating net cell death after an hour but at 15 hours there was evidence of 
recovery in cell growth. The amount of cell growth did not recover back to control 
levels with 50μg/ml and 100μg/ml mCRP but did become positive at 15 hours. . 
However viability remained high (no significant difference to the negative control) 
during the whole process suggesting that dead cells were being removed by one or 
more mechanisms (e.g. phagocytosis and/or cell lysis). 
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5.7.5 The Effect of mCRP on Growth and Viability of Activated Macrophages 
 
 
Figure 5.12 – The effect of various mCRP concentrations on growth and viability of 
activated macrophages at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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 Figure 5.12 indicates the effects of mCRP treatments at several 
concentrations and incubation times on activated macrophages. 
 Treatment with 250μg/ml caused a reduction in the growth of activated 
macrophages that was significantly (P<0.05) lower than the negative control. 
Between 0.5 hours and 6 hours this reduction was around 20% lower than the 
initial cell control used in the assay, indicating that net cell death had occurred. 
However at the 15 hour and 24 hour time points there was  some recovery with  
positive growth of around 9% in both cases, although this remained significantly 
(P<0.05) lower than the negative control. 
 Following 24 hours of treatment with mCRP, there was a significant (P<0.05) 
dose-dependent decrease in the growth of activated macrophages compared to the 
negative control at concentrations of 10μg/ml mCRP and above. However, the 
viability of activated macrophages remained high (>90%) in all cases.   
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5.7.6 The Effect of nCRP on Growth and Viability of Unactivated Monocytes  
 
 
Figure 5.13 – The effect of various nCRP concentrations on growth and viability of 
unactivated monocytes at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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Figure 5.13 indicates the effect of nCRP treatments on unactivated 
monocytes. 
From the outset, treatment with 1000μg/ml caused a significant (P<0.05) 
decline in cell growth and a reduction in viability of unactivated monocytes 
compared to the negative control. Treatment with 500μg/ml also significantly 
(P<0.5)  reduced the growth of unactivated monocytes but  cell viability was only 
significantly reduced at 0.5 hour, 1 hours, 15 hours and 24 hours compared to the 
negative control. In general, treatment with 250μg/ml nCRP also significantly 
(P<0.05) reduced growth of unactivated monocytes compared to the negative 
control but cell viability remained similar to the negative control (except at 15 
hours).  
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5.7.7 The Effect of nCRP on Growth and Viability of Activated Monocytes    
  
Figure 5.14 – The effect of various nCRP concentrations on growth and viability of 
activated monocytes at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
 
106 
 
Figure 5.14 indicates the effect nCRP treatments had on activated 
monocytes. There were no significant changes in either growth or viability 
compared to the negative control until the 6 hour time point. From 6 hours 
onwards there was a significant (P<0.05) decline in the number of activated 
monocytes when treated with 500μg/ml or1000μg/ml nCRP, with negative cell 
growth suggesting net cell death and the higher concentration having the greatest 
reduction on cell growth. The viability of activated monocytes at 500μg/ml and 
1000μg/ml nCRP significantly (P<0.05) decreased compared to the negative control 
from 6 hours onwards, falling to 41.1% and 27.6% respectively at 24 hours.   
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5.7.8 The Effect of nCRP on Growth and Viability of Unactivated Macrophages  
 
  
Figure 5.15 – The effect of various nCRP concentrations on growth and viability of 
unactivated macrophages at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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Figure 5.15 indicates the effect of nCRP treatments on unactivated 
macrophages. There were few significant changes in either growth or viability until 
the 6 hour time point. From 6 hours onwards there was a significant reduction in 
the number of unactivated macrophages when treated with 500μg/ml and 
1000μg/ml with the higher concentration causing negative cell growth (net cell 
death) from the 3 hour time point onwards. At 24 hours all nCRP concentrations 
caused a significant (P<0.05) reduction in the growth of unactivated macrophages. 
The viability of unactivated macrophages at 500μg/ml and 1000μg/ml nCRP was 
significantly (P<0.05) reduced from 6 hours onwards, falling to 27.8% and 13.3% 
respectively at the 24 hour time point.  
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5.7.9 The Effect of nCRP on Growth and Viability of Activated Macrophages  
  
Figure 5.16 – The effect of various nCRP concentrations on growth and viability of 
activated macrophages at each time point (0.5 hr to 24 hr). Negative percentage 
represents a decrease in the number of cells compared to the initial density used to set 
up the assay. Significant differences (P<0.05) compared to the negative control are 
denoted by *. 
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Figure 5.16 indicates the effects of nCRP treatments on activated 
macrophages. From 1 hour onwards there was a significant reduction in cell viability 
when treated with 500μg/ml or1000μg/ml,   and this trend continued through to 
the 24 hour time point. In terms of cell growth, 1000μg/ml nCRP treatment caused 
a significant reduction in the growth of activated macrophages from 1 hour 
onwards with progressively negative cell growth (net cell death) with increasing 
incubation time.  
 
5.7.10 The Effect of CRP Isoforms on Apoptosis 
In summary, both the highest concentrations of mCRP and nCRP exhibited 
negative cell growth in all cell models (phenotypes), suggesting evidence of net cell 
death. However, in many (but not all) cases cell viability remained relatively high, 
suggesting that dead cells may have been removed via phagocytosis or cell lysis. 
Therefore, an apoptosis assay was performed to assess whether the observed cell 
death was due to apoptosis.  
Treatment with 1000μg/ml nCRP provided evidence of cell death via 
apoptosis in all four cell models (phenotypes). Treatment with 250μg/ml mCRP 
showed no evidence of apoptosis in any of the cell models (phenotypes), suggesting 
that cell death following mCRP treatment must have been by some other 
mechanism(s) such as necrosis. Pharmacological inhibitors were then used to 
determine whether the nCRP-induced apoptosis could be reversed (Figure 5.17). 
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Figure 5.17 – The Effects of CRP Isoforms on Apoptosis. 
 
A) Unactivated monocytes   B) Activated monocytes  
C) Unactivated macrophages   D) Activated macrophages 
 
1 – Negative Control  2- Positive Control  3-BSA 1000μg/ml  4-BSA 250μg/ml 
5-nCRP 1000μg/ml  6- mCRP 250μg/ml 
7- nCRP 1000μg/ml with wortmannin  8- nCRP 1000μg/ml with LML 
9- nCRP 1000μg/ml with MEK  10- nCRP 1000μg/ml with nystatin 
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The negative control in lane 1 of all four cell models showed no DNA 
fragmentation (apoptosis) whereas in lane 2 the positive control caused smearing 
indicating apoptosis had occurred. The two lanes of BSA controls (lanes 3 and 4) 
showed no apoptosis had occurred.   Lane 5 (1000μg/ml nCRP) showed extensive 
DNA fragmentation (apoptosis). Lane 6 (250μg/ml mCRP) did not show evidence of 
DNA fragmentation (apoptosis). 
Wortmannin reversed the effect of apoptosis in unactivated monocyte cells 
treated with 1000μg/ml nCRP (Figure 5.17A). All four inhibitors reversed the 
apoptosis in activated monocytes (Figure 5.17B). In unactivated macrophages, none 
of the inhibitors reversed the apoptosis (Figure 5.17C). In activated macrophages, 
only the MAP kinase inhibitor (MEK) reversed the nCRP-induced apoptosis (Figure 
5.17D). 
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5.8 Discussion 
5.8.1 Growth and Viability Assays 
The growth and viability assays were performed to analyse the effects of the 
CRP isoforms on four different states (±LPS activation, ± differentiation) of U937 
cells to model different cell stages in the wound healing process.  
Undifferentiated U937 cells represent/model circulating monocytes prior to 
wounding or infection. Differentiated U937 cells represent/model tissue 
macrophages following wounding. Unactivated and LPS-activated U937 cells 
represent/model the absence and presence of infection respectively.   
Figures 5.1 and 5.2 show that high concentrations (250µg/ml) of mCRP 
caused negative growth from 6 hours onwards, suggesting net cell death was 
occurring. However, the growth/viability assay was not able to determine whether 
necrosis and/or apoptosis were taking place. Indeed, cell viability following 
treatment with 250µg/ml mCRP remained high (between 90% and 100%) at all time 
points, suggesting non-viable cells were already removed by cell lysis or 
phagocytosis.  
 The activation of the cells seem to have a profound effect by delaying the 
effects of the treatment with a reduction in the number of cells at 250μg/ml mCRP 
being seen at 15 hours rather than at 6 hours. This exposure means that the 
monocytes are undergoing the various processes in wound healing; including the 
release of cytokines, chemokines and various other instructional factors (Hart, 
2002a). Mold et al (2002) suggested that CRP causes a moderated cytokine profile 
in previously LPS-activated cells which in turn reduced the toxic side-effect of LPS 
after an infection occurs. This process can be suggested that the LPS activation of 
the cells ‘prepares’ the cells so that they respond more efficiently to the CRP 
treatment. This would be a likely suggestion as to why there is this time delay for 
the effect of mCRP between the unactivated monocytes and the activated 
monocytes.  
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Figures 5.5 and 5.6 show a substantial reduction in the number of viable 
cells with the higher (1000μg/ml) nCRP concentration. A decline in growth was seen 
from the earliest time point with the unactivated monocytes. However, this was 
delayed until 6 hours in the LPS activated monocytes. Again, this suggests pre-
activation with LPS delays subsequent responses. In both unactivated and activated 
monocytes there was a significant (P<0.05) decrease in viability from 6 hours 
onwards following treatment with 1000μg/ml nCRP. This was indicative of cell 
death but the cell viability assay alone could not determine what type of cell death 
was occurring. The cell viability following treatment with lower concentrations 
(100μg/ml and 250µg/ml) of nCRP remained above 90% at all time points. This 
suggests nCRP, which has previously been associated with anti-inflammatory effects 
(Eisenhardt et al, 2012), may reduce the inflammatory cell count by affecting cell 
survival. This supports evidence that nCRP is the only CRP isoform that induces 
apoptosis and that apoptosis ceases following loss of its pentameric structure 
(Khreiss et al, 2000). 
Figures 5.3 and 5.4 present growth/viability data on differentiated 
macrophages treated with mCRP, with Figure 5.4 representing LPS-activated 
macrophages. Figure 5.3 shows that treatment with 250µg/ml mCRP caused a 
decline in growth of unactivated macrophages from the outset but viability was not 
affected, supporting evidence that mCRP does not induce apoptosis of cells. 
Treatment with 50µg/ml and 100µg/ml also showed a decline in the number of 
unactivated macrophages but positive recovery of growth was observed at and 
beyond 15 hours. At 24 hours, there was a dose-dependent effect of mCRP on the 
growth of unactivated macrophages, with increasing mCRP concentration causing a 
greater reduction in the growth of cells. Viability of unactivated macrophages 
remained high at all time points and mCRP concentrations, suggesting that a 
reduced rate of cellular proliferation (rather than increased cell death) was 
mediating the overall effect of mCRP on net cell growth.  
Figure 5.4 shows the effects of mCRP on LPS- activated macrophages. 
Treatment with 250µg/ml mCRP caused a significant decline in the number of 
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activated macrophages from 0.5 hours onwards compared to the negative control 
but in contrast to unactivated macrophages, the cell density recovered from 15 
hours onwards.  Again, at 24 hours there was a dose-dependent effect of mCRP on 
the growth of activated macrophages, with increasing mCRP concentration causing 
a greater reduction in the growth of cells, but the growth was higher than that seen 
in unactivated macrophages. This suggests pre-activation of macrophages with LPS 
may negate the inhibition of cell growth induced by mCRP. 
Figures 5.7 and 5.8 showed the effect of nCRP on unactivated and activated 
macrophages. In general, there was a similar effect of nCRP on macrophages to that 
seen in monocytes. At later time points, higher concentrations of nCRP caused both 
a significant decline in the number of cells and a decline in macrophage viability. 
This effect was similar in both unactivated and activated macrophages. 
In all four cell states and with both sets of isoform treatments it is 
interesting that majority of the significant effects are seen at the 24 hour time point 
since this is when CRP starts to accumulate after an inflammatory signal (Ciubotaru 
et al, 2005).  
Most of the significant changes within these data came from high 
concentration treatments (100μg/ml and 250μg/ml mCRP; 500μg/ml and 
1000μg/ml nCRP) and after 6 hours of treatment. As the growth of cells declined 
over 24 hours this would suggest that cells were not entering into the cell cycle for 
proliferation and that most likely they would be remaining in the G0 phase where 
the cells are in a resting state (Scholey et al, 2003).  
There has been little research conducted into the effect of CRP isoforms 
upon the proliferation of cells and it can be suggested that CRP does not upregulate 
any of the cyclin-dependent kinases that are required to pass through the different 
phases of the cell cycle (van den Heuvel & Harlow, 1993). The results indicated that 
cell death was likely occurring however these cells were not being replaced via 
proliferation. This could potentially indicate that the CRP could be inhibiting the 
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cyclin-dependent kinases that are required for proliferation to occur in order to 
replace those cells.  
Kim & Ryu (2004) suggested that CRP led to the upregulation of p53 which 
led to a G2/M arrest which ultimately leads to apoptosis. As treatment with nCRP 
exhibited declined growth and viability, this would support this conclusion, 
however treatment with mCRP led to a decline in growth without a supporting 
decline in viability suggesting that this pathway was not being utilised in this case.  
Originally lower concentrations of nCRP were tested at similar 
concentrations to those tested for mCRP (1-100μg/ml). However, lower 
concentrations of nCRP had no effect upon any of the cell states investigated with 
U937 cells (data not shown). This is understandable since CRP is usually found at a 
concentration of about 1μg/ml in the absence of inflammation and can increase up 
to 1000 fold in circulation following an acute inflammatory response (Gabay & 
Kushner, 1999). Thus, 1000μg/ml became the upper limit for testing the effects of 
nCRP in this study, in line with published maximal physiological levels found in 
circulation.  
  
5.8.2 Apoptosis Assay 
 As mentioned previously both isoforms caused a decline in cell number 
below that of the initial cell density used to set up the assay. This negative cell 
growth indicated net cell death had taken place, particularly in the case of nCRP 
treatments where the viability also significantly reduced. Treatment with mCRP 
caused negative cell growth without affecting overall cell viability, suggesting dead 
cells were quickly removed by cell lysis or apoptosis.  
 The apoptosis assay was run with a positive control of camptothecin to 
ensure that the electrophoresis gel was detecting fragmented DNA correctly. In all 
four assays for the different cell states, the negative control showed no DNA 
fragmentation and neither did controls treated with two concentrations of BSA to 
mirror those of the CRP isoforms. The assay above showed that addition of a 
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generic (non CRP) protein did not induce apoptosis in any of cell states tested. The 
positive control generated DNA fragmentation in all cell states. 
Treatment with mCRP did not induce apoptosis in monocytes or 
macrophages. This is supported by evidence showing mCRP is associated with 
delayed apoptosis of neutrophils and a prolonged inflammatory response (Khreiss 
et al, 2002). This is interesting since the number of macrophages in chronic wounds 
has been shown to be excessive (Diegelmann & Evans, 2004) and finding potential 
mechanisms to reduce the inflammatory response is a therapeutic strategy for the 
treatment of chronic wounds.  
The net cell death observed by the mCRP treatment must have been 
induced by some other mechanism (e.g. cell lysis/necrosis) rather than apoptosis. 
Thus, the high cell viability observed following mCRP treatment makes sense since 
necrosis can occur quickly, removing dead cells through cell lysis and leaving just 
viable cells.  
 Khreiss et al (2002) suggested a pathway of the inhibition of apoptosis that 
is utilised by the mCRP isoform. Figure 5.18 below shows this pathway.  
 
 
 
 
 
 
 
 
Figure 5.18 – The method of apoptosis inhibition by monomeric CRP. Other pathways 
of inhibition have been added to the diagram. (Modified from Khreiss et al, 2002) 
119 
 
This pathway shows that mCRP inhibits apoptosis via the CD16 receptor by 
activating the MAPK and PI3K pathways to produce ERK and AKT thereby inhibiting 
the p38 MAPK pathway. This is caused by the prevention of p38 to cleave 
procaspase-3, preventing the triggering of the caspase cascade and therefore 
inhibiting apoptosis (McIlwain et al, 2015). 
This supports why the viability in all of the treatments with mCRP remained 
high since there was no evidence of apoptosis but other mechanisms of cell death 
such a necrosis may have occurred. Necrosis leads to the release of intracellular 
contents and the induction of an inflammatory response, including the release of 
cytokines. The induction of cytokines by CRP isoforms is assessed in Chapter 7, 
confirming that mCRP does indeed induce the release of pro-inflammatory 
cytokines at the same time as causing net cell death. 
Another potential mechanism by which mCRP might be inhibiting the 
apoptosis pathway is by preventing the activation of p53 caused by DNA damage or 
by preventing the activation of the death receptor Fas, which is expressed in 
stressed or damaged cells (Elmore, 2007). If this was the case, mCRP may cause the 
inhibition of the caspase cascade through these other pathways.  
 Treatment with nCRP was found to fragment the DNA and cause apoptosis 
of U937 cells, regardless of their cell state. This corresponded to a decline in the 
number of cells and a decrease in the cell viability. It suggested that nCRP can 
trigger the apoptosis pathway by binding to CD32 and CD64 receptors on the cell 
surface to promote the expression of TNF-α and IL-1β. These cytokines trigger the 
upregulation of p53 and triggering the caspase cascade as a result. This process has 
been suggested to occur in about 4 hours (Kim & Ryu, 2014) which coincides with 
the data from the growth/viability assay where most of the significant effects were 
seen after 6 hours.  Blaschke et al (2004) found that CRP can induce apoptosis 
through increased caspase-3 activity. The results of this study indicates that this 
pathway is potentially being activated when treated with nCRP.  
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 The effect of pharmacological inhibitors would also suggest that nCRP is 
having an effect on the pathway in Figure 5.18. With unactivated monocytes, only 
wortmannin reversed the effect of the nCRP. This would suggest that inhibition of 
apoptosis is occurring through the Akt pathway which inhibits p38 MAPK to prevent 
apoptosis. This suggests that monocytes undergo apoptosis through this pathway 
following nCRP treatment. However, the response was not reversed by other 
inhibitors of this pathway, suggesting that one or more other signalling pathway(s) 
could also be contributing to the apoptosis seen in the unactivated monocytes.  
 In the activated monocytes all four inhibitors reverse the effects of 
apoptosis. Three of the four inhibitors that feature on this pathway would inhibit 
this process at various stages of the pathway. All three result in the inhibition of the 
p38-induced cleavage of procaspase-3, resulting in cell survival. The last inhibitor, 
nystatin, inhibits apoptosis via an alternative pathway. Nystatin is a lipid raft 
disruptor that causes the formation of pores in the plasma membrane of eukaryotic 
cells, thereby allowing potassium and other components to cross the membrane. 
Previously it has been noted that delayed apoptosis was observed in neutrophils 
treated with nystatin. This was due to the fact that Fas signalling was needed to 
trigger the activation of capase-8 and therefore the cascade needs an intact lipid 
raft for this to be successful (Scheel-Toellner et al, 2004). This could indicate that 
there were some physiological changes to the membrane when cells became 
activated with LPS that would affect the use of the lipid rafts in the activation of 
apoptosis, however further work would need to be conducted to establish this.  
 Unactivated macrophages saw no changes with the use of inhibitors. This 
would suggest that when the cells become differentiated into tissue macrophages, 
apoptosis is managed via an alternative pathway.  
 When macrophages were activated with LPS, only the use of the MAPK 
inhibitor, MEK, brought about a reversal in apoptosis. This would suggest that nCRP 
induces apoptosis via a different pathway than those in monocytes, and that by 
inhibiting the MAP/ERK pathway in this case would result in the inhibition of 
apoptosis. However, the inhibitor LML did not reverse the effect of nCRP, again 
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suggesting that nCRP may be inducing apoptosis via a different pathway. Further 
investigations would be needed to confirm the precise pathways that are being 
utilised by the native CRP isoform to induce apoptosis.  
 Evidence could also indicate that treatment with nCRP is leading to the 
increased clearance of cells. The nCRP could be binding to apoptotic cells in and 
triggering the classical complement pathway (Gershov et al, 2000), resulting in 
protection against the assembly of terminal complement membrane complex and 
promotes a non-inflammatory clearance of cells (Khreiss et al, 2000). This could 
potentially explain why there is a decline in the growth of the cells but does not 
explain why apoptosis is only seen in cells that have been treated with only high 
concentrations of nCRP.  
 
 
5.9 Future Work 
 These assays only took into consideration four states of inflammatory cell 
and could be repeated with other inflammatory cells such as neutrophils. Another 
expansion would be to treat the monocytes and the macrophages with other 
activators in order to establish their effect (e.g. cytokines) upon the effects of CRP. 
 The apoptosis assay could also be repeated with numerous other inhibitors 
to identify specific apoptosis pathways being utilised by nCRP or if there is a 
combination of pathways working in concert with each other.  
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5.10 Summary 
 Both CRP isoforms caused a decline in the number of monocytes and 
macrophages however only treatment with nCRP caused apoptosis to occur. 
Treatment with mCRP did not cause apoptosis, suggesting the net cell death 
observed following mCRP may be caused by other mechanisms such as necrosis. 
Evidence suggests that nCRP causes apoptosis through a variety of pathways.  
These growth and viability assays have provided evidence to determine the 
range of exogenous CRP concentrations to use in the project. The findings indicate 
that the effect on CRP isoforms on cell number and viability should also be taken 
into consideration when calculating the effects of the CRP isoforms on other cell 
properties and assays investigated throughout this study. 
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Chapter 6: The Effect of Exogenous C-Reactive protein on 
Nitric Oxide Production Assay 
6.1 Introduction  
6.1.1. Nitric Oxide 
 Macrophages and other phagocytes utilise many different processes in 
inflammation. One of these is the generation of reactive oxygen and nitogen 
species (ROS and RNS). These molecules are used to eradicate material that have 
been engulfed by the phagocytes. These species are generated in response to 
inflammatory stimuli such as LPS on bacteria, and results in a process called the 
respiratoy burst (Neidhart, 1996). These bursts mainly result in the production of 
ROS by phagocytes however nitric oxide, an RNS, is produced by almost all 
nucleated cells (Nathan, 1992).  
Nitric oxide (NO) is a short lived, pleiotropic free radical regulator which has 
various biological function in process including vasodilation, neurotransmission, 
inflammation and macrophage-mediated immunity (Weiming et al, 2002). This 
intercellular signalling molecule is important for the immune system as well as 
generating free oxygen radicals called peroxynitrites (ONOO-) which can act in a 
cytotoxic manner causing tissue damage and apoptosis (Bogdan, 2001). NO has 
been identified as playing a functional role in processes such as leukocyte adhesion 
and transmigration, cytokine expression as well as proliferation and apoptosis 
(Clancy et al, 1998; Rawlingson, 2003; Cross & Wilson, 2003; Korhonen et al, 2005).  
Due to the versatility of nitric oxide in its responses it can be classed as 
having both pro- and anti-inflammatory effects ; however the inhibition of the 
pathways has shown to beneficial to the treatment of inflammatory disease (Aktan 
et al, 2003). There are several factors that affect the effectiveness of NO. These are 
the concentration of NO, the rate of reactive nitrogen species formation and the 
physiological environment. Nitric oxide has properties that allow it to be easily 
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soluble and diffuse across membrane to conduct its intracellular processes 
(Coleman, 2001). 
During the inflammation process pro-inflammatory cytokines lead to the 
expression of NO in monocytes and macrophages as well as in neutrophils leading 
to large amounts being produced beyond normal physiological concentrations 
(Sharma et al, 2007). This amount can also be up to 1000-fold higher than normal 
(Fӧrstermann et al, 1994). Nitric oxide also acts as an inflammatory mediator, a 
positive feedback molecule which is released by macrophages during phagocytosis 
in order to recruit more phagocytes to the tissue. However too much NO can lead 
to tissue destruction as seen in autoimmune diseases, providing evidence for both 
anti- and pro-inflammatory responses (Pfeilschifter et al, 1996).  
NO biosynthesis occurs as a by-product during the conversion of L-arginine 
to L-citrulline including other substrates nicontinamide adenine dinucleotide 
phosphate (NADPH) as an electron donor and oxygen (Aktan, 2003).  This two step 
oxidative reaction is catalysed by one of four nitric oxide synthases (NOS); 
endothelial NOS (eNOS), neural NOS (nNOS), inducible NOS (iNOS) and the lesser 
known mitochondrial NOS (mtNOS) (Giulivi, 2003). These subtypes of synthases 
depend on the tissue type they are located in; with eNOS and nNOS found in 
endothliuem. The subtype, iNOS is the only one that is soluble and is not present in 
resting cells (Aktan et al, 2003).  
 Stimulation of iNOS occurs as a result of immunostimulatory cytokines, 
bacterial products or infection (Nathan, 1992) and it generates NO in a manner 
independent of calcium levels (Aktan et al, 2003).  
 The structure of iNOS is classified as having a bi-domain consisting of a c-
terminal and an n-terminal. The c-terminal acts a reductase domain that contains 
the binding site for NADPH and other signalling molecules. The n-terminal acts as an 
oxygenase domain with the biding site for heme and L-arginine (Aktan et al, 2003).  
Macrophages express iNOS in the early stages of the wounding process. The 
production of iNOS in macrophage is mediated by Toll-like receptors and CD14. The 
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CD14 receptor is a receptor for LPS activation and leads to the activation of the 
nuclear factor-κβ (NF-κβ) pathway. IFN-γ can also induce the production of iNOS via 
the JAK-STAT signalling pathway, increasing both iNOS and NO production 
(Korhonen et al, 2005). Inhibition of iNOS significantly impairs reepithelialisation, 
increases the rate of closure of full thickness wounds and decreases collagen 
deposition (Park & Barbul, 2004).  
The levels of NO produced can be regulated at the transcriptional level 
depending on the cell type and the type of stimulation that was utilised to activate 
the pathway. Other pathways can also be affected in this process such as the MAP 
kinase and PI3 kinase pathways (Aktan et al, 2003). There is conflicting evidence if 
the p38 pathway is involved, with studies showing that there is upregulation, 
downregulation and no effect on NO production via this pathway (Chan et al, 1999; 
Cho et al, 2002). NO can also regulate its own production through the use of both 
positive and negative feedback loops. The positive feedback utilises the increase in 
cAMP levels to activate the production of iNOS and increase NO production. The 
negative feedback loop uses the inhibition of NFκβ to lower NO production (Aktan 
et al, 2003). 
 
6.1.2 Nitric Oxide and estrogen 
Nitric oxide is regulated by many differeing endogenous factors inlcuding 
hormones including estrogen (Karpuzoglu & Ahmed, 2006). Studies have shown 
that estrogen has the ability to increase NO production suggesting a role in the 
inducation of vasodilation in the cardiovascular system (Nevzati et al, 2015) and the 
implication in the pathogenesis of other disorders (Karpuzoglu & Ahmed, 2006).  
Estrogen is known to increase the generation of iNOS and NO in immune 
cells by upregulating the levels of iNOS mRNA, iNOS protein and NO. This is 
achieved through the mediation of interferon-gamma (IFN-γ) which is a pro-
inflammatory cytokine which is enhanced through estrogen (Karpuzoglu & Ahmed, 
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2006). These studies have indicated a role for estrogen in inflammation and 
immunse processes but this has not been fully elucidated.  
 
6.1.3 Nitric Oxide and C-Reactive Protein 
 The role of CRP in nitric oxide production has been identified in a few 
studies. Several studies have revealed that nCRP inhibits NO production via 
downregulation of eNOS in cardiovascular endothelial cells, thereby inhibiting 
angiogenesis in vitro. This promotes the pathogenesis of atherosclerotic vascular 
disease through vasoconstriction, leukocyte adherence and inflammation (Verma et 
al, 2002; Venugopal et al, 2002; Devaraj et al, 2006; Singh et al, 2007). The 
restrictive factor of this research is that the CRP isoform responsible for this result 
was not specified but it is assumed that it was the native protein.  Another study 
found that nCRP downregulated eNOS and thus impaired endothelial function in 
ApoE knockout mice, in a mechanism thought to involve iNOS (Schwedler et al., 
2007). This would indicate that the other studies mentioned previously were 
possibly researching the pentameric protein as well. Eisenhardt et al (2009) also 
stated that CRP upregulated the expression of adhesion molecules and inhibited 
endothelial nitric oxide synthase expression indicating a role for CRP in the 
production of NO. 
C-reactive protein has the ability to attenuate NO production which is 
associated with a marked reduction in in vitro angiogenesis but it was also shown 
that both wound cell migration and capillary like tube formation are inhibited by 
CRP at concentrations known to cause cardiovascular risk (Verma et al, 2002). 
Eisenhardt et al (2009) provided evidence that nCRP suppresses 
endothelium dependent nitric oxide-mediated dilation by activating the p38 
mitogen activated protein kinase (MAP kinase) pathway and NADPH oxidase 
suggesting multiple pathways could be interacting with this process.  
Other studies have indicated that mCRP has the opposite effect with  
enhanced NO production in neutrophils via upregulation of eNOS (Khreiss et al, 
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2005). This study found that when neutrophils were incubated with mCRP there 
was a significant increase in the amount of NO that was produced. When reverse 
transcriptase was performed it showed that there was an amplification of the eNOS 
mRNA, but not that of iNOS or nNOS. This study also highlighted that there is a 
calcium (Ca2+) mobilisation and activation of calmodulin and PI3 kinase in order for 
mCRP to induce NO formation (Khreiss et al, 2005).  
There is very little research that has been conducted into the effect of CRP 
isoforms on the production of iNOS and NO in either monocytes or macrophages to 
date.   
 
 
6.2 Aims 
 The aim of this study was to analyse the effect of the CRP isoforms on the 
production of nitric oxide in monocytes and macrophages. The second aim was to 
infer specific signalling pathways being utilised by the C-reactive protein isoforms 
by using pharmacological inhibitors to block/reverse the effect of CRP isoforms on 
NO production. The last aim was to investigate the influence of ageing on CRP-
mediated NO production by using estrogen supplementation to model the 
responses during youth.  
 
6.3 Objectives 
  The objectives of this assay were to: 
 Determine the effect of the nCRP and mCRP isoforms on the production of 
NO. 
 Investigate if pharmacological inhibitors can reverse CRP-mediated NO 
production. Investigate the effect of estrogen supplementation on CRP-
mediated NO production. 
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6.4 Summary of Procedure 
 The method of detecting NO in this study was via the Griess assay (Griess, 
1879). This assay is based upon the diazotition reaction that uses 2% 
sulphanilamide and 0.2% N-1-napthylethylenediamine dihydrochloride (NED) under 
5% phosphoric acid conditions (Giustarini et al, 2008). The assay detects nitrites 
(NO2-) which are a by-product of NO synthesis, which is stable. The procedure 
involves a chemical reaction when treated with NED that generates a pink colour as 
nitrites form a salt. This colour is then detected at a wavelength of 540nm, with a 
darker pink colour being indicating a higher concentration (Sun et al, 2003). 
 
6.5 Materials 
Human monocyte cell line U937 (Health Protection Agency Culture Collections, 
Salisbury) 
RPMI-1640 Media (Lonza, Slough) 
Foetal Bovine Serum (Sigma-Aldrich, Dorset) 
Lipopolysaccharide (Sigma-Aldrich, Dorset) 
Phorbol 12-myristate 13-acetate (Applichem, Darmstadt) 
C-reactive Protein, human >95% native, 5mg/ml (MyBioSource, San Diego) – 
Purified as previously stated in Section 2.4.4.  
Inhibitors – nystatin prepared as mentioned in section 2.4.9. 
Estrogen (Sigma-Aldrich, Dorset) 
Modified Griess Reagent (Sigma-Aldrich, Dorset) 
Sodium Nitrite (Sigma-Aldrich, Dorset) 
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6.6 Methods 
6.6.1 Cell Culture 
Cells were cultured as previously stated in Section 2.4.1. 
 
6.6.2 Activation of Cells 
 Cells were activated as stated in Section 2.4.2. 
 
6.6.3 Differentiation of Cells 
 Cells were differentiated as stated in Section 2.4.3.  
 
6.6.4 CRP Purification 
CRP was purified as stated in Section 2.4.4. The samples were then diluted 
to experimental concentrations using RPMI-1640 media. 
 
6.6.5 Estrogen Preparation 
 Estrogen was prepared at three final concentrations of 1x10-7M, 1x10-8M 
and 1x10-9M, made up in RPMI-1640 complete media with FBS and penicillin-
streptomycin.  
 
6.6.6 Griess Reagent Assay 
Cells at a concentration of 1x106 cells/ml were incubated with physiological 
concentrations of mCRP (100µg/ml or 250µg/ml) or nCRP (500µg/ml or 1000µg/ml) 
for 24 hours. NO production was then measured in each treatment group (n=12) by 
the Griess method (Griess, 1879) with the absorbance of a 1:1 ratio of sample and 
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Griess reagent read using a Biotech Synergy HT ELISA plate reader at a wavelength 
of 540nm. Concentrations were calculated against a standard curve based upon a 
set of standards of sodium nitrite (0μM, 1μM, 10μM, 25μM, 50μM, 75μM and 
100μM) and an example if this can be seen in Appendix 5. In the inhibitor assay and 
ageing model, cells were co-incubated with inhibitors or estrogen during the CRP 
treatment phase.  
 
6.6.7 Inhibitors 
 The Greiss reagent assay was repeated (Section 6.6.6) with the addition of 
the inhibitor nystatin, prepared as stated in Section 2.4.9.  Some potential 
inhibitors, wortmannin, MEK and LML, were not used due to known direct effect on 
iNOS and nitric oxide production (Salh et al, 1998; Ajizian et al, 1999; Kim et al, 
2004).  
 
6.6.8 Statistical Analysis 
Raw data was recalculated for adjust for conditions and cell number. 
Treatment groups were analysed for normality using a Shapiro-Wilke normality test. 
Results were statistically compared by t-tests or Mann-Whitney U-test comparisons 
using SPSS (Version 22) and P<0.05 was considered significant in all cases. Graphs 
were generated using Microsoft Excel 2013.  
 
 
6.7 Results 
6.7.1 The Effect of Exogenous CRP Isoforms on Nitric Oxide Production. 
 Figure 6.1 indicates the effect that each isoform has upon NO production in 
each cell model. Monocytic cells exhibited a significant increase in the production 
of NO at both concentrations of mCRP when compared to the controls. A 
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significantly greater increase in NO was seen when the cells were not treated with 
LPS. Both concentrations of mCRP did not have any significant effect upon NO 
production in the macrophage and activated macrophage cells.  
When treated with the lower concentration of nCRP, only the unactivated 
monocytes showed no significant (p=0.08) difference in the production of NO. The 
other three cell states exhibited a significant reduction in the amount of NO 
produced.  
 
At the higher concentration of nCRP there was a significant (p=0.036) 
increase in the production of NO in unactivated monocytes (from 11.29μM to 
17.77μM) while the other three cell states exhibited a significant reduction in the 
production of NO, with the greatest reduction (from 13.66μM to 6.52μM) observed 
in the activated monocytes.  
Figure 6.1 The effect of C-reactive protein isoforms on nitric oxide production 
in several cell states (monocyte, activated monocyte, macrophage and 
activated macrophage). * indicates significant differences (P<0.05) compared 
with corresponding control. 
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 Samples with significant changes in the production of NO were repeated 
with the inclusion of pharmacological inhibitors in order to evaluate their ability of 
reverse the CRP-mediated NO production, thereby indicating potential CRP-
mediated pathways. 
 
6.7.2 The Effect of Inhibitors on Nitric Oxide Production in C-Reactive Protein 
Treated Cells 
 Sample treatments that exhibited a significant change in NO production 
were repeated with the nystatin inhibitor. Only the nystatin inhibitor was used for 
this element of the project as the three other inhibitors used in other chapters were 
known to have a direct effect upon NO production. Figure 6.2 and 6.3 show the 
successful reversal of NO production by nystatin (non-significant results not shown) 
for figure clarity.   
 When unactivated monocytes were treated with 1000μg/ml nCRP there was 
a significant increase (from 11.29μM to 17.77μM; p = 0.036) in the production of 
NO. When co-treated with the nystatin inhibitor there was a significant (p=0.001) 
reversal in NO production compared to original stimulation of NO produced by 
1000μg/ml nCRP. After treatment with nystatin inhibitor, there was no significant 
(p=0.112) difference in production of NO compared to the control, indicating nCRP-
induced NO production was fully reversed.  
Treatment of activated monocytes with 100 g/ml mCRP induced a 
significant increase (from 13.66μM to 23.23μM; p<0.001) in the production of NO. 
Again, nystatin reversed the effect of mCRP-induced NO production, with no 
significant difference (p=0.504) following nystatin treatment compared to the 
control.  
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Figure 6.2 –Reversal of CRP-mediated NO production by nystatin inhibitor in 
CRP treated unactivated monocyte cells. * indicates significant (P<0.05) 
differences compared with the control. ** indicates significant (P<0.05) 
differences compared with the inhibited CRP treatment.   
Figure 6.3 – Reversal of CRP-mediated NO production by nystatin inhibitor in 
CRP treated activated monocyte cells. * indicates significant (P<0.05) 
differences compared with the control. ** indicates significant (P<0.05) 
differences compared with the inhibited CRP treatment.   
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6.7.3 The Effect of Estrogen on CRP-Induced Nitric Oxide Production 
6.7.3.1 Unactivated Monocytes 
 Treatment with either CRP isoform significantly (P<0.001) increased NO 
production in unactivated monocytes. However, when estrogen was supplemented 
the concentration of NO significantly reduced (Figure 6.4) in unactivated monocytes 
at all three estrogen concentrations.   
 NO significantly increased as the concentration of mCRP increased (Figures 
6.4A and 6.4B) in unactivated monocytes. The addition of estrogen significantly 
reduced (P<0.01) the amount of NO produced to a level similar to that of the 
control (around 10μM).  
 Estrogen had a concentration dependent effect on NO production in 
unactivated monocytes treated with nCRP (Figures 6.4C and 6.4D). Both 
concentrations of nCRP significantly increased the amount of NO to around 12μM. 
Treatment with 1x10-7M estrogen produced the greatest (12.61μM to 4.82μM) 
reduction in NO production in unactivated monocytes. All concentrations of 
estrogen significantly (p<0.001) reduced the amount of NO produced in unactivated 
monocytes following nCRP treatment.  
 
 
 
135 
 
 
 
 
 
 
 
Figure 6.4 – Nitric oxide production in unactivated monocytes treated with 
three concentrations of estrogen. -/- represents the negative control with no 
CRP and no estrogen supplementation. +/- represents treatment with CRP alone 
as a positive control. +/+ represents cells that have been treated with both CRP 
and estrogen. The number in the bracket represent which concentration of 
estrogen has been used (either 1x10-7M, 1x10-8M or 1x10-9M estrogen). * 
denotes significant difference between the negative and positive control. ** 
denotes significant difference to the positive control. Significant difference is 
p<0.05. Errors bars represent SE of the mean (SEM).  
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6.7.3.2 Activated Monocytes 
 The concentration of NO produced in activated monocytes shows a similar 
pattern to the unactivated monocytes in the case of mCRP. With the addition of 
mCRP the amount of NO increased significantly (P<0.001). However, there was a 
dose dependent significant decrease in NO production in activated monocytes 
following treatment with nCRP. Estrogen at all of the three concentrations reduced 
the concentration of NO in activated monocytes. In contrast, treatment with 
estrogen had no significant effect on NO production in nCRP treated cells, with NO 
production remaining relatively constant (Figure 6.5).   
 When mCRP was used as a treatment the amount of NO produced 
significantly increased (P<0.01) as the concentration of mCRP increased (Figures 
6.5A and 6.5B). The addition of estrogen significantly reduced the amount of NO 
produced in activated macrophages to a level similar to the control (around 10μM 
NO  
 The data indicated that even though both concentrations of nCRP 
significantly reduced NO production (P<0.01), there was no significant effect of 
estrogen upon nCRP-mediated NO production in activated monocytes (Figures 6.5C 
and 6.5D). 
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Figure 6.5 – Nitric oxide production in activated monocytes treated with three 
concentrations of estrogen. -/- represents the negative control with no CRP and 
no estrogen. +/- represents treatment with CRP alone as a positive control. +/+ 
represents cells that have been treated with both CRP and estrogen. The 
number in the bracket represent which concentration of estrogen has been used 
(either 1x10-M, 1x10-8M or 1x10-9M estrogen). * denotes significant difference 
(p<0.05) between the negative and positive control. ** denotes significant 
difference (p<0.05) to the positive control. Errors bars represent SE of the mean 
(SEM).  
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6.7.3.3 Unactivated Macrophages 
 The concentration of NO produced in unactivated macrophages shows that 
both concentrations of mCRP caused no significant effects upon the production of 
NO and supplementation with estrogen had no significant effect either (Figures 
6.6A and 6.6B). 
Both concentrations of nCRP caused a significant reduction in the 
production of NO compared to the control, approximately halving the NO from 
around 12.0 M to around 6.5 M regardless of the nCRP concentrations used 
(Figure 6.6C and 6.6D). 
 All three concentrations of estrogen significantly increased (P<0.01) the NO 
concentration following treatment with 500μg/ml nCRP when compared to the 
500μg/ml nCRP treatment alone (Figure 6.6C). However, estrogen at all the 
concentrations used were unable to reverse the nCRP-induced NO production when 
1000μg/ml nCRP was used (Figure 6.6D). 
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Figure 6.6 – Nitric oxide production in unactivated macrophages treated with 
three concentrations of estrogen. -/- represents the negative control with no 
CRP and no estrogen. +/- represents treatment with CRP alone as a positive 
control. +/+ represents cells that have been treated with both CRP and estrogen. 
The number in the bracket represent which concentration of estrogen has been 
used (either 1x10-7M, 1x10-8M or 1x10-9M estrogen). * denotes significant 
(p<0.05) difference between the negative and positive control. ** denotes 
significant (p<0.05) difference to the positive control. Errors bars represent SE of 
the mean (SEM).  
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6.7.3.4 Activated Macrophages  
Both concentrations of mCRP had no significant effect upon the production 
of NO in activated macrophages and the addition of estrogen had no significant 
effect on the production of NO (Figures 6.7A and 6.7B).  
 Both concentrations of nCRP significantly (p<0.001 and p<0.001) reduced 
the amount of NO produced by activated macrophages and supplementation with 
estrogen had no significant effect on this nCRP-induced NO production (Figures 
6.7C and 6.7D).  
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Figure 6.7 – Nitric oxide production in activated macrophages treated with 
three concentrations of estrogen. -/- represents the negative control with no 
CRP and no estrogen. +/- represents treatment with CRP alone as a positive 
control. +/+ represents cells that have been treated with both CRP and estrogen. 
The number in the bracket represent which concentration of estrogen has been 
used (either 1x10-7M, 1x10-8M or 1x10-9M estrogen). * denotes significant 
(p<0.05) difference between the negative and positive control. ** denotes 
significant (p<0.05) difference to the positive control. Errors bars represent SE of 
the mean (SEM).  
 
142 
 
6.8 Discussion 
6.8.1 The Effect of Exogenous CRP Isoforms on Nitric Oxide Production. 
 The mCRP isoform stimulated NO production in monocyte-like cells but had 
no effect on NO levels in macrophage-like cells, regardless of activation by LPS 
(bacterial endotoxin). This suggests mCRP may stimulate NO production in both the 
presence and absence of infection, supporting evidence from Khreiss et al (2005). 
In stark contrast, the nCRP isoform reduced NO production in macrophage-
like cells both in the presence and absence of endotoxin activation. Furthermore, in 
monocytes activated by bacterial endotoxin nCRP reduced NO levels in a 
concentration-dependent manner. These findings support the growing evidence 
that mCRP promotes inflammation whilst nCRP often opposes the actions of mCRP 
and reduces the overall inflammatory response (Ciubotaru et al, 2005; Eisenhardt et 
al, 2009).  
The response to each CRP isoform appeared to be dependent on the 
differentiation state of cells and whether pre-activation with bacterial endotoxin 
had taken place. The findings indicated nCRP may have an inhibitory effect on NO 
production in monocytes following activation by bacterial endotoxin, and in 
macrophages with or without prior LPS-activation.  
In contrast, mCRP had a stimulatory effect on NO production in monocytes 
with or without prior activation by bacterial endotoxin but this effect was lost once 
monocytes differentiated into macrophages. In the absence of infection, the 
findings indicate both nCRP and mCRP may increase NO production in unactivated 
monocytes but the stimulation by nCRP is relatively modest compared to that 
produced by mCRP.   
The relative proportion of each CRP isoform in vivo could possibly influence 
the inflammatory response generated, with the formation of mCRP from the 
dissociation of nCRP promoting inflammation. Elevated levels of NO are known to 
induce the production of pro-inflammatory cytokines (Kobayashi, 2010) including 
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IL-6 (Hur et al, 2004) and tumour necrosis factor alpha (TNF-α) in both monocytes 
and macrophages (Wang et al, 1997) and neutrophils (Dervort et al, 1994). The 
release of these cytokines can then potentially stimulate iNOS further to produce 
more NO (Nathan, 1992) There is also evidence of NO increasing phagocyte 
function in terms of bacterial killing and phagocytosis (Tumer et al, 2007).  
 
6.8.2 The effect of inhibitors upon the production of nitric oxide in CRP treated 
cells  
 Nystatin was the only inhibitor that was applied in this study. The other 
inhibitors could not be used due to their ability to have a direct effect upon the NO 
production (Salh et al, 1998; Ajizian et al, 1999; Kim et al, 2004) and, therefore may 
have provided misleading results. 
 Nystatin showed inhibitory effects in only two cell treatments; with 
1000μg/ml nCRP in unactivated monocytes and with 100μg/ml mCRP treatment in 
activated monocytes. This suggests that nCRP may interact with lipid rafts in 
monocytes in the absence of infection whereas mCRP may associate with lipid rafts 
in monocytes in the presence of infection. In both unactivated and activated 
macrophages, nystatin had no significant effect on the production of NO. This 
suggests that either the nystatin concentration was too low to detect effects or 
once monocytes become mature macrophages the disruption of lipid rafts by 
nystatin has no effect on CRP isoform function in relation to NO production. 
Findings show that mCRP had no effect on NO production in macrophages, in the 
presence or absence of infection, so nystatin inhibition would be irrelevant in that 
case. In terms of nCRP that reduced NO production in macrophages, it would 
suggest either the inhibitor concentration was too low to have effect or that this 
isoform was not associated with lipid rafts in mature macrophages and therefore 
nystatin would have no effect on nCRP-induced NO production. Data from the 
inhibitor assay can only provide tentative evidence to include/confirm involvement 
of particular processes/pathways but cannot provide evidence to exclude them 
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(since an increase in inhibitor concentration may show effects not seen at the 
concentration used). Therefore, no conclusions can be drawn about the 
mechanisms by which nCRP may reduce NO production in macrophages.  
 Nystatin is an inhibitor of the lipid-raft-caveolae endocytosis pathway 
(Ivanov, 2008) as well as being able to form barrel like pores in the membrane 
which leads to potassium leakage (Chen et al, 2011). These lipid rafts are enriched 
in cholesterol and glycosphingolipids which are involved in many trafficking 
pathways (Chen et al, 2011).  The mCRP isoform is known to associate with lipid 
rafts in the cell membranes (Ji, et al., 2009). When activated monocytes are treated 
with higher concentrations of mCRP in particular, this is likely to lead to a more pro-
inflammatory effect as the concentration of NO increases. As cell membranes 
become disrupted by the nystatin, NO production is reduced and this may be at 
least in part due to disruption of the interaction of mCRP with lipid rafts. . 
 The effect of the lower concentration of mCRP on NO production in 
activated monocytes was reversed with the addition of nystatin whereas at higher 
concentrations of mCRP the reversal was not detected. This was most likely due to 
the inhibitor concentration being too low to fully reverse the effects of high 
concentrations of mCRP. Future studies should investigate a range of inhibitor 
concentrations but this was beyond the scope of this current study due to time and 
cost restrictions. 
 The 100μg/ml mCRP treatment caused the concentration of NO to 
significantly increase in activated monocytes, while treatment with the nystatin 
significantly decreased NO production back to control levels. The mCRP is known to 
associate with the cell membrane of the inflammatory cells and as nystatin works 
by disrupting the lipid-rafts in the cell membrane (Scheel-Toellner et al, 2004). If the 
lipid rafts of cell membranes are disrupted by nystatin then mCRP may be 
prevented from inducing NO production. No production in macrophages treated 
with nCRP was not significantly affected by the addition of the nystatin suggesting 
that either the inhibitor concentration was too low to see effects or that the nCRP 
isoform may not associate with lipid rafts in mature macrophages. Therefore, the 
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inhibitor assay provides evidence to suggest mCRP associates with lipid rafts in 
monocytes in the presence and absence of infection and that NO production is 
probably mediated at least in part by lipid raft associated mCRP.  Beyond this, the 
inhibitor assay does not provide any evidence relating to nCRP or other cell states.  
 
6.8.3 The Effect of Estrogen Upon the Production of Nitric Oxide in CRP Treated 
Cells 
 From the data it seems that physiological concentrations of estrogen had 
opposing effects on CRP-induced NO production in the various cells states. Previous 
studies have shown that estrogen can have suppressive and enhancing effects upon 
iNOS and NO production (Karpuzoglu & Ahmed, 2006).  
 
6.8.3.1. Monocytes 
 Evidence from the data shows that when the monocytes have not been 
previously activated with bacterial LPS there is an increase in NO production, 
suggesting pro-inflammatory activity. Estrogen significantly reduced the NO 
production in CRP-treated cells, indicating that estrogen is behaving in an anti-
inflammatory way in the presence of CRP, typical of its properties during wound 
healing during youth. 
 When monocytes were pre-activated using LPS, only treatment with mCRP 
significantly increased NO production. This mCRP-induced NO production in LPS-
activated cells was reversed with estrogen treatment. In contrast, treatment with 
nCRP significantly decreased NO production with no effect observed when 
supplemented with physiological concentrations of estrogen. Evidence has shown 
that mCRP has a more pro-inflammatory effect during inflammation (Thiele et al, 
2014) and therefore will increase the amount of NO. In monocytes, estrogen can 
suppress inflammation by inhibiting the IL-6 inflammatory response which leads to 
the inhibition of NF-κβ activity (Pelekanou et al, 2016). Estrogen also has the ability 
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to block pro-inflammatory effects of inflammation triggered by LPS -activation 
which is an effect mirrored here in LPS-activated monocytes following mCRP 
treatment (Vegeto et al, 2000; Vegeto et al, 2001).   
  
6.8.3.2 Macrophages 
 In both the unactivated and LPS-activated macrophages, treatment with 
mCRP (with or without estrogen supplementation) had no effect upon NO 
production. Treatment with both nCRP concentrations caused a significant decrease 
in NO production, indicative of a more anti-inflammatory effect (Thiele et al, 2014).  
The nCRP-induced reduction of NO in macrophages was only reversed by 
estrogen in unactivated macrophages treated with 500μg/ml nCRP (physiological 
concentrations of estrogen were unable to reverse the effect of very high 
1000μg/ml concentrations of nCRP). In concordance with this finding, Karpuzoglu & 
Ahmed (2006) found that unactivated macrophages exposed to estrogen show 
increased iNOS expression and therefore NO production. This indicates a pro-
inflammatory effect of estrogen in unactivated macrophages. Evidence from the 
literature agrees with this finding since estrogen has been shown to be a potent 
inducer of IFN-γ (Fox et al, 1991), which is secreted by tissue macrophages (Duque 
& Descoteaux, 2015). This increase in IFN-γ leads to a subsequent increase in the 
production of nitric oxide (Karpuzoglu & Ahmed, 2006).  
  
 
6.9 Future Work 
 The findings of this study can be utilised as a basis to investigate which 
particular nitric oxide synthases (NOS) are generating the NO production. Evidence 
would suggest that iNOS would be the synthase involved and this could be 
confirmed by western or dot blots on cell lysate samples to analyse changes in iNOS 
production using an antibody raised against iNOS.  Such an investigation could 
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assess the effect of CRP isoform concentrations on iNOS levels, followed by work 
with the pharmacological inhibitors and estrogen supplementation. 
 The relationship between CRP isoforms and NO levels could be investigated 
in vivo using animal models of wound healing. Using mouse models of acute and 
age-related impaired healing, it would be possible to determine the effect of CRP 
isoforms on NO production in relation to ageing processes.  
 
 
6.10 Summary 
In conclusion, the findings suggest that both mCRP and nCRP may be 
potential targets for mediating NO levels in human monocytes and macrophages. 
NO levels were differentially altered by each CRP isoform in a concentration-
dependent manner and responses were dependent on the differentiation state of 
the cells (monocyte versus macrophage-like cells) and whether there was pre-
stimulation with bacterial endotoxin.  
In the presence or absence of LPS activation, nCRP had an inhibitory effect 
on NO production in macrophage-like cells whereas mCRP had a stimulatory effect 
on NO synthesis in monocyte-like cells. The nCRP isoform had bi-directional effects 
in monocyte-like cells, reducing NO production following LPS-activation but 
stimulating NO in unactivated monocyte–like cells. The mCRP isoform had no effect 
on NO production in macrophage-like cells , regardless of whether pre-stimulation 
with bacterial endotoxin took place. 
This study supports growing evidence that mCRP generally promotes the 
inflammatory response whilst nCRP often has opposing anti-inflammatory 
properties. This highlights potential therapeutic strategies could be developed for 
the treatment of chronic inflammatory conditions that promote the stability of 
nCRP and/or prevent the formation of mCRP from the dissociation of nCRP. 
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Chapter 7 – The Effect of C-Reactive Protein Isoforms on Pro-
inflammatory Cytokine Production 
7.1 Introduction 
 Cytokines are a group of small proteins that induce cell signalling pathways 
in order to trigger the function of a number of other cells (Zhang & An, 2007). 
Cytokines include chemokines, interferons, interleukins and tumour necrosis factors 
that provide a broad range of activation in cells such as macrophages, lymphocytes, 
endothelial cells and fibroblasts (Zhang & An, 2007). 
 Cytokines act through receptors on the surfaces of cells and play major roles 
in the immune process as well as allowing communication between the cells 
(Dinarello, 2000). Cytokines can act in an autocrine action, acting upon the cells that 
have secreted them; or in a paracrine action, acting upon nearby cells; or in an 
endocrine action, acting upon distant cells (Zhang & An, 2007).  
 There are a number of pro-inflammatory cytokines (Dinarello, 2000) and this 
study investigated four that are known to play a key role in CRP-mediated 
inflammatory processes.  
 
7.1.1 Interleukin-6 (IL-6) and C-Reactive Protein 
 Interleukin-6 (IL-6) is a pro-inflammatory cytokine which is encoded by the 
IL-6 gene. IL-6 is a major regulator of the acute phase response and is secreted by T 
cells and macrophages during this response. Its main roles are focused in the host’s 
ability to fight infection (Zhang & An, 2007). Even though it is a pro-inflammatory 
cytokine it does exert anti-inflammatory effects through TNF-α and IL-1 (Scheller et 
al, 2011).   
 IL-6 is a soluble mediator of the acute phase response and is one of few 
cytokines that are capable of crossing the blood-brain barrier (Heinrich et al, 1990). 
IL-6 is secreted in response to pathogen-associated molecular patterns (PAMPs) on 
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pathogens or damage-associated molecular patterns (DAMPs) which are found on 
cell components in dead or damaged cells. These molecules bind to pattern 
recognition receptor (PRRs) which are present in the cell surface. These receptors 
include toll-like receptors (TLRs) and c-type lectin receptors (CLR) as well as many 
others. These receptors are present on cell surfaces and when activated through 
binding induce the intracellular signalling cascade which gives rise to cytokine 
production (Scheller et al, 2011).   
 The IL-6 receptor is expressed mainly on the immune effector cells such as T 
and B cells, monocytes, macrophages and neutrophils however they are also 
expressed on other non-immune cells such as the hepatocytes and pancreatic islet 
cells (Tanaka & Kishimoto, 2014). The receptor is comprised mainly of the gp130 
glycoprotein (Kishimoto et al, 1995) and allows the IL-6/IL6-R complexes to 
associate with gp130 and leads to signal initiation (Scheller et al, 2011).  These 
signals then lead to activation of several pathways including the JAK/STAT, ERK and 
PI3 kinase pathways (Scheller et al, 2011).   
 IL-6 is synthesised in the initial stages of inflammation and then travels in 
the bloodstream to the liver. During this process, the IL-6 induces a number of 
acute phase proteins including CRP (Tanaka et al, 2014). At the same time IL-6 can 
also reduce the production of fibronectin, albumin and transferrin as well as the 
promotion of CD4+ T helper cells which initiates the linking of innate and acquired 
immunity (Tanaka et al, 2014). 
Previous research has shown that CRP plays a role in the inflammation 
processes (Du Clos, 2000) and that there is a correlation between the increasing 
levels of IL-6 during inflammation and the increasing levels of CRP (Szalai et al, 
1998), with IL-6 inducing the CRP gene (Weinhold et al, 1997).  
There is little evidence that the two isoforms of CRP have varying effects 
upon IL-6 production and there has been no record of CRP inducing the production 
of IL-6 in a feedback loop during the inflammatory process. Instead, published 
research considers the production of CRP by IL-6 and generally fails to mention 
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which isoform of CRP is generated by IL-6. In most cases, it can be deduced that the 
CRP isoform being measured is the native isoform due to the antibodies being used 
to detect CRP and the fact that nCRP is the isoform known to be synthesised in the 
hepatocytes (Boras et al, 2014),  where most research to date has been conducted.   
 
7.1.2 Interleukin-8 (IL-8) and C-Reactive Protein 
 Interleukin-8 (IL-8) is a cytokine that is produced by macrophages and is a 
member of the CXC family (Koch et al, 1992). The IL-8 gene encodes a protein 
translation that is 99 amino acids long (Harada et al, 1994). IL-8 is a potent 
chemoattractant with neutrophils and a subset of T-lymphocytes being the main 
targets for this (Koch et al, 1992). Another role is to stimulate the release of 
granules from neutrophils by a process called degranulation. These granules 
contain a range of antimicrobial properties that can help combat infection 
(Palomino & Marti, 2015). 
 It is also suggested that IL-8 can induce the rearrangement of the 
cytoskeleton (Kibayashi et al, 2005). This is due to changes in intracellular calcium 
levels activing integrins. There is also evidence showing that IL-8 can also induce the 
exocytosis of granule proteins and activate the respiratory burst (Palomino & Marti, 
2015). 
 It is known that IL-8 is overexpressed in chronic inflammatory diseases and 
during sceptic shock (Bickel, 1993). It is suggested that this is due to the neutrophil 
being the primary target as it expressed both CXCR1 and CXCR2. As neutrophils are 
the primary cells to arrive at the site of inflammation this leads to the recruitment 
of phagocytic cells. The process of phagocytosis allows for the release of 
chemotactic mediators which then recruit other leukocytes to the affected tissue 
(Palomino & Marti, 2015). 
 C-reactive protein has also been implicated in the expression patterns of IL-
8. Kibayashi et al (2005) indicated that CRP plays a role in atherosclerosis via IL-8 
production. The production of IL-8 was enhanced significantly when the cells were 
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treated with CRP and the expression of IL-8 mRNA increased in a CRP dose 
dependent manner. This effect was also inhibited by using MAPK inhibitors such as 
SB203580. Kibayashi et al (2005) concluded that CRP plays a role in atherosclerosis 
via the production of IL-8 and the activation of the ERK, p38 MAPK and JNK 
pathways.  
 The effect of the different isoforms upon IL-8 production has also been 
investigated. Khreiss et al (2004) showed that nCRP had no detectable effect upon 
the production of IL-8, however mCRP did. Treatment with mCRP increased IL-8 
production as well as increasing gene expression, thus promoting pro-inflammatory 
activity through a p38 MAPK-dependent mechanism. When treated with anti-CD16 
there was inhibition of mCRP stimulated nitric oxide formation and IL-8 release 
(Khreiss et al, 2004).  
 Wigmore et al (1997) indicated that IL-8 can work at a local level and induce 
CRP production in the hepatocytes, indicating that other cytokines may also be 
involved in the activation of the CRP pathways.  
 
7.1.3 Monocyte Chemoattractant Protein-1 (MCP-1) and C-Reactive Protein 
Monocyte chemoattractant protein-1 (MCP-1) is a cytokine that plays a role 
in the regulation of migration and infiltration of monocytes and macrophages. MCP-
1 is also known as CCL2 and is a member of the C-C chemokine family.  It is located 
on chromosome 17 at position q11.2 and is composed of 76 amino acids 
(Deshmane et al, 2009). It is released by a number of cell types in response to 
events such as oxidative stress, cytokine release and growth factor release (Yadav 
et al, 2010). Receptors for MCP-1 are expressed on a number of cells and human 
MCP is known to bind to at least two receptors (Deshmane et al, 2009). The 
production of MCP-1 can be induced by IL-4, IL-1, TNF-α, bacterial LPS and IFN-γ 
(Yadav et al, 2010). 
 There is also increasing evidence that MCP-1 influences T-cell immunity by 
enhancing the secretion of interleukin-4 (IL-4) by T cells as well as having a role in 
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the migration of leukocytes (Deshmane et al, 2009). This in turn has a regulatory 
function on the monocytes and macrophages which are is major source of MCP-1 
(Yadav et al, 2010). MCP-1 is known recruit monocytes to the vessel wall (Han et al, 
2004) as well as the ability to cause the firm arrest of rolling monocytes on 
endothelial monolayers which express E-selectin (Pasceri et al, 2001). This means 
there is an implied role in spreading and shape change of monocytes attached to 
the endothelium (Pasceri et al, 2001).  
 MCP-1 exerts its effect through binding to G-protein coupled receptors on 
the surface of leukocytes. This then activates a number of reactions ultimately 
resulting in the formation of inositol triphosphate. This then allows for intracellular 
calcium release and protein kinase-c (PKC) activation (Yadav et al, 2010). PKC 
activation is required for processes such as gene expression, protein secretion, cell 
proliferation and the inflammatory response (Poole et al, 2004). 
  Multiple pathways have been implicated in MCP-1 signal transduction, 
including the MAP kinase pathways ERK1 and ERK2, p38 MAP kinase pathway and 
the PI3 kinase pathways (Pasceri et al, 2001). However, the full extent of how these 
pathways are involved is not fully understood.  
It has been suggested that CRP can influence the production and function of 
MCP-1. CRP can stimulate endothelial cells to express MCP-1 as well as being a 
monocyte chemoattractant for monocytes itself (Yeh & Willerson, 2003). CRP can 
promote monocyte chemotactic activity in response to MCP-1 via upregulation of 
the monocyte chemotaxis receptor CCR2 (Han et al, 2004). Han et al (2004) 
suggested that CRP can induce the production of MCP-1 by endothelial cells. This 
study suggested that elevated CRP levels promoted the accumulation of monocytes 
in the atherogenic arterial wall via MCP-1 by promoting the activity of chemokines 
and cytokines (Han et al, 2004).  
 When vascular smooth muscle cells were exposed to increasing levels of 
CRP, MCP-1 mRNA substantially increased within 2h, remaining elevated for at least 
24 hours after (Hattori et al, 2003). Incubation with mCRP increased the secretion 
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of MCP-1 leading to pro-inflammatory activity through a p38 MAPK-dependent 
mechanism whereas nCRP had no detectable effect (Khreiss et al, 2004).  
 
7.1.4 Tumour Necrosis Factor-α (TNF-α) and C-Reactive Protein 
Tumour Necrosis Factor-α (TNF-α) is a component of the acute phase 
response of inflammation. Also known as cachectin, this signalling molecule is 
mainly produced by monocytes and macrophages but can be produced by 
numerous other immune cells such as neutrophils, natural killer cells and 
eosinophils (Zelová & Hošek, 2013). The main stimulant of TNF-α production is 
lipopolysaccharide (LPS) however other pathological conditions can stimulate 
production such as trauma infection, burns and heart failure to name a few 
examples (Zelová & Hošek, 2013). 
TNF-α has been implicated in a wide range of inflammatory activities and is 
not usually detectable in a healthy host however levels become elevated in a 
number of inflammatory and infectious conditions (Zelová & Hošek, 2013). 
Evidence shows that it is involved in processes such as cell proliferation, 
differentiation and apoptosis. 
TNF-α has shown to have many biological functions including vasodilation, 
by the stimulation of iNOS in macrophages and leukocytes (Sanders et al, 2001); 
involvement in oedema by augmenting the permeability of vessels during 
inflammation (Chappell et al, 2009); facilitating the adhesion of leukocytes to 
inflamed tissues (Chandrasekharan et al, 2007) and contributing to the generation 
of fever (Steinman, 2010).  
TNF-α is responsible for a number of signalling events within cells which 
usually lead to the apoptotic and necrotic pathways while also providing resistance 
to infection and cancer.  TNF-α is produced in two forms; a soluble form and a 
membrane bound form (Schall et al, 1990); and is produced as needed (Zhou et al, 
2002). TNF-α exerts it main abilities by binding to one of two receptors, TNFR-1 
(CD120a) or TNFR-2 (CD120b). TNFR-1 is expressed in all human cell types where as 
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TNFR-2 is expressed mainly on endothelial and immune cells (Fuchs et al, 1992; 
Santee & Owen-Schaub, 1996). 
 Studies have shown that there is a correlation between the level of TNF-α 
produced and the concentration of CRP in inflammation. TNF-α induces a dose 
dependent secretion of CRP in hepatocytes which also corresponds to an increase 
in CRP mRNA (Calabró et al, 2003). However when CRP levels become elevated in 
atheroma, this leads to the induction of IL-1β, IL-6, and TNF-α release by 
macrophages indicating that CRP may have a direct effect upon both TNF-α and IL-6 
release (Han et al, 2004). 
 Research has shown that there is a relationship between TNF-α and IL-6 
levels in inflammation (Popa et al, 2007). Therefore, TNF-α and CRP may   correlate 
in a very similar way to IL-6 and CRP. TNF-α is also a known activator of CRP, 
alongside IL-6 (Zhang et al, 1996). However, there is some evidence to show that 
there could potentially be an inhibitory effect of CRP upon TNF-α production,  
suggesting there could be a negative-feedback mechanism whereby elevating levels 
of CRP inhibits further stimulation of CRP by inhibiting TNF-α production  (Inatsu et 
al, 2009).  
  
 
7.2 Aims 
 The aim of this study is to observe the effects of the exogenous CRP 
isoforms on the production of four pro-inflammatory cytokines (IL-6, IL-8, MCP-1 
and TNF-α) in a model of ageing. A further aim was to elucidate some of the 
potential mechanisms/pathways involved in CRP-mediated cytokine production by 
using pharmacological inhibitors.  
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7.3 Objectives 
 The fundamental objectives for this assay are: 
 To determine the effect of exogenous nCRP on the production of four pro-
inflammatory cytokines. 
 To determine the effect of exogenous mCRP on the production of four pro-
inflammatory cytokines 
 To determine the effect of estrogen on CRP-induced production of these 
four pro-inflammatory cytokines in a model of age-related impaired healing. 
To elucidate potential mechanisms/pathways that may be mediating the 
CRP-mediated production of cytokines. 
 
 
7.4 Summary of Procedure 
 This assay utilised the Milliplex Map Kit which is a magnetic bead-based 
assay. The assay is based on Luminex xMAP technology that uses internally colour-
coded microspheres with two fluorescent dyes which can be set to specific 
concentrations in each bead.  The beads correspond to a specific antibody designed 
to capture a particular antigen. The analyte was captured by the bead and a 
biotinylated detection antibody was added, followed by Streptavidin-PE conjugate 
which is a reporter molecule that coats the surface of the bead and completes the 
detection reaction. The plate was read through a Luminex analyser, which is based 
on flow cytometry technology to detect the beads and measure fluorescent 
reporter signals for each specific cytokine. This assay was used to detect and 
measure multiple cytokines at the same time from the same sample.  
 
 
 
156 
 
7.5 Materials 
Human monocyte cell line U937 (Health Protection Agency Culture Collections, 
Salisbury) 
RPMI-1640 Media (Lonza, Slough) 
Foetal Bovine Serum (Sigma-Aldrich, Dorset) 
Lipopolysaccharide (Sigma-Aldrich, Dorset) 
Phorbol 12-myristate 13-acetate (Applichem, Darmstadt) 
C-reactive Protein, human >95% native, 5mg/ml (MyBioSource, San Diego) – 
Purified as previously stated in Section 2.4.4.  
Inhibitors – prepared as mentioned in section 2.4.9. 
Estrogen (Sigma-Aldrich, Dorset) 
Milliplex Map Kit – Human Cytokine/Chemokine Magentic Bead Panel (Merck 
Millipore, Hertfordshire) 
Anti-human IL-6 beads 
Anti-human IL-8 beads 
Anti-human MCP-1 beads 
Anti-human TNF-α beads 
Human Cytokine/Chemokine Standard 
Human Cytokine Quality Controls 1 & 2 
Assay Buffer 
Wash buffer 
Human Cytokine Detection Antibodies 
Streptavidin-Phycoerythrin 
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Bead Diluent 
Sheath Fluid (Millipore, Hertfordshire) 
 
 
7.6 Methods 
7.6.1 Cell Culture 
Cells were cultured as previously described in section 2.4.1. 
 
7.6.2 Activation of Cells 
 Cells were activated as described in Section 2.4.2. 
 
7.6.3 Differentiation of Cells 
 Cells were differentiated as described in Section 2.4.3.  
 
7.6.4 CRP Purification 
CRP was purified as described in Section 2.4.4. The samples were then 
diluted to experimental concentrations using RPMI-1640 media. CRP concentrations 
were set to 250μg/ml mCRP and 1000μg/ml nCRP.  
 
7.6.5 Inhibitors 
 The assay was repeated with the addition of pharmacological inhibitors 
(wortmannin, LML, MEK and nystatin) prepared as described in Section 2.4.9.  
 
158 
 
7.6.6 Estrogen Preparation 
 Estrogen was prepared to a final concentration of 1x10-7M, made up in 
RPMI-1640 complete media, with FBS and penicillin-streptomycin.  
 
7.6.7 Sample Preparation 
 U937 cells, set to 1x106, were prepared to obtain the relevant cell status 
before being treated with the CRP isoforms, with or without estrogen 
supplementation, for 24 hours. A negative control was generated with BSA in place 
of CRP. Cell samples were then loaded into the Milliplex Assay plate for further 
analysis (See section 6.6.8). If samples exhibited a significant change in cytokine 
levels compared to the negative control the experiment was repeated with addition 
of inhibitors.  
 
7.6.8 Milliplex Assay 
 The beads in the assay were mixed with bead diluent after sonication for 30 
seconds. Quality controls 1 and 2 provided in the assay kit were reconstituted with 
deionized water and mixed. The human cytokine standard was reconstituted with 
deionized water to 10,000pg/ml followed by serial dilution with assay buffer to 
make 2,000pg/ml, 400pg/ml, 80pg/ml, 16pg/ml and 3.2pg/ml standards according 
to the manufacturer’s guidance. The wells of the assay plate were incubated at 
room temperature for 10 minutes with 200µl wash buffer to prime the wells. The 
wash buffer was removed and 25µl of each of the standards and controls were 
added to relevant wells. The assay buffer was added to appropriate wells as an 
assay background control. This was followed by 25µl of assay buffer to every well 
with cell media being added to control and standard wells. Samples as prepared in 
Section 6.6.7 were then added to relevant triplicate wells at a volume of 25µl. The 
beads were mixed again and 25µl was added to every well prior to incubating the 
plate overnight at 4oC. The plate was then washed twice with 200µl wash buffer 
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using a magnetic plate washer. Detection antibodies were added to the plate, at a 
volume of 25µl prior to incubation for 1 hour at room temperature with agitation. 
This was followed by the addition of 25µl Streptavidin-Phycoerythrin to every well 
before being incubated for 30 minutes at room temperature with agitation. The 
plate was washed again with the magnetic plate washer followed by the addition of 
150µl sheath fluid to every well. The plate was agitated for 5 minutes before being 
read by the Luminex 200TM using xPONENT® software using 100µl and reading 50 
beads per bead set.  
 
7.6.9 Statistical Analysis  
 Data (n=6) for each treatment was normalised to determine cytokine levels 
per million cells, before being analysed with SPSS Statistical Software (Version 22). 
A Shapiro-Wilke normality test was first conducted followed by t-test or Mann-
Whitney U tests dependent upon if the data were parametric or nonparametric. 
Graphs were generated using Microsoft Excel 2013.  
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7.7 Results 
7.7.1 Model of Age-Related Impaired Healing 
7.7.1.1 The Effect of the CRP Isoforms on Interleukin-6 Concentration 
 Overall, treatment with 1000μg/ml nCRP did not have any significant effect 
on cytokine production in any cell type (Figure 7.1). Treatment with 250μg/ml 
mCRP caused a significant (p<0.05) increase in IL-6 production in both activated 
monocytes and unactivated macrophages (Figure 7.1B and 7.1C). 
 Further investigations with inhibitors indicated that no inhibitor could 
reverse the effects of the CRP-induced IL-6 in unactivated macrophages (Figure 
7.1C). However treatment with wortmannin and LML significantly reversed the CRP-
induced IL-6 production in the activated monocytes (Figure 7.1B). 
 It was  noted that there was a massive increase in IL-6 production within the 
LPS-activated macrophages with levels increasing from around 2.5pg/ml in the 
unactivated macrophages to around 23,000pg/ml after LPS-activation (Figure 7.1D), 
suggesting IL-6 levels increase substantially following infection.  
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Figure 7.1 – The effect of the CRP isoforms on IL-6 concentration. A) Monocyte cells B) LPS 
activated monocyte cells. C) Macrophage cells. D) LPS activated macrophage cells. Error bars 
representative of the standard error of the mean (SEM). BSA-treated controls are the first 
bars labelled monocyte, activated monocyte, macrophage or activated macrophage. * 
denotes significance against the control (P<0.05). ** denotes significance against the CRP-
mediated IL-6 production. (P<0.05). n= 6 in all cases. 
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7.7.1.2 The Effect of the CRP Isoforms on Interleukin-8 Concentration 
 Figure 7.2A shows that treatment with both CRP isoforms caused a 
significant (p<0.05) reduction in the production of IL-8 in the unactivated 
monocytes, with nystatin only able to reverse the mCRP-induced reduction of IL-8. 
IL-8 production in the unactivated monocytes was considerably less than in the 
other cells types.  
 In the LPS-activated monocyte treatment with 250μg/ml mCRP significantly 
increased IL-8 production (p<0.05), with nystatin being able to significantly reverse 
this effect (Figure 7.2B). Treatment with 1000μg/ml nCRP significantly decreased 
(p<0.05) IL-8 production with LML and nystatin being able to reverse this effect 
(Figure 7.2B).  
 In unactivated macrophages, treatment with nCRP had no significant effect 
upon IL-8 production (Figure 7.2C). However there was a significant increase seen in 
the LPS-activated macrophages (Figure 7.2D). No inhibitors were able to 
significantly reverse this effect. 
 Treatment with mCRP had the opposite effect, causing a significant increase 
in IL-8 concentration in unactivated macrophages (Figure 7.2C) but no significant 
effect in the LPS-activated macrophages (Figure 7.2D).  
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Figure 7.2 – The effect of the CRP isoforms on IL-8 concentration. A) Monocyte cells B) LPS 
activated monocyte cells. C) Macrophage cells. D) LPS activated macrophage cells. Error bars 
representative of the standard error of the mean (SEM). BSA-treated controls are the first 
bars labelled monocyte, activated monocyte, macrophage or activated macrophage. * 
denotes significance against the control (P<0.05). ** denotes significance against the CRP-
mediated IL-8 production. (P<0.05). n= 6 in all cases. 
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7.7.1.3 The Effect of the CRP isoforms on Monocyte Chemoattractant Protein-1 
Concentration 
 In unactivated monocytes, only treatment with 1000μg/ml nCRP caused a 
significant decrease in MCP-1 concentration, with all inhibitors unable to reverse 
the effect (Figure 7.3A).  
 In LPS-activated monocytes, treatment with both CRP isoforms caused a 
significant increase of MCP-1 concentration, with the treatment with mCRP causing 
higher MCP-1 production than treatment with nCRP (Figure 7.3B). All inhibitors 
were unable to reverse any of the effects seen by the CRP treatments.  
 In both unactivated and activated macrophages, treatment with nCRP 
caused no significant changes in MCP-1 whereas treatment with mCRP caused a 
significant decrease in MCP-1 concentration (Figures 7.3C and 7.3D). The four 
inhibitors were unable to reverse any of the effects seen after the CRP isoform 
treatments.  
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Figure 7.3 – The effect of the CRP isoforms on MCP-1 concentration. A) Monocyte cells B) LPS 
activated monocyte cells. C) Macrophage cells. D) LPS activated macrophage cells. Error bars 
representative of the standard error of the mean (SEM). BSA-treated controls are the first 
bars labelled monocyte, activated monocyte, macrophage or activated macrophage. * 
denotes significance against the control (P<0.05). ** denotes significance against the CRP-
mediated MCP-1 production. (P<0.05). n= 6 in all cases. 
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7.7.1.4 The Effect of the CRP Isoforms on Tumour Necrosis Factor-α Concentration 
 Treatment with both CRP isoforms caused a significant decrease (p<0.05) in 
TNF-α concentration in unactivated monocytes (Figure 7.4A) as well as in LPS-
activated monocytes (Figure 7.4B).  Inhibitors could not reverse the effects of the 
CRP in the unactivated monocytes or the treatment of the activated monocytes 
treated with 1000μg/ml nCRP. However, all four of the inhibitors could reverse the 
effect of the 250μg/ml mCRP treatment in the LPS-activated monocytes (Figure 
7.4B) with nystatin having the greatest effect.  
 In the unactivated macrophages, only nCRP caused a significant decrease 
(p<0.05) in the concentration of TNF-α with wortmannin and nystatin reversing the 
effects (Figure 7.4C). In activated macrophages, only treatment with mCRP caused a 
significant decrease in TNF-α concentration with no reversal was observed using 
inhibitors (Figure 7.4D).  
 Again, levels produced by activated macrophages far exceeded those seen 
in the other cell types with levels increasing from around 18pg/ml in the 
unactivated macrophages to 1600pg/ml in the LPS-activated macrophages.  
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Figure 7.4 – The effect of the CRP isoforms on TNF-α concentration. A) Monocyte cells B) LPS 
activated monocyte cells. C) Macrophage cells. D) LPS activated macrophage cells. Error bars 
representative of the standard error of the mean (SEM). BSA-treated controls are the first 
bars labelled monocyte, activated monocyte, macrophage or activated macrophage. * 
denotes significance against the control (P<0.05). ** denotes significance against the CRP-
mediated TNF-α production. (P<0.05). n= 6 in all cases. 
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7.7.2 Model of Acute Healing in Youth  
7.7.2.1 The Effect of Estrogen on CRP-Mediated Levels of Interleukin-6. 
 In unactivated monocytes, both CRP isoforms caused a significant increase 
(p<0.05) in the concentration of IL-6 (Figure 7.5A).  This increase in IL-6 was only 
seen following mCRP treatment in LPS-activated monocytes (Figure 7.5B).  
 In unactivated macrophages, treatment with mCRP significantly increased 
IL-6 concentration whereas the nCRP treatment significantly decreased the IL-6 
concentration (Figure 7.5C). In the activated macrophages, both treatment with 
nCRP and mCRP significantly decreased IL-6 concentration, with mCRP inducing a 
greater reduction in IL- than nCRP (Figure 7.5D).  
  A substantial increase in IL-6 production was noted in unactivated 
macrophages when compared to the other cell types (Figure 7.5C).   
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Figure 7.5 – The effect of the CRP isoforms and estrogen on IL-6 concentration. A) Monocyte 
cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS activated macrophage cells. 
Error bars representative of the standard error of the mean (SEM). * denotes significant 
differences (P<0.05). n=6 in all cases. 
E2 – Addition of Estrogen 
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7.7.2.2 The Effect of Estrogen on CRP-Mediated Levels of Interleukin-8 
 In both unactivated and LPS-activated monocytes, there was a significant 
increase (p<0.05) in IL-8 concentration when treated with either mCRP or nCRP.  
Treatment with mCRP caused a higher concentration of IL-8 when compared to the 
nCRP treatment (Figures 7.6A and 7.6B). 
 In unactivated macrophages, treatment with mCRP significantly increased 
IL-8 concentration (Figure 7.6C). However, in the LPS-activated macrophages mCRP 
significantly decreased IL-8 concentration (Figure 7.6D).  Treatment with nCRP had 
no significant effect upon IL-8 concentration in macrophages, regardless of 
activation. 
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Figure 7.6 – The effect of the CRP isoforms and estrogen on IL-8 concentration. A) Monocyte 
cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS activated macrophage cells. 
Error bars representative of the standard error of the mean (SEM). * denotes significant 
differences (P<0.05). n=6 in all cases. 
E2 – Addition of Estrogen 
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7.7.2.3 The Effect of Estrogen on CRP-Mediated Levels of Monocyte 
Chemoattractant Protein-1 
 Treatment with nCRP did not yield any significant changes in MCP-1 levels in 
any of the cell states.  
 Treatment with 250μg/ml mCRP caused a significant increase (p<0.05) in 
MCP-1 concentration in unactivated monocytes (Figure 7.7A), LPS-activated 
monocytes (Figure 7.7B) and unactivated macrophages (Figure 7.7C). In the LPS-
activated macrophages there was a significant decrease (p<0.05) in the 
concentration of MCP-1 (Figure 7.7D). 
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Figure 7.7 – The effect of the CRP isoforms and estrogen on MCP-1 concentration. A) 
Monocyte cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS activated 
macrophage cells. Error bars representative of the standard error of the mean (SEM). * 
denotes significant differences (P<0.05). n=6 in all cases. 
E2 – Addition of Estrogen 
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7.7.2.4 The Effect of Estrogen on CRP-Mediated Levels of Tumour Necrosis Factor-
α 
 Treatment of unactivated monocytes with either CRP isoform did not 
produce any significant changes to TNF-α concentration following estrogen 
supplementation (Figure 7.8A). However, in LPS activated monocytes, both 
isoforms caused a significant increase (p<0.05) in the concentration of TNF-α 
(Figure 6.8B) following estrogen supplementation.  
 In unactivated macrophages, only treatment with 250μg/ml mCRP caused a 
significant increase (p<0.05) in TNF-α concentration following estrogen 
supplementation, with nCRP having no significant effect on levels of TNF-α (Figure 
7.8C). In contrast, when macrophages were activated with LPS, both isoforms 
caused a significant decrease (p<0.05) in the concentration of TNF-α following 
estrogen supplementation (Figure 7.8D).  
 It was noted that unactivated and activated macrophages produced higher 
levels of TNF-α when compared to monocytic cells following estrogen 
supplementation. Levels of TNF-α were higher in the unactivated macrophages than 
in LPS-activated macrophages following estrogen supplementation.  
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Figure 7.8 – The effect of the CRP isoforms and estrogen on TNF-α concentration. A) 
Monocyte cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS activated 
macrophage cells. Error bars representative of the standard error of the mean (SEM). * 
denotes significant differences (P<0.05). n=6 in all cases. 
E2 – Addition of Estrogen 
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7.7.3 Comparison of models of healing 
7.7.3.1 Comparison of IL-6 Production in Models of Young and Age-Related 
Impaired Healing  
 Supplementation of estrogen to treatments was used to model the 
inflammatory response during acute healing found in youth. Treatments in the 
absence of estrogen supplementation were used to model age-related impaired 
healing. 
Supplementation of monocytes with estrogen leads to a significant increase 
(p<0.05) in the concentration of IL-6 in unactivated monocytes (Figure 7.9A). In 
activated monocytes, estrogen supplementation only caused a significant decrease 
following treatment with mCRP, with other treatments not showing any difference 
in IL-6 levels (Figure 7.9B).  
 In the unactivated macrophages there was a significant (p<0.05) increase in 
the concentration of IL-6 in all treatments following estrogen supplementation 
(Figure 7.9C). However this effect was reversed in the LPS-activated macrophages 
where the addition of estrogen significantly decreased (p<0.05) IL-6 concentration 
following treatment with mCRP or nCRP (Figure 7.9D).  
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Figure 7.9 – The difference in IL-6 profiles between models of young and age-related 
impaired model. A) Monocyte cells B) LPS activated monocyte cells. C) Macrophage cells. D) 
LPS activated macrophage cells. Error bars representative of the standard error of the mean 
(SEM). BSA-treated controls are the first bars labelled monocyte, activated monocyte, 
macrophage or activated macrophage. * denotes significant differences (P<0.05). n=6 in all 
cases. 
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7.7.3.2 Comparison of IL-8 Production in Models of Young and Age-Related 
Impaired Healing  
 Supplementation with estrogen in unactivated monocytes caused a 
significant increase (p<0.05) in IL-8 within all CRP treatments (Figure 7.10A). When 
the cells were LPS activated both CRP isoform caused a significant increase (p<0.05) 
in IL-8 concentration following estrogen supplementation when compared to the 
absence of estrogen (Figure 7.10B).  
 Supplementation with estrogen in unactivated and LPS-activated 
macrophages led to a significant increase (p<0.05) in the production of IL-8 for all of 
the CRP treatments (Figure 7.10C and 7.10D) 
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Figure 7.10 – The difference in IL-8 profiles between healthy model and age-impaired 
model. A) Monocyte cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS 
activated macrophage cells. Error bars representative of the standard error of the mean 
(SEM). BSA-treated controls are the first bars labelled monocyte, activated monocyte, 
macrophage or activated macrophage. * denotes significant differences (P<0.05). n=6 in all 
cases. 
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7.7.3.3 Comparison of MCP-1 Production in Models of Young and Age-Related 
Impaired Healing 
Estrogen supplementation in unactivated and LPS-activated monocytes 
caused a significant increase (p<0.05) in the concentrations of MCP-1 for all CRP 
treatments compared to levels found in the absence of estrogen. (Figure 7.11A and 
7.11B).  
Estrogen supplementation significantly decreased (p<0.05) the MCP-1 
concentration in unactivated macrophages following treatment with nCRP 
compared to levels found in the absence of estrogen.  However, estrogen 
supplementation caused a significant increase (p<0.05) in MCP-1 concentration 
following treatment with mCRP compared to levels found in the absence of 
estrogen. (Figure 7.11C).   
There was no significant difference in the concentration of MCP-1 between 
activated macrophages supplemented with estrogen and those in the absence of 
estrogen following treatment with either CRP isoform (Figure 7.11D). 
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Figure 7.11 – The difference in MCP-1 profiles between healthy model and age-impaired 
model. A) Monocyte cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS 
activated macrophage cells. Error bars representative of the standard error of the mean 
(SEM). BSA-treated controls are the first bars labelled monocyte, activated monocyte, 
macrophage or activated macrophage. * denotes significant differences (P<0.05). n= 6 in all 
cases. 
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7.7.3.4 Comparison of TNF-α Production in Models of Young and Age-Related 
Impaired Healing  
 In unactivated monocytes, supplementation with estrogen caused a 
significant increase (p<0.05) in the TNF-α concentration compared to levels found in 
the absence of estrogen following treatment with all CRP isoforms (Figure 7.12A). 
 Estrogen supplementation caused a significant decrease (p<0.05) in TNF-α 
concentration in LPS-activated monocytes compared to levels in the absence of 
estrogen. However, in contrast estrogen supplementation in LPS-activated 
monocytes caused a significant increase (p<0.05) in TNF-α concentration (Figure 
7.12B) following treatment with CRP isoforms compared to levels in the absence of 
estrogen. 
 Estrogen supplementation in unactivated macrophages caused a significant 
increase (p<0.05) in TNF-α following treatment with CRP isoforms compared to 
levels in the absence of estrogen (Figure 7.12C). Estrogen supplementation in LPS-
activated macrophages caused a significant decrease (p<0.05) in TNF-α 
concentration following treatment with CRP isoforms compared to levels in the 
absence of estrogen (Figure 7.12D). 
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Figure 7.12 – The difference in TNF-α profiles between healthy model and age-impaired 
model. A) Monocyte cells B) LPS activated monocyte cells. C) Macrophage cells. D) LPS 
activated macrophage cells. Error bars representative of the standard error of the mean 
(SEM). BSA-treated controls are the first bars labelled monocyte, activated monocyte, 
macrophage or activated macrophage. * denotes significant differences (P<0.05). n=6 in all 
cases. 
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7.8 Discussion 
7.8.1 Interleukin-6 Production 
 Figures 7.1, 7.5 and 7.9 all provide evidence to show the effect of CRP on 
interleukin-6 (IL-6) levels in both a young and age-related impaired models of 
healing. IL-6 is a known stimulator of CRP in hepatocytes (Weinhold et al, 1997); 
however, the data presented here indicates that CRP could also alter IL-6 levels in a 
reciprocal manner. In both models of healing, in general, treating monocytes (both 
unactivated and LPS-activated) and unactivated macrophage cells with 250µg/ml 
mCRP increased IL-6 levels. However, mCRP caused a significant decrease in the 
production of IL-6 in LPS-activated macrophages in both models of healing. It is 
known that IL-6 levels increase during periods of inflammation (Scheller et al, 
2011); however the findings of this study indicate that mCRP can increase IL-6 levels 
in monocytes (both unactivated and LPS-activated)  and unactivated macrophages .  
In contrast, treatment of LPS-activated macrophages with mCRP caused a 
significant decrease in the amount of IL-6 being produced in both models of 
healing. These cells were already in a heightened inflammatory response due to the 
LPS-activation and therefore mCRP could be inhibiting its own production in a 
feedback loop by reducing IL-6, thereby bringing about a resolution of inflammation 
rather than acting in a typical pro-inflammatory manner (Thiele et al, 2014).  
 In the age-related impaired model of healing, treatment with nCRP did not 
have any effect upon IL-6 levels in any of the cell states. In the model of acute 
healing in young adults, the addition of nCRP caused an increase in IL-6 production 
in the unactivated monocytes, but a decrease in IL-6 in both unactivated and LPS-
activated macrophages. Taking into consideration that nCRP is considered to be 
more anti-inflammatory in nature (Thiele et al, 2014), this would indicate that the 
reduction of IL-6 in tissue macrophages afforded by nCRP during youth (estrogen 
supplementation) may be lost with increasing age (absence of estrogen).  The 
literature supports this theory since IL-6 levels are elevated in age-related healing 
compared to the healing seen in young adults (Ogura et al, 2008). Estrogen seems 
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to a key mediator of IL-6. Estrogen caused an increase in IL-6 levels in both 
unactivated and LPS-activated monocytes. However, in LPS-activated macrophages, 
estrogen caused a significant decrease in IL-6 levels. This comparison shows that 
estrogen can act in a dual manner, being both pro-inflammatory and anti-
inflammatory depending on the cell status. This is supported by Chakrabarti et al 
(2008) who showed estrogen can promote or inhibit inflammation in different 
tissues at the same time. In cells indicative of tissue macrophages typically found in 
wounds (activated macrophages) estrogen was anti-inflammatory in nature, 
reducing IL-6 levels. In cells indicative of circulating monocytes (unactivated and 
activated monocytes), estrogen was pro-inflammatory in nature, stimulating IL-6 
levels.  Vegeto et al (2002) showed estrogen has a protective role in tissue 
inflammation, inhibiting the synthesis of pro-inflammatory cytokines such as IL-6. In 
line with this, estrogen has been shown to promote the infiltration of immature 
monocytes from circulation but this pro-inflammatory effect is reversed in mature 
tissue macrophages, causing the down-regulation of inflammation at wound sites 
(Ashcroft et al, 2003). Macrophages are recruited to sites of inflammation and local 
levels of cytokines in tissues are controlled accordingly without affecting circulating 
levels (Corcoran et al, 2010). In the model of age-related impaired healing, there 
were only a few cases where the addition of an inhibitor significantly reduced the 
effect of the CRP treatment on IL-6 levels. In activated monocytes, the mCRP-
induced IL-6 production was significantly reduced with the addition of either 
wortmannin or LML (Figure 7.1B).  
 The addition of wortmannin indicates that mCRP is at least in part 
interacting with the PI3K pathway, of which IL-6 is a main activator (Heinrich et al, 
2003). Inhibition of the PI3K pathway would suggest that either the feedback loop 
of IL-6 has been disrupted or that mCRP is contributing to the increasing levels of IL-
6 through this pathway. The p38 pathway is utilised to activate the IL-6 gene in 
order to lead to the production of IL-6. By inhibiting p38 using LML this pathway is 
blocked, suggesting that the mCRP could potentially be activating IL-6 production 
via p38 activation (Craig et al, 2000). Both the PI3K and p38 pathways utilise nuclear 
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factor-κβ (NF-κβ) to induce the production of IL-6 (Heinrich et al, 2003; Craig et al, 
2000). This suggests that in LPS-activated monocytes, mCRP could potentially be 
stimulating the production of NF-κβ in order to produce higher levels of IL-6, and 
this process may be blocked by either wortmannin or LML. 
 
7.8.2 Interleukin-8 Production 
Figures 7.2, 7.6 and 7.10 all provide evidence on the effects of CRP isoforms 
on interlekin-8 levels in models of young and age-related impaired healing. 
Estrogen supplementation in the model of acute healing in young adults led 
to a significant increase in IL-8 production following mCRP treatment in three of 
four cell states. Indeed, estrogen is known to generally increase the levels of IL-8 so 
this is not unexpected (Bengtsson et al, 2004).  However, similar to IL-6, levels of IL-
8 significantly decreased in LPS-activated macrophages supplemented with 
estrogen, suggesting it is mechanism to bring about the resolution of inflammation 
by mature macrophages in young adults. In the age-related impaired model of 
healing a significant decrease in IL-8 was seen in unactivated monocytes and 
significant increases in IL-8 were seen in activated monocytes and unactivated 
macrophages following mCRP treatment. The increases in IL-8 are concordance 
with research showing mCRP increases IL-8 production, thus leading to the 
promotion of pro-inflammatory activity (Khreiss et al, 2004). 
Wigmore et al (1997) indicated that IL-8 can work at a local level and induce 
CRP production. Thus the induction of IL-8 by mCRP detected in this study may 
contribute to a positive feedback mechanism, causing further production of CRP via 
the stimulation of IL-8, if the CRP generated by IL-8 includes the mCRP isoform. In 
line with this, Kibayashi et al (2005) showed CRP plays a role in atherosclerosis 
through the activation of CRP and that mCRP generally causes IL-8 levels to rise. 
Significant increases in IL-8 in unactivated macrophages following mCRP treatment 
could also be partly due to the fact that IL-8 is mainly produced by macrophages 
(Koch et al, 1992).  
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 Previous studies suggested that treatment with nCRP produces no 
significant effect on the production of IL-8 (Khreiss et al, 2004). However this study 
has shown that nCRP can increase IL-8 production in both unactivated and activated 
monocytes in the model of healing in young adults, indicating a pro-inflammatory 
role for nCRP in circulation. In the age-related impaired model of healing, treatment 
with nCRP led to a significant decrease in IL-8 production in unactivated and LPS-
activated monocytes and a significant increase in LPS-activated macrophages. The 
study conducted by Khreiss et al (2004) did not specifically look at macrophages 
and therefore could be the reason why they discovered no detectable effects.  
The use of inhibitors to reverse significant results in the age-related 
impaired healing model showed multiple inhibitors could reverse CRP-mediated IL-
8 levels. Nystatin reversed the mCRP-mediated reduction in IL-8 in unactivated 
monocytes (Figure 7.2A) and the mCRP-mediated increase in IL-8 in LPS-activated 
monocytes (Figure 7.2B). In addition, LML and nystatin reversed the nCRP-mediated 
reduction in IL-8 in LPS-activated monocytes (Figure 7.2B). Wortmannin reversed 
the mCRP-induced increase in IL-8 in unactivated macrophages (Figure 7.2C).  
Kibayashi et al (2005) provided evidence that IL-8 production could be 
inhibited using MAPK inhibitors such as SB203580 (LML) in a study of 
atherosclerosis. However, LML treatment did not reverse the CRP-mediated 
changes in IL-8 observed in this study, suggesting the mechanisms mediating IL-8 
levels may be dependent on cell type and state.  
The inhibitor, nystatin, had a significant effect upon CRP-mediated IL-8 
levels. Nystatin is an inhibitor of the lipid-raft-caveolae endocytosis pathway 
(Ivanov, 2008) as well as being able to form barrel like pores in the membrane 
which leads to potassium leakage (Chen et al, 2011). It is known that mCRP can 
associate with the cell membrane via lipid rafts (Ji et al, 2009) which could lead to 
the changes observed in mCRP treated cells. When nystatin reversed nCRP-
mediated changes in IL-8, it could in part be due to nCRP molecules dissociating into 
mCRP.  
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 The fact that wortmannin had some effect on IL-8 levels is interesting. The 
activation of IL-8 does not usually occur through the PI3K pathway but usually 
through activation of the ERK, p38 MAPK and JNK pathways (Kibayashi et al, 2005). 
However, it has been suggested that IL-8 activation can occur through the 
activation of PI3K having downstream effects ultimately leading to the activation of 
IL-8 (Takami et al, 2002).  Thus, mCRP might be affecting IL-8 through the PI3K 
pathway in unactivated macrophages via some downstream inhibition of the IL-8 
production.  
  
7.8.3 Monocyte Chemoattractant Protein-1 Production 
 Figures 7.3, 7.7 and 7.11 provide evidence on the effect of CRP isoforms on 
monocyte chemoattractant protein-1 levels in both models of healthy and age-
related impaired healing. 
 In the age-related impaired model, the addition of mCRP caused a 
significant increase in MCP-1 production in unactivated and LPS-activated 
monocytes but a significant decrease in both unactivated and LPS-activated 
macrophages. In the model of acute healing in young adults, both unactivated and 
LPS-activated monocytes and unactivated macrophages had significantly increased 
MCP-1 levels whereas LPS-activated macrophages showed significantly less MCP-1 
production following treatment with mCRP.  
This is supported by the literature since estrogen has been shown to 
promote the infiltration of immature monocytes from circulation via production of 
MCP-1 but this pro-inflammatory effect is reversed in mature tissue macrophages, 
causing the down-regulation of inflammation at wound sites (Ashcroft et al, 2003). 
In both the young and age-related impaired models of healing, the monocytes 
produced more MCP-1 following mCRP treatment, which fits with evidence that 
MCP-1 is principally produced in monocytes (Deshmane et al, 2009) and mCRP is 
pro-inflammatory in general (Khreiss et al, 2004). It is known that CRP can also 
activate monocytes in the arterial wall, leading to the promotion of atherosclerosis 
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through the release of MCP-1 (Han et al, 2004). Macrophages exhibited a profile of 
CRP isoforms that was indicative of a reduced inflammatory response compared to 
the profile of CRP isoforms in monocytes. This is evidence that CRP increases MCP-1 
levels in atherosclerosis (Han et al, 2004).  
  In the age-related impaired model of healing, unactivated macrophages 
produced higher levels of MCP-1 following mCRP treatment, which was not seen 
following estrogen supplementation in the model of healing in young adults. This 
suggests that the reduction of estrogen in the age-related impaired model of 
healing, results in a more profound (excessive) pro-inflammatory response, with 
higher levels of MCP-1 leading to the further recruitment of monocytes. In both the 
young and age-related models of healing however MCP-1 levels were significantly 
reduced in LPS-activated macrophages, indicating a more dampened inflammatory 
response in activated tissue macrophages, potentially leading to a resolution of the 
inflammatory response. 
 Treatment with nCRP yielded no significant findings in the model of acute 
healing in the young. However in the age-related impaired healing model treatment 
with nCRP only had an effect on monocytes, significantly decreasing MCP-1 levels in 
unactivated monocytes but significantly increasing MCP-1 levels in the LPS-
activated monocytes.  This response would lead to reduced monocyte recruitment 
from circulation in the absence of infection and increased monocyte recruitment in 
the presence of infection, suggesting the anti-inflammatory nature of nCRP (Khreiss 
et al, 2004) relates to situations where infection is absent. This involvement of 
monocytes also concurs with literature showing MCP-1 is produced predominantly 
in monocytes (Deshmane et al, 2009). The fact nCRP only regulated MCP-1 in the 
age-related impaired model of healing suggests that the loss of estrogen during 
ageing changes the profile of MCP-1 production by monocytes, leading to a more 
pronounced inflammatory response in the presence of infection.  
 In summary, supplementation of estrogen led to significantly higher levels of 
MCP-1 in the monocytes following treatment with mCRP but no effect was 
observed following nCRP treatment. The addition of estrogen is known to increase 
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the levels of MCP-1 production in the monocytes, therefore this change was not 
unexpected (Bengtsson et al, 2004).  In contrast, supplementation of estrogen 
reduced MCP-1 levels in activated macrophages following treatment with mCRP 
and no effect was observed following nCRP treatment. Estrogen has been shown 
previously to reduce MCP-1 in mature tissue macrophages of wounds (Ashcroft et 
al, 2003). 
Pervin et al (1998) stated that treatment with estrogen supressed MCP-1 
expression in macrophages in atherosclerosis. Ashcroft et al (2003) also showed 
that estrogen suppresses MCP-1 expression by mature tissue macrophages, thus 
inhibiting further infiltration of immature monocytes into murine wounds. These 
publications agree with the lower levels of MCP-1 found in the estrogen-treated 
macrophages in this study.  
 
7.8.4 Tumour Necrosis Factor-α Production 
 Data from Figures 7.4, 7.8 and 7.12 all provide evidence on the effect of CRP 
on tumour necrosis factor-α (TNF-) levels in both a model of acute wound healing 
in young adults and a model of age-related impaired healing. 
 In the model of age-related impaired healing, in general both CRP isoforms 
caused a significant decrease in TNF-α levels. In the model of acute wounding in the 
young there was a significant increase in TNF-α levels in LPS-activated monocytes 
but not unactivated monocytes following treatment with both CRP isoforms. This 
concurs with the literature since LPS is the main stimulator of TNF-α production 
(Zelová & Hošek, 2013) and suggests TNF- levels in monocytes are likely to be 
higher in the presence of infection.  TNF- levels in activated macrophages were 
significantly reduced following treatment with either CRP isoform. 
 When the estrogen was removed in the age-impaired model, the effects of 
the CRP isoforms caused significant decreases in the TNF-α levels. This can possibly 
be explained through the fact that CRP can bind and crosslink FcγR1 receptors on 
cells, which in turn induces the production of interleukin-10 (IL-10). This leads to 
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the cells becoming immunosuppressive and thus turning off the production of 
interleukin-12 (IL-12) and TNF-α (Marnell et al, 2005). The indication is that the 
presence of estrogen can supress this process, explaining why the production of 
TNF-α in the healthy model increases.  
Treatment with the nystatin inhibitor reversed the mCRP-mediated 
reduction of TNF-α levels in LPS-activated monocytes (Figure 7.4B). Treatment of 
nystatin reversed the nCRP-mediated reduction of TNF-α in unactivated 
macrophages (Figure 7.4C). The other inhibitors (wortmannin, LML and MEK) were 
not used in this case since they are known to also directly reduce TNF- levels 
(Smith et al, 2007; Campbell et al, 2004), similar to the response observed with the 
CRP isoforms. The inhibitor, nystatin, also reversed the effects on TNF-α levels in 
both LPS-activated monocytes and unactivated macrophages. As mCRP can 
associate with the cell membrane via lipid rafts (Ji et al, 2009), nystatin may disrupt 
the inhibition of TNF- in LPS-activated monocytes following treatment with mCRP. 
Nystatin reversal of nCRP-mediated reduction of TNF-α suggests that nCRP might 
become dissociated in unactivated macrophages to form mCRP that then interacts 
with lipid rafts in the membrane.   
 Supplementation with estrogen has shown that estrogen is having a dual 
function in regards to cell type. In unactivated monocytes and unactivated 
macrophages, estrogen is behaving in a pro-inflammatory manner leading to higher 
amounts of TNF-α. However, in LPS-activated monocytes and LPS-activated 
macrophages, estrogen significantly decreased TNF-α levels. There have been many 
studies that have shown that estrogen has a dual-modality, increasing or decreasing 
inflammation depending on cell type/status (Chakrabarti et al, 2008).  The 
reduction of TNF- by estrogen is achieved through the inhibition of the Hun NH(2)-
terminal kinase (JNK) (Srivastava et al, 1999).  
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7.9 Future Work 
 Due to time and financial constraints, this study investigated levels of only 
four cytokines in inflammatory cells. Several other cytokines that are also involved 
in the actions and function of CRP would also be good candidate proteins to 
investigate in future work. Three of the main cytokines that could be analysed are 
interleukin-1β (IL-1β), interleukin-10 (IL-10) and interleukin-12 (IL-12). CRP can 
interact with FcγRI receptors to upregulate the production of cytokines; including 
IL-1, especially IL-1β which can also stimulate production of CRP; and IL-10 which is 
an inhibitor of IL-12 (Du Clos & Mold, 2004). IL-12 production is upregulated during 
periods of pronounced inflammation induced by LPS (Du Clos & Mold, 2004). IL-1β 
has been shown to act in a similar way to IL-6 and TNF-α, stimulating the 
production of CRP in the hepatocytes (Berger et al, 2002).  
 
 
7.10 Summary 
  In general, the two CRP isoforms had varying effects upon the production of 
these four pro-inflammatory cytokines, dependent on the cell type and status. 
Comparison of the model of acute healing in the young and the model of age-
related impaired healing, indicates that estrogen plays a substantial role in how 
these CRP isoforms function during the inflammatory response.   
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Chapter 8: The effect of C-reactive protein isoforms on the 
recovery of MRSA colonies from an in vitro phagocytosis 
assay  
 
8.1 Introduction 
8.1.1 C-Reactive Protein and Pathogens  
 C-reactive protein is a marker for inflammation and its levels increase during 
bacterial infection (Healy & Freedman, 2006). Kingsley and Jones (2008) stated that 
during infection CRP rises in response to monocytic mediators such as IL-1 and IL-6 
and that it has a stable decay rate. It is thought that most of the interaction 
between CRP and the immune response to pathogens lies within the binding of CRP 
to phosphocholine (PCh) and the activation of the classical complement pathway 
(Mortensen, 2001). There is much evidence that CRP can confer some protection 
against pathogenic infections. It was first documented by Mold et al (1981) who 
found CRP provides mice with protection against infection with the gram-positive 
pathogen Streptococcus pneumoniae by binding to a PC determinant of the 
pathogen cell wall and activating the complement pathway. Mice pre-treated with 
200µg CRP before being infected showed an increase in percentage survival across 
all pathogen doses tested. The study concluded that the ability of CRP to protect 
against infection lies in its ability to bind to pneumococcal polysaccharide C in the 
bacterial cell wall (Mold et al, 1981). 
 Szalai et al (2000) also showed that CRP can confer protective benefits 
against Salmonella enterica serovar Typhimurium; a gram-negative pathogen which 
provides a model of typhoid fever in mice. Using transgenic mice expressing human 
CRP the study found that CRP offered protection against a low dose of Typhimurium 
and increased resistance to a fatal infection with a low dose of Typhimurium. CRP 
can bind both PC and phosphoethanolamine (PEt) but Typhimurium has PEt, yet 
does not bind to CRP in vitro and therefore should not be opsonised. Szalai (2000) 
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concluded that CRP increases the early clearance of IV-injected bacteria from the 
blood and reduces dissemination of bacteria to the liver and spleen during the 
initial stages of infection, thus allowing the mice to survive infection.   
 Marnell et al (2005) confirmed that CRP can also protect against 
Haemophilus influenza infection in both transgenic mice and wild-type mice treated 
by passive inoculation. This was stated to be because CRP binds the pneumococcal 
C-polysaccharide of bacteria and opsonises them for phagocytosis. This process 
does not require the use of the Fcγ receptors meaning that it is not primarily 
protective by direct opsonisation but more likely through the activation of 
complement and subsequent opsonophagocytosis. Marnell et al (2005) also stated 
that CRP was needed for serum bactericidal activity against the Haemophilus 
influenza pathogen but that complement activation was more effective.  
Kinglsey and Jones (2008) tested the ability of CRP as a marker of 
inflammation and if it could be used to distinguish different infection types. They 
discovered that mean CRP levels in a spreading infection were higher than those in 
the other colonised, critically colonised and locally infected groups. All cases of 
infection showed an increase in CRP levels compared to non-infected controls but 
CRP levels could not distinguish between the infection types, showing that it is the 
infection in general that causes CRP levels to rise, rather than the type of infection. 
This was also noted by Healy & Freedman (2006) who showed that CRP levels can 
only be used as a method of detecting infection, rather than distinguishing it.  
 This evidence shows that CRP is not only a marker of infection and 
inflammation but that the CRP also has a protective role against bacterial infections, 
principally through the activation of complement and subsequent opsonisation of 
pathogens. 
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8.1.2 Methicillin-resistant Staphylococcus aureus (MRSA) 
 Staphylococcus aureus is a gram-positive coccal bacterium that is frequently 
found in the respiratory tract and on the skin. It is considered part of the normal 
host skin flora and so is not normally pathogenic but is a common cause of wound 
infections and abscesses, with most strains promoting infection through the release 
of toxins that bind and inactivate host antibodies (Chambers, 2001; Stryjewski & 
Corey, 2014).  
 Antibiotics, such as penicillin, are the main treatment for infection with 
Staphylococcus aureus but this has conferred antibiotic resistance in the pathogen. 
In 1959, methicillin was introduced as a treatment for penicillin-resistant 
Staphylococcus aureus but the first case of methicillin-resistant Staphylococcus 
aureus (MRSA) was documented just two years later in the United Kingdom. Cases 
of MRSA remained rare until the 1990s when there was an increase of cases leading 
to a worldwide problem (Enright et al, 2002). There are two types of MRSA 
infection; hospital acquired and community acquired. Hospital acquired infections 
tend to be contracted in the healthcare system from one patient to another 
whereas community acquired infections tend be found in places where there are a 
lot of people in an enclosed area, with lots of contact and humidity as well as in 
conditions of poor hygiene. Community acquired MRSA infections are common in 
schoolchildren, prisoners, soldiers and athletes (Köck et al, 2010).  
 MRSA can live in the host undetected and without causing symptoms until 
the host becomes immunocompromised or if the pathogen is introduced into the 
bloodstream which can lead to endocarditis, meningitis and sepsis. The only 
antibiotic used to treat MRSA is vancomycin however resistance to this is now being 
observed (Stryjewski & Corey, 2014). 
 Staphylococcus aureus develops resistance to methicillin via a part of the 
Staphylococcal cassette chromosome mec known as the mec operon (SCCmec). The 
resistance is conferred upon the penicillin binding protein 2A (PBP2a) leading to 
lower affinity of binding (Enright, 2003). This prevents the ring structure of 
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antibiotics to bind to the enzymes that help to form the cell wall of the bacterium 
(Enright, 2003). The SCCmec genomic island is of unknown origin and contains the 
cytolysin gene PSM-mec which suppresses virulence as well as ccrA and ccrB that 
mediate site specific integration and excision of the SCCmec element (Enright, 
2003). 
 
8.1.3 C-reactive Protein and MRSA 
There is little research into the direct effect of CRP on MRSA. It is known 
that CRP levels rise when the host is infected with MRSA. Povoa et al (2005) stated 
that the normal CRP level for the healthy population is about 0.08mg/dL and this 
rises to more than 8.7mg/dL during chronic infection. Thus CRP can be used as an 
indicator of infection, alongside a body temperature of more than 38.2oC.  
CRP mediates host responses to Staphylococcus aureus including some 
protective function against infection and an increase in phagocytosis of this 
pathogen.  
 Patterson and Mora (1965) observed that enhanced resistance to intra-
articular infection with Staphylococcus aureus in chickens was associated with an 
increase in serum CRP and that isolated preparations of the protein produced 
antibacterial activity. Mulholland and Cluff (1964) discovered that endotoxin-
induced changes in resistance to local infection with Staphylococcus aureus in 
rabbits was correlated with the circulating levels of leukocytes in the blood. The 
results of this study showed that the induced resistance was paralleled by the 
increase in CRP and leukocytes. This finding was supported by Patterson, Harper 
and Higginbotham (1968) who found an association between CRP and non-specific 
resistance to infection, including Staphylococcus aureus, and showed CRP was 
acting upon the polysaccharide bacterial cell wall.  
 Black, Kusher and Samols (2004) stated that CRP enhances the in vitro 
phagocytosis of many microorganisms (including Staphylococcus aureus) by 
leukocytes. Their work confirmed this finding even in the absence of complement, 
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suggesting that the enhancement of phagocytosis by CRP is due to the interactions 
with Fcγ receptors.  
 
 
8.2 Aims 
 The aim of this study was to determine the effects of different isoforms of 
CRP upon an in vitro model of phagocytosis using MRSA as the pathogen of choice 
since it is associated with chronic wound infections and immunocompromised 
hosts.  
 
 
8.3 Objectives 
 The fundamental objectives of this study were: 
 To determine whether CRP isoforms mediate the recovery of MRSA colonies 
in vitro. 
 To determine whether CRP isoforms have differential effects upon the 
recovery of MRSA colonies in vitro. 
 To use of inhibitors where appropriate to block the effects of CRP isoforms 
on the recovery of MRSA colonies in vitro. 
 
 
 
 
 
 
198 
 
8.4 Summary of Procedure 
 An in vitro model of macrophage phagocytosis was utilised whereby the 
recovery of viable bacteria after a defined period of host-pathogen interaction was 
measured using a fixed number of starting bacteria and CRP-treated macrophages. 
The methodology was similar to that utilised by Drevets et al (2015). 
 In summary, the U937 monocyte cell line was differentiated into 
macrophages and activated using LPS and IFN-γ to stimulate phagocytosis. A fixed 
number of macrophages (host) were then treated with CRP isoforms (with or 
without inhibitors) for 24 hours before incubation with a fixed number of MRSA 
(pathogen) for a period of 3 hours to enable host-pathogen interaction to take 
place. MRSA were subsequently recovered and cultured on agar plates to 
determine the number of surviving (non-internalised) bacteria following the 
defined period of host-pathogen interaction.  Where CRP treatments caused 
significant changes in the number of recovered MRSA colonies, the assay was 
repeated to determine whether the findings could be reversed with the use of 
pharmacological inhibitors. 
 
 
8.5 Materials 
Materials for cell culture was as previously mentioned in Section 2.3.1. However, 
penicillin-streptomycin was removed from the phagocytosis assay to prevent any 
anti-bacterial effect on MRSA colonies. 
Human monocyte cell line U937 (Health Protection Agency Culture Collections, 
Salisbury) 
RPMI-1640 Media (Lonza, Slough) 
Foetal Bovine Serum (Sigma-Aldrich, Dorset) 
Lipopolysaccharide (Sigma-Aldrich, Dorset) 
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Phorbol 12-myristate 13-acetate (Applichem, Darmstadt) 
Inhibitors – Prepared as previously mentioned in Section 2.4.9.  
IFN-γ (Sigma-Aldrich, Dorset) 
Bovine Serum Albumin (BSA) (Sigma-Aldrich, Dorset) 
C-reactive Protein (CRP), human >95% native, 5mg/ml (MyBioSource, San Diego) – 
Purified as previously stated in Section 2.4.4.  
Methicillin Resistant Staphylococcus aureus (MRSA) – Strain 11 is a patient isolate 
collected at Withington Hospital, Manchester. Many thanks to Dr K Whitehead 
(Manchester Metropolitan University) for this gift. 
Nutrient Broth (Oxoid, Basingstoke) 
Nutrient Agar (Oxoid, Basingstoke) 
Saline (Sigma-Aldrich, Dorset) 
Trypsin (Thermo Fisher Scientific, Loughborough) 
 
 
8.6 Methods 
8.6.1 Cell Culture 
 U937 cells were cultured and prepared as described in Section 2.4.1. U937 
cells at a concentration of 1x106 cells, were differentiated with PMA for 72 hours as 
previously described (Section 2.4.3) before being activated for 2 hours with 1µg/ml 
LPS and 100ng/ml IFN-γ.   
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8.6.2 C-reactive Protein Isoforms 
 CRP isoforms were purified and quantified as previously described in Section 
2.4.4.  
 
8.6.3 MRSA Assay 
  Activated macrophages prepared in Section 8.6.1 were treated for 24 hours 
with physiological concentrations of mCRP (100µg/ml and 250µg/ml) or nCRP 
(500µg/ml and 1000µg/ml) to mirror levels found in humans during acute 
inflammatory responses.   All sample wells and controls were then incubated with 
MRSA bacteria at 5000 colony forming units/ml (CFU/ml), to a total of 5000 
colonies, for 3 hours to simulate a fixed period of host-pathogen interaction. 
Controls included a phagocytosis-negative control lacking macrophages to provide a 
measure of maximum bacterial recovery in the absence of any host-pathogen 
interaction. Background phagocytosis was determined from measuring bacterial 
recovery following a period of host-pathogen interaction using untreated 
macrophages (i.e. macrophages lacking treatment with CRP isoforms). Additional 
negative controls were prepared using BSA as an alternative (control) protein at the 
same concentrations as the CRP isoforms (100µg/ml, 250µg/ml, 500µg/ml and 
1000µg/ml) to confirm effects on bacterial recovery were CRP isoform specific and 
not simply due to the presence of an arbitrary polypeptide. 
After a 3 hour host-pathogen incubation period all wells were treated with 
trypsin to promote detachment and recovery of non-internalised bacterial cells. 
Ten-fold dilutions were plated onto nutrient agar plates and incubated at 37°C 
overnight to recover viable bacterial colonies. The number of colony forming units 
were counted to calculate the bacterial recovery as a measure of bacteria that have 
not undergone phagocyte internalisation. 
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8.6.4 Inhibitors 
 Where appropriate (i.e. for those CRP treatments that significantly mediated 
bacterial recovery), the assay was repeated with the addition of the 
pharmacological inhibitors wortmannin, LML, MEK and nystatin to assess their 
ability to reverse the effects of CRP isoforms.  
 
8.6.5 Statistical Analysis 
 Graphs were drawn using Microsoft Excel and all statistics performed using 
IBM SPSS Statistics (Version 22). The Shapiro-Wilkes normality test was conducted 
on the data before performing a one way ANOVA with Tukey pairwise comparisons.  
 
 
8.7 Results 
8.7.1 Microbiology Assay – General Effects of CRP on the Recovery of MRSA 
Colonies  
Figure 8.1 shows the recovery of MRSA colonies after treatment of activated 
macrophages with CRP isoforms. A significantly decreased number of MRSA 
colonies were recovered when macrophages were present (background 
phagocytosis) compared to the negative control (bacteria alone) that lacked 
phagocytic macrophages. This is expected since macrophages activated with LPS 
and IFN are known to carry out effective phagocytosis (Patel et al, 2012). 
The negative BSA controls, regardless of BSA concentration, showed no 
significant change (P>0.05) in the number of MRSA CFUs recovered compared to 
the background level of bacterial recovery obtained with untreated macrophages, 
thus indicating that observed changes in recovery were due to specific CRP isoforms 
rather than just the presence of an arbitrary polypeptide. 
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The treatment with mCRP showed no significant difference (P>0.05) in the 
recovery of MRSA colonies compared to the background level of MRSA recovery, 
suggesting mCRP had no detectable effect on phagocytosis.  
However, both concentrations (500µg/ml and 1000µg/ml) of nCRP showed a 
significant (P=0.01) reduction in the recovery of the MRSA CFUs.  The nCRP 
concentration of 500µg/ml was subsequently taken forward to see if the addition of 
pharmacological inhibitors could reverse the nCRP-induced reduction in MRSA 
recovery. 
 
 
 
 
 
Figure 8.1 – The recovery of MRSA colonies after treatment with C-reactive 
protein isoforms. * denotes significant decrease in bacterial recovery (P<0.05) 
compared to the background level of bacterial recovery with untreated 
macrophages. 
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8.7.2 The Effect of Pharmacological Inhibition on the Reduction of MRSA Recovery 
Produced by 500µg/ml nCRP. 
 Figure 8.2 indicates the effect on four inhibitors on the recovery of MRSA 
colonies after treatment with nCRP at 500µg/ml. Treatment with the inhibitors 
showed a significant increase (P<0.01 in all cases) in the number of MRSA colonies 
recovered following treatment with nCRP at 500µg/ml. There were no significant 
(P>0.05) differences between the background level of bacterial recovery and results 
obtained from negative controls that contained activated macrophages incubated 
with just inhibitors alone (i.e. no treatment with CRP isoforms), thus confirming 
that the pharmacological inhibitors were blocking the biological action of nCRP 
rather than directly influencing bacterial recovery themselves.  
  
Figure 8.2 – Recovery of MRSA colony forming units (CFUs) after treatment 
with nCRP at 500µg/ml and pharmacological inhibitors. * indicates significant 
decrease (P<0.05) when compared to the background level of MRSA recovery 
with untreated macrophages.   ** indicates significant increase in bacterial 
recovery (P<0.05) when compared to treatment with nCRP 500µg/ml alone. 
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8.8 Discussion 
8.8.1 General Effects of CRP Isoforms on the Recovery of MRSA colonies 
 The phagocytosis assay showed a decrease in the number of MRSA colonies 
recovered in the presence of activated macrophages. This confirmed that host-
pathogen interaction was indeed taking place within the assay. 
 Furthermore, the addition of the various concentrations of negative control 
(BSA) protein did not significantly alter the recovery of the MRSA colonies 
compared to the background level indicating that any changes observed with the 
CRP isoforms were protein-specific.  
 When the macrophages were treated with the nCRP isoform there was a 
significant (P<0.05) decrease in the number of MRSA colonies recovered compared 
to the background level of bacterial recovery, suggesting nCRP stimulates 
phagocytosis. This increase in host-pathogen interaction could be to the activation 
of the complement pathway. The nCRP can activate the classical complement 
pathway by binding to the C1q with the opposite face of the binding site (Du Clos, 
2004). When C1q becomes enzymatically activated it triggers the binding and 
cleavage of C4 and C2, resulting in the C3b2b complex being formed. The C3b2b 
complex becomes covalently attached to the microbial surface and triggers the 
conversion of C3 to C3b, which also binds to the microbial surface. C3b can also 
bind to the complex to form the C5 convertase, which helps to create the 
membrane attack complex (C5b-C9). This process is known as opsonisation and will 
promote phagocytosis by macrophages (Mold et al, 1999). This process is shown in 
Figure 8.3.  
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 The nCRP isoform can also act in a different manner as it is directly opsonic 
through interaction with Fcγ receptors. CRP was named for its ability to bind to the 
C-polysaccharide of Streptococcus pneumoniae. This reaction is mediated through 
the phosphocholine (PCh) moiety of the polysaccharide. This means that the nCRP 
can bind to the PC-containing phospholipids of the microbial polysaccharides and 
further opsonisation utilises FcγRI and FcγII (Mold et al, 2002). 
 This would suggest that the nCRP increases the opsonisation of the 
microbial surface and promotes the phagocytosis of bacterial pathogens. This is 
supported by other research findings including those of Black et al (2004) that 
showed CRP increases phagocytosis of Staphylococcus aureus even in the absence 
of complement. This study suggested the use of Fcγ receptors in the phagocytosis 
of pathogen. This study however did not state which isoform of CRP was 
responsible for the result. 
Figure 8.3 – The classical complement pathway leading to opsonisation and 
phagocytosis. Opsonisation occurs with the generation of C3b. Phagocytosis 
occurs when the membrane attack complex is formed. Modified from Xu et al, 
2013.  
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When the results of the mCRP isoform are compared to those of nCRP there 
is a very different outcome.  There were no significant differences observed in the 
recovery of MRSA colonies compared to the background level of bacterial recovery 
following mCRP treatment. This could be explained via the fact that when the 
native protein was dissociated into its monomeric form the opposite face, which is 
the C1q binding site, is lost and therefore there is no subsequent binding to the 
microbial surface to trigger opsonisation. The fact that the recovery of MRSA 
colonies was very similar to that of the background level would indicate that the 
mCRP isoform is not having any effect upon phagocytosis.  
Overall, our findings indicate that the protective effect of CRP against 
pathogens seen in previous studies such as Mold (1981) and Szalai (2000) is likely to 
be due to the native protein rather than the monomeric isoform.  The next stage 
was to observe if the addition of pharmacological inhibitors could reverse the 
effects of nCRP on MRSA recovery.  
 
8.8.2 The Effect of Inhibitors on the Recovery of MRSA Colonies Following 
Treatment with 500µg/ml nCRP 
All four of the chemical inhibitors significantly (P<0.05) increased in the 
recovery of MRSA colonies, suggesting they all blocked the phagocytic effect of 
nCRP to some degree. 
 
8.8.2.1 The Effect of Wortmannin on MRSA Recovery 
 Wortmannin is an inhibitor of the PI3 kinase pathway that plays a major role 
in the regulation of phagocytosis (Figure 1.3). Class I and III are regulators of the 
process but Class II PI3Ks have no function in phagocytosis (Cox et al, 1999). Class I 
and III PI2 kinases act consecutively in the formation and maturation of the 
phagosome, the vesicle which is formed around the particle that is to be 
phagocytosed. These PI3 kinases produce two products; PI(3,4,5)P3 and PI(3)P, 
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which accumulate throughout phagocytosis at the different stages (Gillooly et al, 
2001).  
 The formation of the phagosome requires actin reorganisation to allow the 
pseudopodia to extend around the particle to be ingested. Pseudopodia are 
extension of the cell which extend out from the cell and engulf the particle. This 
engulfment forms the phagosome of which when matured uses a combination of 
low pH, reactive oxygen metabolites and hydrolytic enzymes to break down the 
engulfed particle (Stephens et al, 2002).  
 Class I PI3 kinases are involved in the formation of the phagosome by 
allowing PI(3,4,5)P3 to accumulate in the phagocytic cup in early phagocytosis, 
allowing for actin reorganisation to engulf large particles over 3μm in size (Tamura 
et al, 2009). This is followed by the accumulation of PI(3)P which seals the vacuole, 
creating the phagosome.  
 Class III PI3 kinases are mainly required to help the targeting of the 
phagosome to the membrane compartments during phagocytosis. This leads to the 
maturation on the phagosome and digests the large particle (Stephens et al, 2002). 
The engulfment of large particles is dependent upon this mechanism. Small 
particles however are phagocytosed in a PI3K-independent manner. Evidence has 
shown that the phagocytosis of large particles has been inhibited through the use 
of PI3 kinase inhibitors. This has also been correlated though the inhibition of actin 
reorganisation (Gillooly et al, 2001).  
  Thus the literature would suggest that wortmannin, which is a PI3K 
inhibitor, may be inhibiting actin reorganisation and therefore inhibiting the 
phagocytosis of MRSA colonies in this study, thereby accounting for the significant 
increase in MRSA colonies recovered.  
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8.8.2.2 The effect of LML on MRSA Recovery 
 The inhibitor LML is a p38 MAP kinase inhibitor. This pathway is also 
involved in the phagocytosis process (Figure 1.4). There are many genes that 
regulate the phagocytosis process and upregulation of these genes depends upon 
p38 activation downstream of TLR signalling (Tricker & Cheng, 2008). The main 
target for this activation is the actin cytoskeleton (May & Machesky, 2001).  
 As with the PI3 kinase pathway, the p38 MAP kinase pathway is involved in 
the remodelling of the actin cytoskeleton that is required for phagocytosis to occur. 
This is because p38 is a modulator of actin polymerisation which is downstream 
from Rac1. By inhibiting p38 MAPK phosphorylation, actin polymerisation cannot 
occur, which leads to the macrophage being unable to internalise the pathogen 
(Ninković & Roy, 2012).  Also by inhibiting the p38 MAP kinase pathway in this 
manner it does not have any effect upon the ERK1/2 pathway nor does inhibiting 
ERK1/1 have any effect upon inhibition of the actin cytoskeleton (Ninković & Roy, 
2012).   
 If p38 is being inhibited in this assay, it could block the polymerisation of the 
actin cytoskeleton and as a result inhibit the engulfment of the pathogen during 
phagocytosis.  
   
8.8.2.3 The Effect of MEK on MRSA Recovery 
 In the MEK pathway, MEK 1 and MEK 2 are phosphorylated and trigger the 
activation of the ERK proteins (Figure 1.4).  The MEK inhibitor inhibits these two 
enzymes and therefore inhibits the activation of ERK. When MEK 1 and 2 have are 
inhibited some anti-microbial functions are inhibited, including the oxidative burst 
and phagocytosis (Downey et al, 1998).  
 During phagocytosis, especially IgG-mediated phagocytosis, ERK 1 and ERK 2 
are tyrosine phosphorylated in the preceding steps to ingestion. This activation can 
also be Fcγ receptor mediated through MAP kinase phosphorylation and activation 
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when the receptor is engaged and signal transduction occurs. It is the activation of 
this pathway that leads to phagocytosis (Suchard et al, 1997). 
 IgG is known to activate the classical complement pathway through C1q 
which can also be achieved through CRP binding. This would suggest that nCRP is 
activating phagocytosis through this pathway (Du Clos, 2004).  The MEK inhibitor 
blocks this pathway by preventing the phosphorylation of MEK 1 and MEK 2, which 
in turn inhibits ERK. This type of inhibition does not affect the PI3 kinase pathway or 
the p38 MAP kinase pathway. This would suggest that in this assay, the MEK 
inhibitor was preventing the signalling pathway and preventing phagocytosis.  
 
8.8.2.4 The Effect of Nystatin on MRSA Recovery 
 Nystatin is an inhibitor of the lipid raft-caveolae endocytosis (Razonable et 
al, 2005). Endocytosis is the process by which cells can engulf molecules. 
Phagocytosis is one type of endocytosis; however, lipid raft-caveolae endocytosis is 
via a different mechanism. Lipid raft-caveolae are membrane domains that are rich 
in cholesterol and glycosphingolipids which are involved in the internalisation of 
many molecules such as certain toxins, GPI-anchored proteins and other cargos. 
These membrane domains are also involved in cholesterol trafficking. Caveolae are 
‘flask-shaped’ pits in the membrane and are non-clatharin coated.  
Nystatin is known to bind to ergosterol in fungi, which is the equivalent of 
cholesterol in humans. Nystatin binds to this and forms pores in the membrane to 
allow the crossing of potassium and other cell constituents to cross the membrane 
(Coutinho & Prieto, 2003).  
Evidence would suggest that instead of targeting the pathways that control 
phagocytosis, nystatin is targeting the lipid-rafts in the cell and preventing the lipid 
rafts from assembling signalling molecules to influence protein trafficking 
(Razonable et al, 2005).  
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8.8.3 The Role of Inhibitors on MRSA Colony Recovery 
 This assay does not indicate that just one single pathway can be targeted to 
inhibit the effects of the native protein on the recovery of MRSA colonies. The 
results would suggest that the native protein is having a significant effect on 
phagocytosis by upregulating various potential pathways, and that pharmacological 
inhibition of one or more of these mechanisms reverses the nCRP-induced 
phagocytosis. 
 This could have future implications for healthcare interventions. Levels of 
CRP increase dramatically during bacterial infections and this study would suggest 
that the native protein is promoting pathogen uptake and destruction by 
phagocytosis. Thus, pharmacological inhibition of nCRP-mediated pathways or the 
conversion of nCRP to mCRP during the inflammatory response should be avoided 
in the presence of infection since this may impede pathogen destruction by 
impairing phagocytosis. Diseases and inflammatory conditions that induce the 
mCRP isoform and/or reduce the presence of nCRP are likely to be more prone to 
infection as a comorbidity in a non-sterile environment due to impaired 
phagocytosis.  Furthermore, therapeutic strategies that would prevent the 
disassociation of nCRP to mCRP could potentially promote phagocytosis and 
pathogen elimination.  
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8.9 Future Work 
 The findings of this assay are indicative of phagocytosis taking place but 
confirmation of phagocytosis has not been demonstrated.  The assay could be 
enhanced by adding a fluorescent label/tag the bacterial colonies using a 
fluorescent dye, such as fluorescein isothiocyanate, so that the process of 
phagocytosis can be observed by microscopy during the three hour incubation 
period. This would provide real time evidence of host-pathogen interaction and 
bacterial internalisation.  
 Future work could identify how the nCRP is triggering phagocytosis. This 
could consist of observing the effects of nCRP on phagocytosis in the presence of 
inhibitors of complement or the FCγ receptors to analyse which particular pathways 
are being utilised. 
 The assay could also be repeated with a number of pathogens. MRSA is only 
one of many pathogens that can infect a wound or abscess. Other potential 
pathogens include Pseudomonas aeruginosa, Enterococcus faecalis and 
Streptococcus pyogenes that are commonly associated with leg ulcers and chronic 
wounds (Siddiqui & Bernstein, 2010). 
 Further work could be conducted to confirm precisely how the mechanisms 
of phagocytosis are being inhibited by the four pharmacological inhibitors used in 
the assay. This could confirm how nCRP is acting upon those pathways and 
potentially lead to therapies that can promote pathogen destruction. 
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8.10 Summary 
 In summary, it is the native form of CRP that exhibits an effect upon the 
recovery of MRSA colonies, suggesting that nCRP enhances host-pathogen 
interaction via increased phagocytosis. This may be due to nCRP remaining intact 
and therefore enabling C1q binding to occur, triggering the complement pathway. 
This pathway would lead to the opsonisation of the microbial surface and the 
promotion of phagocytosis, supporting evidence that nCRP exhibits anti-microbial 
traits. The monomeric CRP has no effect upon the recovery of MRSA colonies 
suggesting that it has no affect upon phagocytosis. 
 The four pharmacological inhibitors all showed a significant increase in the 
recovery of MRSA colonies suggesting that these inhibitors are affecting the 
pathways controlling nCRP-induced phagocytosis.  Further work would be needed 
to establish the exact mechanisms involved in enhancement of bacterial 
destruction by nCRP. 
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Chapter 9: The Effect of Estrogen on in vivo C-reactive Protein 
Levels 
 
9.1 Introduction  
9.1.1 Age-related Impaired Healing 
 Age is a major factor that can impair the normal healing process (Guo & 
DiPietro, 2010). The main effect of age is that wound healing is delayed but does 
not cause an impairment to the quality of the healing (Guo & DiPietro, 2010). The 
main association with age-impaired healing is that there is an altered inflammatory 
response as well as an altered skin morphology. As skin ages there is a decline in 
dermal thickness as well as a decrease in the absolute number of cells (Ashcroft et 
al, 2002). Specific age-related changes to inflammation also occur including altered 
cell adhesion, migration and function responses (Ashcroft et al, 2002) leading to the 
impairment of the healing process; delayed T-cell infiltration to the wound area as 
well as changes in the production of chemokines and a reduced ability of 
macrophages to phagocytose (Swift et al, 2001). Cohen et al (1987) provided in vivo 
evidence that with age there was an increase in wound inflammatory cell numbers. 
Studies with aged mice have also shown delayed re-epithelialisation, collagen 
synthesis and angiogenesis when compared to young mice (Swift et al, 1999) and 
that there was increased production of pro-inflammatory cytokines such as IL-6 and 
TNF-α from human donors (Fagiolo et al, 1992). 
   
9.1.2 Estrogen and Inflammation 
 There has been increasing evidence of the role of sex-steroid hormones in 
the wound healing and inflammation (Gulshan et al, 1990; Ashcroft et al, 1997; Guo 
& DiPietro, 2010). This is especially seen in age-related research into healing where 
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there is a substantial influence of these hormones on the inflammatory response in 
vivo. 
Estrogen is mainly produced by the ovaries (Nelson & Bulun, 2001) and is 
released into the bloodstream however there is evidence that other peripheral 
tissues such as adipose tissue (Hemsell et al, 2001), skin fibroblasts (Sawaya & 
Penneys, 1992) and osteoblasts (Yaffe et al, 1998) are also sources of estrogen. 
Postmenopausal women see a depletion in their levels of estrogen and a result start 
to see impaired healing as well as other effects such as dry skin that bruises easily. 
These effects can be reversed with hormone replacement therapy (HRT) which also 
deposits collagen in the skin and thickens the skin (Ashcroft et al, 1999).  
  Estrogen has been shown to increase the rate of healing of acute wounds in 
both male and female patients by reducing the inflammatory response (Ashcroft et 
al, 1997; Ashcroft et al, 1999). In contrast testosterone delays acute wound healing 
and increases the inflammatory response (Ashcroft & Mills, 2002). As circulating 
testosterone levels do not tend to alter much with age, this could provide a reason 
as to why males tend to heal slower than females even after treatment with 
estrogen (Ashcroft et al, 1999). 
  Evidence also indicates that women have an enhanced immune system in 
comparison to a male immune system which can be depressed in cases such as 
trauma haemorrhage (Wichmann et al, 1996). This difference is attributed to the 
regulation of the immune system by hormones, with the male hormones causing a 
depression (Grossman, 1989). Other studies have shown that estrogen has an 
immune-enhancing effect during stress and by providing resistance to some 
bacterial infections (Yamamoto et al, 1991).  
 Human skin and inflammatory cells express estrogen receptors (ER) which 
provides evidence that local levels of estrogen may influence the wound healing 
and inflammation processes (Gulshan et al, 1990). This is achieved through the 
modulation of the inflammatory response, cytokine expression and matrix 
deposition leading to accelerated re-epithelialisation, stimulated angiogenesis and 
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wound contraction (Ashcroft & Ashworth, 2003; Hardman & Ashcroft, 2008). It has 
also been shown that topical and systemic estrogens improve the rate of wound 
healing in the elderly.  
 Estrogen modulates the inflammatory process by causing the inhibition of 
neutrophil migration through an alteration of the expression of neutrophil adhesion 
molecules (Ashcroft et al, 1999). This leads to increased wound collagen and 
fibronectin levels as a result of reduced neutrophil numbers in the wound area and 
consequently reduced neutrophil-derived elastase. In chronic wounds such as 
venous ulcers there is an elevated production of neutrophil-derived elastase and 
associated tissue breakdown (Herrick et al, 1997).  Ashcroft et al (2003) also 
indicated that estrogen may have a direct effect upon monocytes and macrophages 
due to the estrogen receptors on their cell surface. However, the effect of estrogen 
upon these cells varies dependent upon their state of differentiation and local 
concentrations of estrogen. Estrogen causes the infiltration of immature monocytes 
to wound sites by increasing the secretion of MCP-1 but this effect is reversed in 
mature tissue macrophages, causing a downregulation of inflammation (Ashcroft et 
al, 2003). It is also suggested the estrogen can have an effect on the differentiation 
of monocytes into mature macrophages during the inflammation process (Calvin et 
al, 1998).  
 
9.1.3 C-Reactive Protein and Estrogen 
 There has been tentative evidence of correlations and interactions between 
estrogen and CRP within inflammatory processes. As with most other previous 
research into CRP and its effects, the research conducted has referred to CRP as just 
a single entity and not differentiated between the two isoforms.  Numerous studies 
have confirmed that CRP is a predictive marker for cardiovascular disease and that 
HRT use in post-menopausal women increases the risk of stroke and blood clots 
(Ridker et al, 1999; Ridker et al; Decensi et al, 2002; Vongpatanasin et al, 2003; 
Silvestri et al, 2003). Ridker et al (1999) found that healthy postmenopausal women 
216 
 
had nearly two-fold increased levels of circulating CRP when they were taking HRT 
and that CRP was the most affected inflammatory marker. As CRP is a marker of 
cardiovascular risk, this suggested that those on HRT were at a higher risk of 
cardiovascular implications such as stroke and blood clots (Ridker et al, 2000). 
However, there is some debate on the effect on CRP levels with HRTs where 
estrogens are combined with progestogens, with those taking oral HRT showing an 
increase in CRP levels in the first 12 months of therapy compared to those with 
transdermal therapy demonstrating no change in circulating CRP levels (Decensi et 
al, 2002).  However, Vongpatanasin et al (2003) also showed that estrogen 
administered orally increases CRP levels twofold whereas estrogen administered 
transdermally had no effect upon circulating CRP levels.  Furthermore, Silvestri et al 
(2003) showed that the effect of HRT on CRP decreased over time.  
Corcoran et al (2010) found a variable response in CRP levels relating to the 
estrogen levels in both older men and postmenopausal women. No effect on CRP 
levels was seen when estrogen was replaced with testosterone, another steroid sex 
hormone found in circulation and peripheral tissues of both genders but produced 
at higher circulatory levels in males (Corcoran et al, 2010). This study  highlighted  a 
relationship between CRP and estrogen (Corcoran et al, 2010) which is concordance 
with work by Ashcroft et al (1999) showing that estrogen is the predominant sex 
steroid hormone mediating inflammation and wound healing processes.  
 Collectively, these studies suggest that estrogen increases circulating levels 
of CRP, leading to a more pro-inflammatory environment in circulation and thus an 
increased risk of certain cardiovascular events such as stroke. The effect of estrogen 
on local CRP levels in many peripheral tissues including skin has not been elucidated 
and studies using transdermal administration of estrogen have presented 
conflicting findings in terms of circulating levels of CRP. Multiple studies have 
shown that estrogen administered transdermally has no effect on circulating CRP 
levels (Decensi et al, 2002; Vongpatanasin et al, 2003). In contrast, other research 
has shown that circulating CRP levels are reduced in humans treated with 
transdermal estrogen (Giltay et al, 2000; Dencensi, Omodei & Robertson, 2002; 
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Nunomura et al, 1994).  A reduction in CRP levels following an increase in 
peripheral estrogen concentration supports the findings of Ashcroft et al (1999) 
demonstrating that estrogen reduces the inflammatory response in wounds. Most 
CRP research in the literature has focused on cardiovascular risk and measured 
circulating CRP levels, principally in plasma or serum rather than in whole blood 
that contains leukocytes and platelets involved in the inflammatory response. 
Moreover, local production of CRP in many peripheral tissues like skin has not been 
investigated to date. Therefore, this study has investigated the effect of estrogen 
on peripheral levels of both CRP isoforms in murine wound and whole blood 
samples using an ovariectomised (OXV) model of age-related (estrogen-deprived) 
impaired healing with and without estrogen supplementation.  
 
 
9.2 Aims 
 The aim of this study was to assess the levels  of CRP isoforms in murine 
wound samples and determine the effect of ageing on CRP levels  in an in vivo 
model of age-related (estrogen-deprived) impaired healing  
 
 
9.3 Objectives 
The fundamental objectives of this section were: 
 To measure circulating amounts (both cellular and extracellular) of CRP 
isoforms in whole blood an in-vivo murine model of age-related impaired 
healing. 
 To measure peripheral concentrations of CRP isoforms in the wounds of in-
vivo murine models of age-related impaired healing. 
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9.4 Summary of Procedure 
 The in-vivo murine model of age-related impaired healing uses 
ovariectomised (OVX) female mice that have had both their ovaries surgically 
removed. This surgical procedure blocks the production of estrogen (since 
peripheral estrogen production is absent in mice) and represents a model of 
impaired healing typically found in elderly humans such as post-menopausal 
women. The supplementation of estrogen in OVX mice (OVX+E) reverses the 
impaired healing due to estrogen-deprivation found in ageing and is a model of 
hormone replacement therapy (HRT) in post-menopausal women. Blood samples 
from the OVX and OVX+E mice were used to measure total (both cellular and 
extracellular) circulating levels of CRP isoforms at day 7 post wounding. Normalised 
wound protein obtained from wound samples were used to determine peripheral 
levels of CRP isoforms in wounds of OVX and OVX+E mice at day 7 post wounding.  
 
 
9.5 Materials 
Mouse blood samples – OVX and OVX+E2 (provided by Dr M Hardman, University of 
Manchester) 
Mouse wound protein samples – OVX and OVX+E2 (provided by Dr M Hardman, 
University of Manchester) 
C - reactive protein, human >95% native, 5mg/ml (MyBioSource, San Diego) Purified 
as previously stated in Section 2.4.4.  
Nitrocellulose membrane (Scientific Laboratories Supplies, Nottingham) 
C-reactive protein buffer, adjusted to pH 7.4 (pH is varied for dissociation assay) 
140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
20mM Tris-hydrochloride (Fisher Scientific, Cheshire) 
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2mM Calcium Chloride (Sigma-Aldrich, Dorset) – Calcium concentration is varied for 
dissociation assay 
Primary anti-monomeric-CRP made up 1:10 ratio with blocking buffer 
Anti-monomeric-CRP 8C10 culture supernatant (this was a kind gift from Dr LA 
Potempa) 
Primary anti-native-CRP made up 1:10 ratio with blocking buffer 
Anti-native-CRP 1D6 culture supernatant (this was a kind gift from Dr LA Potempa) 
TBS/Tween buffer, adjusted to pH 7.4 
10mM Tris-base (Fisher Scientific, Cheshire) 
140mM Sodium Chloride (Sigma-Aldrich, Dorset) 
0.1% Tween-20 (Sigma-Aldrich, Dorset) 
Blocking buffer, adjusted to pH 7.4 
1% Albumin from Bovine serum (Sigma-Aldrich, Dorset) in TBS-Tween 
Milk Solution, adjusted to pH 7.4 
5% semi-skimmed milk powder in TBS-Tween 
Polyclonal rabbit, anti-mouse immunoglobulins/HRP (Dako, Cambridge) 1:1000 
dilution in milk solution 
EZ-ECL chemiluminescence detection kit (Geneflow, Lichfield) 
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9.6 Methods 
9.6.1 Mouse Model 
Murine blood and wound protein samples were kindly provided   by our 
collaborators (Dr M Hardman et al) at the University of Manchester. Samples (n=4) 
came from a murine model of age-related impaired healing that had undergone 
ovarectomomy (OVX) and  an OVX model supplemented with a slow release (0.05 
mg/21 day) 17β-estradiol pellet (E2) (Innovative Research, USA) inserted 
subcutaneously in the scapula region, using a trocar, on the day of wounding. 
Wounding (day zero) was conducted in the form of a 1cm scalpel incision on the 
dorsum of each mouse as described previously in Section 4.6.1 and blood samples 
and wounds were collected at day 7 post-wounding and the whole blood samples 
were lysed by storage at -80oC prior to subsequent analysis. Total protein was 
extracted from wound samples via Trizol extraction and total protein 
concentrations normalised (Section 9.6.2) prior to storage at -80oC.  
 
9.6.2 Total Wound Protein Normalisation 
 Total wound protein was normalised to 20mg/ml using CRP buffer (150mM 
NaCl, 20mM Tris-Hcl and 2mM CaCl2, pH 7.4) in preparation for dot blotting.  
 
9.6.3 C-reactive Protein Isoforms 
 CRP isoforms were purified and quantified as previously described in Section 
2.4.4.  
 
9.6.4 Dot Blots 
 Dot blots were conducted as previously described in Section 2.4.7. An 
example of a dot blot for this section is located in Appendix 1.  
221 
 
9.6.5 Statistical Analysis 
Graphs were drawn using Microsoft Excel 2013 and all statistics performed 
using IBM SPSS Statistics (Version 22). Data were analysed with the Shapiro-Wilkes 
normality test before t-tests or Mann-Whitney tests were conducted upon all the 
data. Images from the Bio-Rad ChemiDocTM Touch Imaging System were analysed 
using the Bio-Rad Image Lab Software (Version 5.2.1). 
 
 
9.7 Results 
9.7.1. The Effect of Estrogen on Levels of C-Reactive Protein in the Circulating 
Blood 
  Figures 9.1A and 9.1B show the differing levels of the CRP isoform in the 
lysed whole blood of OVX and OVX+E mice (n=4).  There was a higher amount of 
circulating mCRP than nCRP, with only small levels of nCRP detected in lysed whole 
blood. With the addition of estrogen (OVX+E), the concentration of both isoforms in 
lysed whole blood increased significantly (P<0.001 in both cases) compared to the 
model of age-related impaired healing (OVX). The mean level of mCRP increased 
from 449μg/ml to 576μg/ml while the level of nCRP increased from 2μg/ml to 
5μg/ml.  
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9.7.2. The Effect of Estrogen on Levels of C-Reactive Protein in Murine Wounds 
Figures 9.2A and 9.2B show the differing levels of the CRP isoform in the 
murine wounds from OVX and OVX+E mice (n=4).  There was a significantly 
(p<0.001 and p<0.001) in OVX and OVX+E mice respectively) lower concentration of 
each CRP isoform in wounds compared to total circulating levels measured from 
lysed blood. Again there was a higher concentration of mCRP than nCRP, with only 
small levels of nCRP being detected in wound samples. The concentration of both 
CRP isoforms decreased significantly (P=0.003 in the case of mCRP and P<0.001 for 
nCRP) following estrogen supplementation (OVX+E) to reverse the effects of age-
related impaired healing in OVX mice. The level of mCRP decreased from 89μg/ml 
to 53μg/ml while the level of nCRP decreased from 0.86μg/ml to 0.45μg/ml 
following estrogen supplementation. 
 
Figure 9.1 – The concentration of CRP isoforms in lysed whole blood from  a 
murine model of age-related impaired healing (OVX) and the reversal of age-
related impaired-healing by estrogen supplementation (OVX + E2). A) The 
concentration of total circulating mCRP B) The concentration of total circulating 
nCRP. Error bars represent standard error of the mean. ** denotes significant 
difference (P<0.001). 
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9.8 Discussion 
Research has suggested that estrogen plays a vital role in wound healing as 
well as estrogen and CRP levels being linked. The data in this study provides 
evidence to this theory. 
 
9.8.1 Circulating Blood C-Reactive Protein Levels 
Figures 9.1A and 9.1B show total circulating (cellular and extracellular) levels 
of CRP isoforms in lysed whole blood of mice. In estrogen-deficient mice (OVX), the 
level mCRP and nCRP was significantly (P<0.001) lower than when estrogen was 
supplemented indicating that the presence of estrogen induces circulating levels of 
CRP. Moreover, the levels of mCRP were 1.3 times higher in the estrogen-
supplemented (OVX+E) mice compared to the OVX mice, suggesting a more pro-
inflammatory environment in circulation due to the fact that mCRP tends to exhibit 
Figure 9.2 – The concentration of CRP isoforms in wounds of a murine model of 
age-related impaired healing (OVX) and the reversal of age-related impaired-
healing by estrogen supplementation (OVX + E2). A) The concentration of mCRP 
levels found in murine wounds. B) The concentration of nCRP levels found in 
murine wounds. Error bars represent standard error of the mean. ** denotes 
significant difference (P<0.001). 
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more pro-inflammatory functions than nCRP (Zhao & Shi, 2010). These data support 
evidence that pre-menopausal women are at greater risk of certain cardiovascular 
events such as stroke due to elevated CRP levels (Kurtz et al, 2011). Thus in 
circulation, estrogen is working in a pro-inflammatory manner, elevating total CRP 
levels. These data supported by previous research indicating that post-menopausal 
women taking hormone replacement therapy (HRT) had much higher levels of CRP 
than women who were pre-menopausal or had no HRT treatment (Kurtz et al, 2011; 
Liukkonen et al, 2010). 
   
9.8.2 Wound C-reactive Protein Levels 
 Figures 9.2A and 9.2B show the effect of estrogen supplementation on 
levels of CRP isoforms in a model of age-related impaired healing. When estrogen is 
supplemented back there is a significant (P<0.001) decrease in the concentration of 
both CRP isoforms.  
 The reduction in CRP levels, particularly the substantial decrease (40.5%; 
36μg/ml) in mCRP, suggests that in peripheral tissues such as skin estrogen is 
behaving in an anti-inflammatory manner during wound healing.  This supports 
extensive findings within the literature indicating that estrogen reduces the 
inflammatory response during animal and human wound healing (Ashcroft & 
Ashworth, 2003).  
 
9.8.3 The Effect of Estrogen on CRP Levels 
 These results confirm that estrogen has a dual nature, exhibiting both pro- 
and anti-inflammatory properties at the same time in different tissues. In 
circulation, estrogen behaves in a pro-inflammatory manner by increasing the levels 
of CRP (mCRP in particular). In murine wounds that have a propensity for impaired 
healing and excessive inflammation, estrogen acts in an anti-inflammatory manner 
by reducing CRP levels (mCRP in particular) at the wound site. 
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Previous research has shown that gender has a substantial influence on the 
risk of cardiovascular events with higher estrogen levels during youth elevating the 
risk of blood clots and HRT use in post-menopausal increasing the risk of stroke.  
The findings of this study showing greater levels of CRP isoforms (particularly 
mCRP) associated with circulating whole blood following estrogen supplementation 
are in concordance with the literature.  For example, it is known that mCRP plays a 
role in the pathology of cardiovascular disease due to its pro-angiogenic nature and 
its ability to promote thrombus formation (Slevin & Krupinski, 2009). However, in 
direct contrast to the situation found in circulation, this study has shown that in 
skin tissues estrogen reduces local (peripheral) wound levels of CRP isoforms (mCRP 
in particular). Estrogen promotes healing by dampening inflammation, regulating 
cytokine expression, stimulating angiogenesis and promoting wound contraction 
and re-epithelialisation (Ashcroft & Ashworth, 2003; Hardman & Ashcroft, 2008).  
The postmenopausal decline in estrogen has been shown to lead to impaired 
healing due to an excessive inflammatory response. The decline in estrogen is 
accompanied by the overproduction of pro-inflammatory cytokines including IL-6 
which is known to stimulate CRP production (Chakrabarti et al, 2008). Thus, the 
findings of this study suggest that estrogen may inhibit the inflammatory response 
in wounds at least in part by reducing local CRP levels, particularly mCRP, through 
the down-regulation of cytokines such as IL-6. The findings of this study help to 
clarify why HRT can be beneficial to wound healing but at the same time can be 
linked to a higher risk of particular cardiovascular events such as stroke.  The results 
have confirmed the dual nature of estrogen in promoting or inhibiting inflammation 
at the same time in different tissues (Chakrabarti et al, 2008) and highlights a 
potential role for CRP isoforms during wound healing processes.  
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9.9 Future work 
 Future work could investigate the effect of ageing (estrogen deprivation) on 
CRP isoforms in CRPtg mice that can produce human CRP via a transgenic gene 
(Szalai et al, 2002).  This transgenic model could be used to assess whether 
estrogen mediates the expression of human CRP in a similar manner to that shown 
in this study. In vitro studies using human cells typical of the wound environment, 
particularly macrophages and neutrophils, should be performed to determine 
whether exogenous estrogen treatments are able mediate CRP isoform levels. 
  Other steroid sex hormones, such as testosterone, that are known to 
mediate the inflammatory response during wound repair (Gilliver et al, 2007) 
should be investigated to determine their effects on CRP levels in wounds.  
 
9.10 Summary 
 In summary, this study has shown that estrogen can affect levels of both 
isoforms of CRP in opposing directions in circulation and wounds.  The findings 
suggest that estrogen may play a pro-inflammatory role in circulation by stimulating 
CRP levels but appears to be anti-inflammatory in wounds by inhibiting CRP levels. 
The mechanism by which estrogen mediates CRP levels in not fully elucidated but 
may involve the regulation of cytokines such as IL-6. The findings suggest CRP 
isoforms may have a role in wound healing processes, particularly the inflammatory 
response.  
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Chapter 10 - Discussion, Future Work and Conclusions 
  
10.1 Discussion 
10.1.1 Results Summary 
This study has provided novel data on the effects of CRP isoforms on 
inflammation in the context of wound healing processes, particularly age-related 
impaired healing. Understanding the effect of CRP isoforms on monocytes and 
macrophages in vitro will form the basis for future work confirming these findings in 
animal models and investigating the precise mechanisms and pathways involved. 
Ultimately, a body of evidence confirming a role for CRP in wound repair may lead 
to therapeutic strategies that may mediate age-related impaired healing and 
chronic wounds in elderly humans. 
 
10.1.1.1 Stability of C-Reactive Protein 
The preliminary results of Chapter 3 indicated that calcium concentration of 
local tissues is a major factor in the stability of the pentameric protein with pH 
playing a lesser but detectable role. The stability of nCRP is a key factor maintaining 
the balance of the two CRP isoforms and the resulting inflammatory response in 
tissues.  
 
10.1.1.2 Immunohistochemistry 
The data in Chapter 4 of this study confirmed that both isoforms of CRP 
were differentially localised to inflammatory cells (neutrophils and 
monocytes/macrophages) in both the early (D3) and late (D7) inflammatory stage 
of murine wound healing. By observing changing levels of the CRP isoforms, notable 
differences in CRP localisation were identified between models of acute healing in 
young (INTACT) mice and age-related impaired healing in OVX mice.  
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10.1.1.3 Growth and Apoptosis 
The assays in Chapter 5 provided evidence that both CRP isoforms can affect 
the cell growth, having a detrimental effect upon the growth and/or viability of 
inflammatory cells at high concentrations. Both isoforms caused a decline in the 
number of monocytes and macrophages but only nCRP caused apoptosis. Evidence 
would suggest that the nCRP is causing apoptosis through a variety of pathways 
potentially through increased capase-3 activity (Blaschke et al, 2004).  
 
10.1.1.4 Nitric Oxide Production 
The findings in Chapter 6 suggested that both mCRP and nCRP had the 
ability to differentially mediate NO levels in monocytes and macrophages in a cell 
type/state- and concentration-dependent manner. The response of cells to CRP 
isoforms were dependent on the differentiation state of the cells and whether 
there was pre-stimulation with bacterial endotoxin. Treatment with nCRP had an 
inhibitory effect on NO production in macrophage-like cells, displaying anti-
inflammatory properties, whereas mCRP had a stimulatory effect on NO synthesis 
in monocyte-like cells promoting the inflammatory response. 
 
10.1.1.5 Cytokine Production 
The results in Chapter 7 provided evidence that the two CRP isoforms had 
differential effects upon the production of pro-inflammatory cytokines in a cell 
type/state-dependent manner. The findings indicate that estrogen plays a 
substantial role in how CRP isoforms function during the inflammatory response.  
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10.1.1.6 Phagocytosis 
In Chapter 8, nCRP reduced the recovery of MRSA colonies, suggesting nCRP 
enhances host-pathogen interactions via increased phagocytosis. The literature 
suggests this occurs due to nCRP triggering the complement pathway and leading to 
the opsonisation of the microbial surface.  Treatment mCRP had no effect upon the 
recovery of MRSA colonies suggesting that it has no effect upon phagocytosis. 
 
10.1.1.7 Estrogen Deficiency 
Chapter 9 provided evidence that estrogen mediates levels of both isoforms 
of CRP in both murine circulating blood and wounds. The findings indicated 
estrogen induces a pro-inflammatory response in circulating blood but acts in an 
anti-inflammatory manner in wounds by differentially altering the profile of CRP 
isoforms.   
 
10.1.2 General Discussion 
10.1.2.1 Presence of CRP isoforms on Inflammation 
 The results of the immunohistochemistry have shown that both isoforms of 
CRP are localised in neutrophils, monocytes and macrophages at the site of 
inflammation during murine wound repair. This corroborates the use of U937 cells 
in subsequent in vitro investigations since it has been confirmed that the U937 cell-
line can produce CRP (Ciubotaru et al, 2005). The fact that there are changes in the 
temporal and spatial localisation of CRP isoforms during the inflammatory phase of 
wound repair suggests that CRP isoforms may play an active role in inflammatory 
processes during wound repair. There is existing evidence that CRP can activate the 
classical complement pathway (Du Clos, 2004) leading to the opsonisation and 
phagocytosis of cell debris and invading organisms (Mold et al, 1999).  
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This study has shown that both CRP isoforms are present in inflammatory 
cells throughout the inflammatory phase of acute wound healing at both D3 and 
D7. There was a significantly reduced amount of the CRP isoforms at the D7 time 
point but this could be accounted for due to the apoptosis of neutrophils (Li et al, 
2007) following their peak at D3 and the subsequent recruitment of tissue 
macrophages (Kaplanski et al, 2003). However the results indicted that the D7 
macrophages still had the ability to produce both isoforms and thus providing 
evidence for an enhanced role in the inflammation process.  
 
10.1.2.2 Biological Functions of CRP Isoforms 
The findings from in vitro studies have confirmed that the two CRP isoforms 
have differing biological functions in monocytes and macrophages.  
The nCRP isoform exhibited more anti-inflammatory effects such as 
promoting apoptosis, decreasing nitric oxide secretion, reducing pro-inflammatory 
cytokines levels and increasing phagocytosis.  These findings are in concordance 
with published studies indicating that nCRP is more anti-inflammatory in nature 
than mCRP (Thiele et al, 2014). Further corroboration of the differing roles of CRP 
isoforms comes from the distinct receptors they bind in order to exert biological 
function. The proposed receptor for mCRP is FcγRIII (CD16), whereas the proposed 
receptors for nCRP are FcγRIIa (CD32) and FcγRI (CD64) (Khreiss et al 2002). In vitro 
studies have proposed mCRP interacts with lipid raft microdomains within the 
plasma membrane since interruption of these with nystatin abrogates mCRP 
responses including cytokine secretion, ROS formation and upregulation of 
adhesion molecules (Ji, et al., 2009).  
The results of this study have shown that inflammatory cells exhibit 
different functions in response to CRP isoforms, in a cell type/status manner. This 
may be explained by the expression of varying cell receptors on each of the cell 
types as well as varying activation processes (Geissmann et al, 2010).  
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The results in Chapter 5 show that high concentrations of nCRP (1000μg/ml) 
can cause apoptosis of cells while high concentrations of mCRP (250μg/ml) inhibits 
apoptosis. It is suggested that both of these isoforms are utilising the caspase 
cascade in which to trigger their effects. The nCRP isoform is most likely increasing 
caspase-3 activity to induce apoptosis (Blaschke et al, 2004) while the mCRP 
isoform is inhibiting apoptosis through the p38 MAPK pathway to prevent the 
triggering of the caspase cascade (McIlwain et al, 2015). 
Chapter 6 indicated the differing functions of the isoforms on nitric oxide 
production. The mCRP isoform stimulated NO production in monocyte-like cells but 
had no effect in macrophage-like cells, regardless of activation by LPS (bacterial 
endotoxin). The nCRP isoform reduced NO production in macrophage-like cells both 
in the presence and absence of endotoxin activation and furthermore, in 
monocytes activated by bacterial endotoxin nCRP reduced NO levels in a 
concentration-dependent manner. These results suggest that mCRP may stimulate 
NO production in both the presence and absence of infection leading to a pro-
inflammatory response whilst nCRP often opposed the actions of mCRP reducing 
the overall inflammatory response (Ciubotaru et al, 2005).  
Chapter 8 provided evidence that high concentrations of nCRP (500μg/ml 
and 1000μg/ml) increased phagocytosis of MRSA while treatment with mCRP did 
not have any effect upon phagocytosis. When the macrophages were treated with 
the nCRP isoform there was a significant (P<0.05) decrease in the number of MRSA 
colonies recovered compared to the background level of bacterial recovery. This 
increase in host-pathogen interaction could be to the activation of the classical 
complement pathway by nCRP. When nCRP dissociates into the monomeric form 
there is a loss of the C1q binding site on the opposite face of the CRP molecule, 
meaning that opsonisation and phagocytosis cannot occur (Du Clos, 2004; Mold et 
al, 1999). 
The findings from this study indicate that the balance between the two CRP 
isoforms (mCRP:nCRP ratio) may mediate the resulting inflammatory response and 
that this balance may be disrupted in impaired healing, including age-related 
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impaired healing and chronic wounds that affect the elderly. The balance of CRP 
isoforms could be disrupted by an increase in the dissociation of nCRP into mCRP, 
leading to a more pro-inflammatory effect. This imbalance in CRP isoforms could be 
brought about by detrimental changes in hormone levels (particularly estrogen 
deprivation) and calcium levels with increasing age. . 
 
10.1.2.3 Mechanisms of Action of C-Reactive Protein 
The evidence provided by this study shows that CRP plays a more extensive 
role in inflammation than just acting as a marker of inflammation or activating 
complement. There is a potential link between the processes that have been 
investigated in this study. The results in Chapter 5 indicated that the CRP isoforms 
mediate the nitric oxide (NO) pathway. The nCRP isoform generally decreased NO 
levels whereas mCRP increased NO levels. The other results seen in Chapter 5 
(apoptosis), Chapter 7 (pro-inflammatory cytokine secretion) and Chapter 8 
(phagocytosis) can all be linked to the NO results obtained in Chapter 6. The NO 
pathway is utilised in all these processes (as well as many others). The pro-
inflammatory mCRP isoform increased the amount of NO produced, especially in 
monocytes. In contrast, the amount of NO produced decreased following treatment 
with nCRP. When NO levels decrease this leads to increased apoptosis (Verma et al, 
2004), altered phagocytosis regulation (MacMicking et al, 1997) and reductions in 
pro-inflammatory cytokine production (Andrew et al, 1995; Khreiss et al, 2004; 
Wetzler et al, 2000; Schwentker et al, 2002), as shown within this study. 
Previous research has shown that CRP downregulates eNOS transcription in 
endothelial cells by destabilising eNOS mRNA, thereby decreasing NO release 
(Verma et al, 2002). However, this research only referred to CRP with no reference 
to the isoform involved but it can be deduced it was the nCRP isoform. This 
research is supported by the findings of this study showing the nCRP isoform 
reduces levels of NO in monocytes and macrophages. However, the NO synthases 
involved in inflammatory cells have not been confirmed. 
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Decreased NO production is known to facilitate endothelial cell apoptosis 
(Verma et al, 2004).  In line with this, the nCRP isoform reduced levels of NO and 
led to apoptosis (Chapter 5). In contrast, the mCRP isoform did not induce 
apoptosis, possibly because it increased NO production. Since high concentrations 
of mCRP (250μg/ml) led to some cell death that could not be identified as apoptosis 
(Chapter 4), necrosis was highlighted as a potential cause of cell death.  
From Chapter 5 it was shown that mCRP did not induce apoptosis and 
inhibited the process of apoptosis by preventing the activation of the caspase 
cascade (Figure 5.18) (Khreiss et al, 2002). However apoptosis can be NO-
dependent or NO-independent (Li & Wogan, 2005) showing that NO is a regulatory 
mechanism in these processes. Thus, inhibiting this pathway via increased NO 
production leads to the inhibition of apoptosis. 
NO is also known to directly inhibit caspase proteases which are the main 
mediators in cell death (Kim et al, 2001). This is achieved by NO directly 
nitrosylating the active site of the caspases and preventing protein function (Kim et 
al, 1997). As mCRP has been shown to increase NO levels, this would have a direct 
inhibitory effect upon the apoptotic pathway. 
NO inhibits apoptosis by preventing activation of caspase-3 activation by 
regulating the expression of death receptors in a cyclic guanosine monophosphate 
(cGMP)-dependent manner (Brüne et al, 1998). This leads to altered expression of 
proteins that trigger the early signalling events in death receptor signalling and thus 
reduced death-inducing signalling complexes. NO can also alter the expression of 
Bcl-2 proteins, which can be both pro- and anti-apoptotic (Brüne et al, 1998). This 
process alters the release of further downstream mediators and is regulated 
through the production of cGMP (Brüne, von Knethen & Sandau, 1998). 
Nitric oxide is a key regulator of phagocytosis in macrophages (MacMicking 
et al, 1997). Usually high levels of NO are required within the phagosome to aid the 
breakdown of material without leading to a toxic effect within the cell (MacMicking 
et al, 1997). The results from Chapter 8 and Chapter 6 show that nCRP caused a 
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reduction in the recovery of MRSA and reduction in NO levels. This suggests the 
ability of nCRP to improve phagocytosis most likely occurs though increasing 
activation of the complement pathway. Thus, nCRP is probably causing the 
activation of the C1q molecule, thus triggering the complement cascade and 
leading to opsonisation of bacteria and increased phagocytosis by macrophages 
(Mold et al, 1999).  
The release of cytokines by inflammatory cells initiates inflammation and 
NO is a key modulator of cytokines. NO can activate the promotor of the IL-8 gene 
but also in turn IL-8 can suppress the activation of NO (Andrew et al, 1995). The 
results of Chapter 6 indicated that CRP has an effect upon the release of IL-8, 
highlighting a potential pathway for further investigation. Significantly higher levels 
of IL-8 were detected when cells were treated with mCRP, indicating a more pro-
inflammatory effect, which corresponds to the effect of the mCRP (Khreiss et al, 
2004).  
NO has also been implicated in the downregulation of the inflammatory 
phase of wound healing through the suppression of MCP-1 (Frank et al, 2000). In 
Chapter 5, NO levels were elevated in monocytes following treatment with the pro-
inflammatory mCRP isoform. This highlights a possible mechanism by which 
elevated NO levels in monocytes may move the process of wound repair forward by 
subsequently inhibiting MCP-1 s (Wetzler et al, 2000).  
Other studies have indicated correlations between the production of NO 
and levels of IL-6 and TNF-α within wound healing and inflammation processes. NO 
has previously been found to directly affect the expression of TNF-α through a 
cGMP-independent mechanism (Lander et al, 1993). There has been debate 
regarding the effect of NO on IL-6 production, with some studies showing 
stimulation and others showing suppression of IL-6 (Schwentker et al, 2002). 
 When all of the studies are considered collectively it appears the nitric oxide 
pathway may possibly be a link between the various effects of CRP isoforms.  To 
determine if the NO pathway mediates other functions associated with CRP 
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isoforms future work could utilise specific inhibitors of the NO pathway to see if 
other functions such as phagocytosis, apoptosis and cytokine production are 
significantly perturbed.   
 
10.1.2.4 CRP and Estrogen 
The results of this study have shown that estrogen supplementation causes 
an increase in CRP levels in murine circulating blood and a decrease in wounds 
(Chapter 9). The addition of estrogen mediates the CRP-induced changes in 
cytokine levels (Chapter 7)  
Estrogen is a key regulator of healing, with impaired healing occurring in its 
absence (Gulshan et al, 1990). The OVX in vitro model used in this study represents 
this age-related impaired healing and the effects seen when estrogen is not present 
in these inflammation processes. The use of this model also allowed for the use of 
an addition of an exogenous source of estrogen (E2) in order to observe the 
representative effect of HRT in this model (Chapter 9).  
Previous research has shown that by using HRT in post-menopausal women 
there is a sustained increase in CRP levels in circulating blood (Ridker et al, 1999). 
However, at wound sites estrogen reduces CRP (particularly mCRP) levels. This 
highlights the the dual nature of estrogen; functioning in a pro-inflammatory 
manner in circulating blood but functioning in an anti-inflammatory manner in 
peripheral tissues such as wounds. In terms of the anti-inflammatory nature of 
estrogen, research has shown estrogen can reduce NO production in monocytes 
(Vegeto et al, 2000; Vegeto et al; 2001). The results in Chapter 6 have shown that 
estrogen supplementation generally reduced NO production in monocytes but 
increased levels in the macrophages following treatment with mCRP or nCRP.  
 The ratio of mCRP:nCRP should be considered when analysing the effects of 
the CRP isoforms on the wound healing process. From the results, the mCRP 
isoform is considered to be more pro-inflammatory (Khreiss et al, 2004) than the 
nCRP isoform. The results in Chapter 4 indicated that in the age-related impaired 
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(OVX) model of healing, both time points indicated a higher mCRP:nCRP ratio and 
therefore a higher number of mCRP-positive cells. This high ratio indicates that the 
inflammation in impaired healing is excessive and prolonged, while corresponding 
wounds from INTACT mice have a lower ratio of mCRP:nCRP indicating fewer cells 
with the pro-inflammatory CRP isoform. It can be suggested that in the INTACT 
wounds this lower ratio of the two CRP isoforms leads to a resolution of 
inflammation, thus allowing the wound to heal more rapidly and 
successfully (Eming et al, 2007).   
  
10.1.2.5 Inhibition of Function 
Nystatin is known to disrupt the plasma membrane of cells allowing for 
membrane leakage. These barrel-like pores allow for potassium and other cell 
constituents to pass across the membrane and cause cell death (Razonable et al, 
2005; Coutinho & Prieto 2003). C-reactive protein, especially mCRP, is known to 
associate with the cell membrane and therefore any disruption of the cell 
membrane can lead to a decline in the function of the CRP isoforms. The use of 
nystatin as an inhibitor of the effects of CRP could be a potential therapeutic target 
in terms of disrupting the negative effects of the mCRP, thus reducing the pro-
inflammatory actions of the CRP and helping to reduce inflammation.  
The other three pathways; the PI3K, MEK and p38 pathway showed some 
inhibition over the effects of the CRP isoforms. One potential downstream target of 
these three pathways is nuclear factor-κβ (NF-κβ). NF-κβ is a protein complex that is 
involved in the transcription of DNA, the production of cytokines and is involved in 
cell survival (Tak & Firestein, 2001). Studies have shown that it plays a key role in 
the regulation of inflammation and incorrect regulation leads to inflammatory 
disorders including atherosclerosis and sepsis (Tak & Firestein, 2001).The results 
show a possibility that the CRP isoforms could be utilising these three inflammatory 
pathways to regulate NF-κβ and therefore regulate many inflammatory process. 
However any potential link between CRP and NF-κβ has not been identified.  
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There is the possibly a variety of pathways maybe utilised by CRP isoforms 
and therefore these pathways need to Interrogated in future work investigating 
CRP isoforms. 
 
10.1.2.6 Clinical Implications 
The results of this study have shown that CRP should be a potential 
therapeutic target for treatment of inflammation. Prevention of the dissociation of 
the native CRP to the monomeric isoform can be a potential target of clinical 
significance.  
CRP is a marker of inflammation and is implicated in a variety of different 
disease states such as atherosclerosis (Osman et al, 2006), arthritis and meningitis 
(Clyne & Olshaker, 1999). Research has shown that CRP plays a role within these 
aetiologies rather than just indicating the presence of disease. These responses 
include the activation of complement, induction of cytokines and alteration of cell 
adhesion proteins. 
This study shows that CRP is a major component in inflammation and 
dysregulation of CRP-mediated responses may be involved in impaired healing and 
the pathogenesis of chronic wounds. The pro-inflammatory effects of mCRP relative 
to nCRP could acerbate the inflammation associated with chronic wounds.  The 
mCRP:nCRP ratio is indicative of the effects of the CRP isoform on the wound 
healing process. In the age-impaired model there was a high mCRP:nCRP ratio, 
indicating a prolonged and excessive inflammation process due to a high number of 
mCRP positive cells. By targeting the mCRP isoform and potentially increasing the 
amount of the anti-inflammatory nCRP, could potentially accelerate repair in 
impaired wounds as this would lower the mCRP:nCRP ratio and bring the two 
inflammatory effects into balance and allowing the resolution of healing (Eming et 
al, 2007).   
Targeting the dissociation of nCRP, potentially with calcium 
supplementation or pharmacological inhibition, or mediating CRP-mediated 
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responses using estrogen (or selective estrogen receptor modulators) in the elderly 
may reverse age-related impaired healing and offer therapeutic strategies to treat 
chronic wounds. 
  
 
10.2 Future Work 
Future investigations could use the compound 1,6 bis-phosphocholine 
(Habersberger et al, 2012) that has the ability to prevent the dissociation of the 
nCRP in vitro. This compound works by combining two nCRP molecules to prevent 
them from binding to the cell membrane (Habersberger et al, 2012). By using this 
compound, the effects observed following treatment with nCRP could be attributed 
entirely to nCRP, excluding the possibility of dissociation into mCRP. To determine if 
the NO pathway is a key mediator of other functions associated with CRP isoforms 
future work could utilise specific inhibitors of the NO pathway to see if other 
functions such as phagocytosis, apoptosis and cytokine production are significantly 
perturbed.  Additional work should also be done with selective estrogen receptor 
modulators (SERMs) to determine which estrogen receptors are mediating the 
estrogen-induced changes in CRP isoform profile and biological activity.  
This study has only mainly considered the effects of the CRP isoforms upon 
the monocytes and macrophages in the inflammation process. This means that 
there is the potential for this work to be repeated utilising other cell types including 
the use of neutrophil cell models, such as HL60, or an endothelial cell models, such 
as HUVEC. This would help to build a profile of cell-specific responses and functions 
mediated by CRP isoforms. This study can be progressed further by considering 
many other processes and functions of inflammation and wound healing including 
assays to investigate neutrophil/monocyte cell adhesion and chemotaxis, 
keratinocyte proliferation and migration, angiogenesis, fibroblast proliferation, 
extracellular matrix production and wound contraction). Further work with is also 
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needed to identify the precise mechanisms and pathways by which CRP isoforms 
may exert biological effects. 
The findings from cell culture experiments conducted in vitro could be 
verified in vivo using animal models of wound repair and providing exogenous CRP 
isoforms locally to wounds.  A mouse model that can express the human CRP gene 
(CRPtg mice) could also be adopted to investigate the effect of endogenous CRP 
production on wound healing processes. Additional studies could take ex vivo 
samples (e.g. inflammatory cells and skin biopsies) from human subjects to confirm 
findings in human tissues. Replication of findings from this study using in vivo and 
ex vivo models would provide a growing body of evidence confirming the extent of 
involvement of CRP isoforms in wound repair and may ultimately indicate potential 
therapeutic strategies for the treatment of age-related impaired acute wound 
healing and chronic wounds in the elderly. 
   
 
10.3 Conclusion 
 C-reactive protein appears to be not just a marker of inflammation; the 
findings of this study indicate CRP isoforms are present in inflammatory phases of 
murine wounds and may differentially mediate  key aspects of the inflammatory 
process in human cells; including phagocytosis, apoptosis, cytokine profile and NO 
production.  The findings show that CRP isoforms regulate biological processes in a 
cell type/status-specific manner.  
 This novel research has shown that the ratio of CRP isoforms (mCRP:nCRP) 
reflects the degree of inflammation present in wounds with higher values indicating 
a more pro-inflammatory response that is associated with age-related impaired 
healing. These findings suggested the nCRP isoform is a potential therapeutic target 
and that preventing dissociation of nCRP or increasing the stability of nCRP may 
shift the balance toward reduced inflammation and accelerated wound repair. 
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 This study has identified the NO pathway as a potential mechanism that 
could be mediating many of the functions associated with CRP isoforms during the 
inflammatory response. Finally this research has highlighted a relationship between 
estrogen and the activity of CRP isoforms during inflammation and the effect of 
estrogen on CRP isoform localisation in murine circulating blood and wounds. 
Estrogen mediated CRP-induced responses in a cell type/status-specific manner, 
leading to a more pro-inflammatory phenotype in circulation and a more anti-
inflammatory phenotype in wounds. Estrogen deprivation in age-related impaired 
healing was associated with a more pro-inflammatory CRP isoform profile, with 
higher levels of mCRP than nCRP.    
In conclusion, this study has provided novel data implicating CRP isoforms as 
important regulators of the inflammatory response in relation to wound healing. 
The work highlights the need to investigate CRP isoforms further to determine their 
precise roles during wound repair, particularly in age-related impaired healing and 
chronic wounds in the elderly.  
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Appendix 
 
Appendix 1  
 
Appendix 1 – An example standard curve used to quantify the concentration of purified 
mCRP and purified nCRP. Line of best fit is CRP Concentration = (0.0005 x absorbance at 
595nm) + 0.0067 
 
Appendix 2 
 
Appendix 2 – Example of annotated dot blot showing mCRP and nCRP presence in blood 
and wound protein (data collected for Chapter 9) 
y = 0.0005x + 0.0067
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Appendix 3 
 
 
 
 
Appendix 3 - an annotated example dot blot showing the layout of for the cacium test in 
Chapter 3 
 
Appendix 4  
 
 
 
 
 
 
 
 
 
Appendix 4 – An example of a standard curve used to cacluate mCRP concentration in 
Chapter 3. Line of best fit is density = (238.89 x mCRP concentration) - 1.136 
y = 238.89x - 1.136
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Appendix 5 
 
 
 
 
 
 
 
Appendix 5 – An example of a standard curve used to calculate nitric oxide concentration in 
Chapter 6. Line of best fit is Nitric oxide concentration = (0.005 x absorbance at 540nm) + 
0.0052 
y = 0.0005x + 0.0052
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